text,chunk_id,title,publication_date,authors,disease
"Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches Hereditary angioedema (HAE) is a rare genetic disease characterized by transient and recurrent attacks of edema in the subcutaneous tissue, mucosa, and submucosa, which are not accompanied by itching or swelling and are caused by a temporary and localized increase in endothelial permeability [<xref rid=""R1"" ref-type=""bibr"">1</xref>]. HAE is most frequently caused by mutations in the <italic toggle=""yes"">SERPING1</italic>",0_0,Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches,12 2024,,Hereditary_Angioedema
"in the <italic toggle=""yes"">SERPING1</italic> gene, which are usually transmitted as an autosomal dominant trait, and in 25% of the cases, the disease is caused by a de novo mutation that results in congenital deficiency of complement inhibitor 1 (C1-INH). HAE caused by C1-INH deficiency (C1-INH-HAE) is classified as type 1 (reduced antigenic plasma levels) or type 2 (dysfunctional C1-INH at normal or high levels) [<xref rid=""R2"" ref-type=""bibr"">2</xref>,<xref rid=""R3"" ref-type=""bibr"">3</xref>]. C1-INH",0_1,Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches,12 2024,,Hereditary_Angioedema
"rid=""R3"" ref-type=""bibr"">3</xref>]. C1-INH regulates the activation of the contact system by inhibiting the activation of factor XII (FXII) and kallikrein that generate bradykinin (BK), which binds to its specific receptor B2 at the endothelial level to enhance vaso-permeability and vasodilation and cause the formation of angioedema (Fig. <xref rid=""F1"" ref-type=""fig"">1</xref>) [<xref rid=""R4"" ref-type=""bibr"">4</xref>].  The clinical onset of HAE generally occurs during childhood or adolescence [<xref",0_2,Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches,12 2024,,Hereditary_Angioedema
"occurs during childhood or adolescence [<xref rid=""R5"" ref-type=""bibr"">5</xref>] and can potentially affect all districts, but mostly affects the skin, gastrointestinal tract, and upper airways [<xref rid=""R5"" ref-type=""bibr"">5</xref>]. Some angioedema attacks are preceded by prodromic symptoms and signs such as fatigue, a tingling sensation, or a skin rash without itching that may be mistaken for an allergy, called erythema marginatum [<xref rid=""R6"" ref-type=""bibr"">6</xref>,<xref rid=""R7""",0_3,Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches,12 2024,,Hereditary_Angioedema
"rid=""R6"" ref-type=""bibr"">6</xref>,<xref rid=""R7"" ref-type=""bibr"">7</xref>]. The attacks may be very painful, disfiguring, and associated with functional impairment (e.g., attacks on the extremities), leading to a strong impact on the patients’ quality of life (QoL) [<xref rid=""R8"" ref-type=""bibr"">8<sup>▪</sup></xref>]. Without specific treatment, the attack can last 2–5 days and may be associated with mortality (e.g., life-threatening episodes of laryngeal edema) [<xref rid=""R9"" ref-type=""bibr"">9</xref>].",0_4,Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches,12 2024,,Hereditary_Angioedema
"edema) [<xref rid=""R9"" ref-type=""bibr"">9</xref>]. HAE should be suspected in patients with a history of recurrent angioedema without urticaria, positive family history, episodes of laryngeal edema, and recurrent abdominal pain that does not respond to antihistamine therapy, adrenaline, and/or glucocorticoids. Considering these clinical factors, diagnosis should be confirmed by laboratory tests assessing the levels of C4 and quantitative and functional C1-INH [<xref rid=""R10"" ref-type=""bibr"">10</xref>].",0_5,Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches,12 2024,,Hereditary_Angioedema
"[<xref rid=""R10"" ref-type=""bibr"">10</xref>]. Patients with HAE type 1 show a reduction in the levels of C4 and quantitative and functional C1-INH, while those with HAE type 2 show normal or increased, but functionally reduced (<60%), levels of C1-INH. In HAE with normal C1-INH levels, the levels of antigenic and functional C1-INH and antigenic C4 are normal. Genetic tests for mutations responsible for HAE with normal C1-INH levels should be performed in suggestive clinical settings [<xref rid=""R11""",0_6,Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches,12 2024,,Hereditary_Angioedema
"in suggestive clinical settings [<xref rid=""R11"" ref-type=""bibr"">11</xref>]. For several years, the options for HAE treatment have been limited to drugs with substantial adverse effects, insufficient efficacy, and difficult administration routes. The implementation of newer therapies has facilitated the application of individualized action plans with the goal of minimizing the number of attacks and addressing the complex needs of patients. Moreover, switching from one treatment to another due to",0_7,Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches,12 2024,,Hereditary_Angioedema
"switching from one treatment to another due to insufficient efficacy and/or adverse events has become easier. Over the next few years, disease control up to attack-free remission may become possible.",0_8,Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches,12 2024,,Hereditary_Angioedema
"<italic toggle=""yes"">None.</italic>",0_9,Hereditary angioedema due to C1-inhibitor deficiency: current therapeutic approaches,12 2024,,Hereditary_Angioedema
"Unveiling the Complexities of Hereditary Angioedema Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder, constituting approximately 2% of all clinical cases of angioedema, with a global prevalence estimated between 1 in 50,000 and 1 in 150,000 individuals. The condition affects individuals of all genders and ethnic backgrounds without significant variation. HAE is classified into three types. Type I HAE, which accounts for 85% of cases, is characterized by a deficiency of",1_0,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"85% of cases, is characterized by a deficiency of the C1 esterase inhibitor (C1-INH) gene. Type II HAE, making up 15% of cases, involves a dysfunctional C1-INH. Type III HAE, which represents about 5% to 10% of cases, is often estrogen-dependent and although several mutations have been identified, it typically involves normal C1-INH activity. Despite the differences in C1-INH functionality, all three types of HAE manifest with similar clinical symptoms. HAE leads to recurrent episodes of non-pruritic",1_1,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"HAE leads to recurrent episodes of non-pruritic angioedema, which occurs in the absence of urticaria. Breakthroughs in understanding HAE pathophysiology have revolutionized treatment, leading to the development of highly targeted therapies for both acute management and long-term prevention. Meanwhile, cutting-edge advancements in omics technologies are unlocking new possibilities for biomarker discovery, paving the way for more precise diagnoses and personalized treatment strategies that could",1_2,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"and personalized treatment strategies that could significantly enhance patient outcomes. This review will delve into the intricate pathophysiology, diverse clinical presentations, and diagnostic challenges of HAE while exploring emerging biomarkers and innovative approaches to therapeutic management and prevention strategies. Additionally, it will underscore the vital importance of screening family members of affected individuals, even when symptoms are not present. Hereditary angioedema (HAE) is a rare",1_3,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"present. Hereditary angioedema (HAE) is a rare genetic disorder caused by either a deficiency or dysfunction of the C1 esterase inhibitor (C1-INH) gene, which underlies both type I and type II HAE, as well as the existence of hereditary angioedema with normal C1-INH activity (type III HAE) [<xref rid=""B1-biomolecules-14-01298"" ref-type=""bibr"">1</xref>,<xref rid=""B2-biomolecules-14-01298"" ref-type=""bibr"">2</xref>,<xref rid=""B3-biomolecules-14-01298"" ref-type=""bibr"">3</xref>,<xref",1_4,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"ref-type=""bibr"">3</xref>,<xref rid=""B4-biomolecules-14-01298"" ref-type=""bibr"">4</xref>,<xref rid=""B5-biomolecules-14-01298"" ref-type=""bibr"">5</xref>]. The Hereditary Angioedema Working Group (HAWK) classification has helped clarify the confusion that has surrounded this topic for years by distinguishing between hereditary and acquired forms of angioedema, regardless of whether they are associated with C1-INH deficiency [<xref rid=""B6-biomolecules-14-01298"" ref-type=""bibr"">6</xref>]. Recent research has",1_5,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"ref-type=""bibr"">6</xref>]. Recent research has identified additional mechanisms in angioedema pathogenesis, including the unchecked activation of factor XII, the production of vasoactive mediators that disrupt endothelial function, and the interplay between mast cell-derived mediators and the plasma contact system [<xref rid=""B6-biomolecules-14-01298"" ref-type=""bibr"">6</xref>]. The pathogenesis of HAE involves the accumulation of extravascular fluid in various tissues through a non-inflammatory and",1_6,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"in various tissues through a non-inflammatory and non-allergic mechanism [<xref rid=""B7-biomolecules-14-01298"" ref-type=""bibr"">7</xref>]. The increase in vascular permeability that leads to angioedema in HAE is closely associated with the mediators of the contact system, specifically the kallikrein–kinin pathway, where C1-INH plays a critical regulatory role across several physiological pathways, including fibrinolysis, coagulation, the contact system, and the complement system [<xref",1_7,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"contact system, and the complement system [<xref rid=""B1-biomolecules-14-01298"" ref-type=""bibr"">1</xref>,<xref rid=""B7-biomolecules-14-01298"" ref-type=""bibr"">7</xref>]. Inhibition of plasma kallikrein and coagulation factor FXIIa by C1-INH is essential [<xref rid=""B7-biomolecules-14-01298"" ref-type=""bibr"">7</xref>]. When C1-INH function is compromised, bradykinin overproduction occurs, which then activates B2 receptors, increasing vascular permeability and leading to angioedema [<xref",1_8,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"permeability and leading to angioedema [<xref rid=""B7-biomolecules-14-01298"" ref-type=""bibr"">7</xref>,<xref rid=""B8-biomolecules-14-01298"" ref-type=""bibr"">8</xref>,<xref rid=""B9-biomolecules-14-01298"" ref-type=""bibr"">9</xref>]. As the pathophysiological mechanisms underlying HAE involve numerous molecules, they may serve as potential biomarkers [<xref rid=""B10-biomolecules-14-01298"" ref-type=""bibr"">10</xref>]. There are three types of HAE, namely type I, II, and III, which are differentiated by etiology",1_9,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"II, and III, which are differentiated by etiology and blood levels of the C1 inhibitor [<xref rid=""B1-biomolecules-14-01298"" ref-type=""bibr"">1</xref>,<xref rid=""B10-biomolecules-14-01298"" ref-type=""bibr"">10</xref>]. HAE types I and II result from mutations in the SERPING1 gene, which encodes the synthesis of the C1-INH protein responsible for regulating inflammation [<xref rid=""B1-biomolecules-14-01298"" ref-type=""bibr"">1</xref>,<xref rid=""B10-biomolecules-14-01298"" ref-type=""bibr"">10</xref>]. Type III HAE,",1_10,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"ref-type=""bibr"">10</xref>]. Type III HAE, often referred to as estrogen-dependent HAE or HAE with normal C1-INH activity, typically occurs in individuals with normal C1-INH levels and is often influenced by hormonal factors such as estrogen [<xref rid=""B1-biomolecules-14-01298"" ref-type=""bibr"">1</xref>]. Symptoms of HAE generally begin in childhood or young adulthood, often worsening around puberty [<xref rid=""B1-biomolecules-14-01298"" ref-type=""bibr"">1</xref>]. Clinically, HAE is characterized by the",1_11,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"Clinically, HAE is characterized by the sudden onset of swelling [<xref rid=""B7-biomolecules-14-01298"" ref-type=""bibr"">7</xref>]. Angioedema, a hallmark of HAE, presents as non-pitting edema in subcutaneous and submucosal tissues, commonly affecting the lips, face, neck, extremities, oral cavity, and larynx [<xref rid=""B1-biomolecules-14-01298"" ref-type=""bibr"">1</xref>,<xref rid=""B11-biomolecules-14-01298"" ref-type=""bibr"">11</xref>]. It is important to acknowledge the possibility of genital and intestinal",1_12,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"the possibility of genital and intestinal angioedema, as these sites are often overlooked in clinical assessments [<xref rid=""B1-biomolecules-14-01298"" ref-type=""bibr"">1</xref>,<xref rid=""B11-biomolecules-14-01298"" ref-type=""bibr"">11</xref>]. Patients typically experience recurrent episodes of swelling or abdominal pain and on occasion, a serpentine, non-itchy rash may appear [<xref rid=""B1-biomolecules-14-01298"" ref-type=""bibr"">1</xref>,<xref rid=""B12-biomolecules-14-01298"" ref-type=""bibr"">12</xref>,<xref",1_13,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"ref-type=""bibr"">12</xref>,<xref rid=""B13-biomolecules-14-01298"" ref-type=""bibr"">13</xref>,<xref rid=""B14-biomolecules-14-01298"" ref-type=""bibr"">14</xref>,<xref rid=""B15-biomolecules-14-01298"" ref-type=""bibr"">15</xref>,<xref rid=""B16-biomolecules-14-01298"" ref-type=""bibr"">16</xref>]. Most acute episodes of HAE resolve within one to several days [<xref rid=""B7-biomolecules-14-01298"" ref-type=""bibr"">7</xref>]. The most concerning complication is laryngeal edema, which can lead to breathing difficulties and",1_14,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"which can lead to breathing difficulties and asphyxiation, though such severe cases are relatively rare [<xref rid=""B17-biomolecules-14-01298"" ref-type=""bibr"">17</xref>,<xref rid=""B18-biomolecules-14-01298"" ref-type=""bibr"">18</xref>]. Recent advances in understanding the pathophysiology of HAE have led to the development of newer, targeted therapies for both acute management and long-term prevention. High-throughput omics-based technologies are also advancing rapidly, offering the potential for identifying",1_15,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"rapidly, offering the potential for identifying new candidate biomarkers, which could significantly improve diagnosis and enable a more personalized approach to prevention and treatment [<xref rid=""B10-biomolecules-14-01298"" ref-type=""bibr"">10</xref>]. However, keeping up with these evolving therapeutic options can be challenging for clinicians. This review will explore the pathophysiology, clinical manifestations, and diagnosis of HAE, as well as discuss potential biomarkers, therapeutic management",1_16,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"potential biomarkers, therapeutic management strategies, and prophylaxis options. Additionally, the review will emphasize the importance of screening family members of affected individuals, even if they are asymptomatic, to ensure early diagnosis and intervention. We conducted online research using Web of Science Core Collection, Medline (PubMed), ResearchGate, and Cochrane electronic databases for review articles written in English from the last 10 years, using keywords such as “hereditary angioedema”,",1_17,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"using keywords such as “hereditary angioedema”, “bradykinin”, “C1 inhibitor protein”, and “SERPING 1 gene”. Articles were selected based on their relevance to our study, excluding those without direct relevance. From the initial 1854 articles reviewed, we focused our analysis on 130 review articles published in English over the past 10 years (<xref rid=""biomolecules-14-01298-f001"" ref-type=""fig"">Figure 1</xref>). J. L. Milton first mentioned HAE in 1876 and in 1882, Quincke introduced the term",1_18,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"in 1876 and in 1882, Quincke introduced the term “angioneurotic edema” to describe the condition [<xref rid=""B19-biomolecules-14-01298"" ref-type=""bibr"">19</xref>,<xref rid=""B20-biomolecules-14-01298"" ref-type=""bibr"">20</xref>,<xref rid=""B21-biomolecules-14-01298"" ref-type=""bibr"">21</xref>]. The term “neurotic” was included because mental stress was observed to exacerbate the disease [<xref rid=""B19-biomolecules-14-01298"" ref-type=""bibr"">19</xref>,<xref rid=""B21-biomolecules-14-01298""",1_19,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"rid=""B21-biomolecules-14-01298"" ref-type=""bibr"">21</xref>]. In 1888, Sir William Osler provided a comprehensive description of HAE across five generations, highlighting the hereditary nature of the condition [<xref rid=""B19-biomolecules-14-01298"" ref-type=""bibr"">19</xref>,<xref rid=""B22-biomolecules-14-01298"" ref-type=""bibr"">22</xref>]. The biochemical basis of hereditary angioneurotic edema—specifically, the deficiency of C1-INH—was uncovered by Donaldson and Evans in 1963 [<xref",1_20,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"uncovered by Donaldson and Evans in 1963 [<xref rid=""B19-biomolecules-14-01298"" ref-type=""bibr"">19</xref>,<xref rid=""B23-biomolecules-14-01298"" ref-type=""bibr"">23</xref>]. Since then, substantial progress has been made in understanding the genetic basis, pathophysiology, clinical manifestations, and management of HAE, leading to a wealth of published research on the topic [<xref rid=""B19-biomolecules-14-01298"" ref-type=""bibr"">19</xref>]. HAE presents a complex challenge requiring a multifaceted approach to",1_21,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"challenge requiring a multifaceted approach to management. Advances in understanding the pathophysiology of C1 inhibitor deficiency have led to significant progress in treatment options. Biomarkers have the potential to improve diagnostic accuracy, facilitate personalized management, and support clinical trials in HAE. The advent of novel high-throughput techniques now enables non-targeted multi-omics analyses, allowing for the identification of a cohort of biomarkers for further in-depth research. The",1_22,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"of biomarkers for further in-depth research. The choice of therapy should be guided by factors including the frequency and severity of attacks, patient-specific considerations, and the potential for side effects. The development of targeted therapies, such as plasma-derived and recombinant C1 inhibitor concentrates, bradykinin receptor antagonists, and plasma kallikrein inhibitors, has revolutionized both acute and prophylactic care for HAE patients. Ongoing research continues to expand our options, with",1_23,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"research continues to expand our options, with emerging therapies promising further advancements in the management of HAE. Short-term prophylaxis effectively mitigates the risk of attacks during high-risk situations, while long-term prophylaxis options offer sustained protection against recurrent episodes. Despite the efficacy of these newer treatments, individual patient response and treatment tolerability remain critical factors in therapy selection. Overall, a personalized approach, combining acute",1_24,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"Overall, a personalized approach, combining acute management with appropriate prophylaxis and regular patient education, ensures optimal outcomes. Interdisciplinary collaboration among specialists is essential for effective disease management, improving patient quality of life, and reducing the burden of this challenging condition.",1_25,Unveiling the Complexities of Hereditary Angioedema,14 10 2024,,Hereditary_Angioedema
"Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) is a rare congenital disorder that causes episodic swelling. Decreased or dysfunctional C1INH, the key inhibitor of the kinin-kallikrein system, leads to increased plasma kallikrein activity and the resultant excessive bradykinin causes angioedema (<xref rid=""B1"" ref-type=""bibr"">1</xref>). The morbidity and decreased quality of life of",2_0,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"The morbidity and decreased quality of life of HAE-C1INH patients has motivated the increasing use of long-term prophylaxis (LTP) to prevent swelling attacks, when modern LTP agents became available a few years ago. The oral kallikrein antagonist berotralstat was approved in the United States and European Union in 2020 and 2021, respectively. The 2021 international HAE-C1INH guideline recommends berotralstat as a first-line therapy alongside plasma-derived C1 inhibitor (pd-C1INH) and lanadelumab (<xref",2_1,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"C1 inhibitor (pd-C1INH) and lanadelumab (<xref rid=""B2"" ref-type=""bibr"">2</xref>). Herein, we present a practical guide to aid the clinician in the optimal use of berotralstat in HAE-C1INH based on available data and the experience at the Angioedema Centers of Reference and Excellence (<xref rid=""B3"" ref-type=""bibr"">3</xref>) in Berlin, Germany and Edmonton, Canada. Berotralstat is an oral small molecule that specifically inhibits plasma kallikrein. It is administered once daily at a dose of 150 mg. In the",2_2,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"once daily at a dose of 150 mg. In the United States, a 110 mg dose is also available. It achieves a steady state plasma concentration in 6-12 days and has an elimination half-life of 93 hours (<xref rid=""B4"" ref-type=""bibr"">4</xref>). Administration with food does not impact the maximum serum concentration or total exposure of the medication (<xref rid=""B4"" ref-type=""bibr"">4</xref>). The efficacy of berotralstat was established in a double-blind, parallel-group study of 24 weeks duration (APEX-2). There",2_3,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"study of 24 weeks duration (APEX-2). There were n=121 subjects randomized 1:1:1 to placebo, berotralstat 150 mg daily, or berotralstat 110 mg daily, and there was a 44% and 30% reduction in attack frequency/month in the treatment versus placebo arm at the 150 and 110 mg doses, respectively (<xref rid=""B5"" ref-type=""bibr"">5</xref>). The subsequent extension studies showed persistent and perhaps increased efficacy over time, with the 150 mg arm achieving a 79% reduction in attack frequency compared to",2_4,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"a 79% reduction in attack frequency compared to baseline (<xref rid=""B6"" ref-type=""bibr"">6</xref>, <xref rid=""B7"" ref-type=""bibr"">7</xref>) after 6 months (n=21). Real-world evidence studies have confirmed these results in various countries (<xref rid=""B8"" ref-type=""bibr"">8</xref>–<xref rid=""B10"" ref-type=""bibr"">10</xref>). Berotralstat was generally well tolerated at both doses. There was one severe adverse event (SAE) in the 110-mg berotralstat and three SAEs in the placebo arm, none of which were",2_5,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"three SAEs in the placebo arm, none of which were classified as drug related (<xref rid=""B5"" ref-type=""bibr"">5</xref>). The most frequent side effects observed in APEX-2 were gastrointestinal (GI) symptoms (<italic toggle=""yes"">e.g.</italic>, abdominal discomfort, diarrhea). These were seen in 50% (20/40) of subjects receiving berotralstat 150 mg <italic toggle=""yes"">versus</italic> 36% (14/39) of subjects receiving placebo but tended to resolve over time. The GI symptoms can be mitigated by taking the",2_6,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"The GI symptoms can be mitigated by taking the medication with the largest meal of the day. Additionally, the graded introduction of berotralstat using the Berlin protocol, which involves starting with 1 tablet (150 mg) every third day and then increasing dosing frequency as tolerated to 1 tablet every other day and finally to 1 tablet daily, can improve tolerability (<xref rid=""B11"" ref-type=""bibr"">11</xref>). Some clinicians worry that GI upset may be misattributed to abdominal angioedema and result in",2_7,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"to abdominal angioedema and result in inappropriate use of on-demand therapy. But, in our experience, patients (including those who have and have not had previous abdominal episodes) are generally able to differentiate between these when given anticipatory guidance. Before initiating therapy with berotralstat, patients must be informed about the possibility of gastrointestinal side effects, but care should be taken not to overemphasize this point in order to avoid nocebo effects. Additionally, headache was",2_8,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"avoid nocebo effects. Additionally, headache was seen in 10.0% (4/40) of patients in the 150 mg arm of APEX-2 but also in 5.1% (2/39) of patients in the placebo arm. In our experience, it has not been a patient concern. QT interval prolongation was observed with berotralstat at doses 3-fold greater than that used clinically. At the approved dose of 150 mg daily berotralstat does not cause significant QT interval prolongation and electrocardiographic monitoring is not required. In APeX-2, one patient",2_9,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"is not required. In APeX-2, one patient discontinued therapy due to elevated liver enzymes in the context of prior therapy with attenuated androgens. However, no regular laboratory monitoring is needed according to the drug monograph (<xref rid=""B4"" ref-type=""bibr"">4</xref>) and we have not observed elevated liver enzymes in our patients. Berotralstat is metabolized in the liver by CYP2D6 and CYP3A4 and hence may increase the plasma concentration of concomitant medications also metabolized by these enzymes",2_10,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"medications also metabolized by these enzymes (<xref rid=""T1"" ref-type=""table"">",2_11,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
<bold>Table 1</bold>,2_12,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"</xref>) (<xref rid=""B4"" ref-type=""bibr"">4</xref>). In some instances, reducing the dose of an interacting medication may be helpful. For example, one author has combined amlodipine with berotralstat and reduced the dose of the former (amlodipine 10 mg to 5 mg daily) without any loss of blood pressure control. Patients using a statin also metabolized by CYP3A4 (<italic toggle=""yes"">e.g.</italic>, atorvastatin) can be switched to rosuvastatin, which is not a major CYP3A4 substrate (<xref rid=""B12""",2_13,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"is not a major CYP3A4 substrate (<xref rid=""B12"" ref-type=""bibr"">12</xref>) and thus does not interact with berotralstat. Given the potential increased risk of bleeding in patients taking the direct oral anticoagulants rivaroxaban and apixaban, switching patients to edoxaban or dabigatran prior to starting berotralstat is advisable. Berotralstat is also a P-glycoprotein (P-gp) substrate. Thus P-gp inducers (<italic toggle=""yes"">e.g.</italic>, rifampin, St. John’s wort) may decrease the serum concentration",2_14,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"John’s wort) may decrease the serum concentration of berotralstat and should be avoided. P-gp inhibitors (<italic toggle=""yes"">e.g.</italic>, carvedilol) could increase the plasma concentration of berotralstat and therefore the lower 110 mg dose of berotralstat should be used in such patients, if available. There is a paucity of data to guide clinicians on how to transition a patient from one LTP treatment to another. When switching to berotralstat, the main issues of concern are possible breakthrough",2_15,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"main issues of concern are possible breakthrough attacks during the transition period, heightened patient anxiety regarding the possibility of breakthrough attacks, and premature discontinuation of an effective treatment due to breakthrough attacks prior to the new drug taking effect. The possibility of breakthrough attacks is likely greatest when transitioning from pd-C1INH therapy due to its half-life (69 hours for subcutaneous pd-C1INH [Haegarda<sup>®</sup>/Berinert 2000 and 3000<sup>®</sup>] and 56",2_16,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"2000 and 3000<sup>®</sup>] and 56 hours for intravenous pd-C1INH [Cinryze<sup>®</sup>]). Since berotralstat achieves a plasma steady state within 2 weeks, it is reasonable to overlap it with pd-C1INH by up to 4 weeks (<xref rid=""B8"" ref-type=""bibr"">8</xref>). This could be extended when the Berlin protocol of graded introduction is used to ensure that the first weeks of daily berotralstat are covered by pd-C1INH. The half-life of lanadelumab is 2-3 weeks, so if daily berotralstat is started immediately",2_17,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"so if daily berotralstat is started immediately after the last dose of lanadelumab, further overlap is unlikely to be needed. Though the mechanism of action of both lanadelumab and berotralstat is plasma kallikrein inhibition, they bind to kallikrein at different locations [lanadelumab binds to the surface of the enzyme and obstructs substrate access to the active site (<xref rid=""B14"" ref-type=""bibr"">14</xref>) whereas berotralstat binds deep within the active site (<xref rid=""B15""",2_18,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"deep within the active site (<xref rid=""B15"" ref-type=""bibr"">15</xref>)], and patients hence may have different responses to each drug. Failure to respond to one should, therefore, not preclude the use of the other. When transitioning from attenuated androgen therapy to berotralstat, caution is required given the risk of liver enzyme elevation in a minority of patients. This was seen in those who stopped androgens <14 days before starting berotralstat and may be due to abrupt discontinuation of androgens",2_19,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"may be due to abrupt discontinuation of androgens and/or latent hepatoxic effects of androgens that emerge if berotralstat is started too soon after androgen discontinuation (<xref rid=""B16"" ref-type=""bibr"">16</xref>). We thus suggest a gradual tapering of androgen therapy and a washout period of 14 days prior to starting berotralstat. The washout phase of androgens and the time to steady state of berotralstat can be covered with temporary pd-C1INH until the full efficacy of berotralstat has been reached.",2_20,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"full efficacy of berotralstat has been reached. In jurisdictions where this is not feasible due to logistical or cost considerations, co-administration of berotralstat and androgen therapy whilst gradually reducing the androgen dose (and monitoring liver enzymes) could be considered as part of a shared decision-making process. In clinical practice, scenarios other than just the smoothest possible transition from one long-term prophylaxis to another are also conceivable. The interruption of long-term",2_21,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"also conceivable. The interruption of long-term prophylaxis (and temporary on-demand therapy alone) can be used to re-establish the indication for continuing long-term prophylaxis with another therapy. Ultimately, switching long-term prophylaxis therapies is a highly individualized decision in which the patient’s values and preferences should play an important role. Berotralstat is an effective treatment and provides patients with an oral LTP option. GI side effects occur in a minority of patients, can be",2_22,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"effects occur in a minority of patients, can be mitigated by graded introduction, and tend to resolve over time. Berotralstat may increase the plasma concentrations of certain concomitant medications, and dose reductions of those medicines may be needed. When switching to berotralstat from pd-C1INH, a treatment overlap period could help prevent breakthrough angioedema episodes during the transition period. Prospective studies to help establish optimal transition protocols are warranted.",2_23,Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians,08 10 2024,,Hereditary_Angioedema
"Early Diagnosis of Hereditary Angioedema in Japan Based on a US Medical Dataset: Algorithm Development and Validation The rare genetic disease hereditary angioedema (HAE) induces acute attacks of swelling in various regions of the body, including the face, hands, arms, legs, abdomen, genitals, buttocks, and throat. Gastrointestinal disturbances such as abdominal pain, nausea, and vomiting are frequently associated with edema. Laryngeal edema is rare, even though more than half of the patients with HAE",3_0,Early Diagnosis of Hereditary Angioedema in Japan Based on a US Medical Dataset: Algorithm Development and Validation,2024,,Hereditary_Angioedema
"though more than half of the patients with HAE encounter this life-threatening condition [<xref rid=""ref1"" ref-type=""bibr"">1</xref>]. Its global prevalence is estimated to be 1 in 50,000 people, with no reported bias among different ethnic groups [<xref rid=""ref2"" ref-type=""bibr"">2</xref>]. In Japan, about 1 in 250,000 people are diagnosed with HAE, which suggests that only 20% of potential HAE cases are identified [<xref rid=""ref3"" ref-type=""bibr"">3</xref>], suggesting that many patients with HAE remain",3_1,Early Diagnosis of Hereditary Angioedema in Japan Based on a US Medical Dataset: Algorithm Development and Validation,2024,,Hereditary_Angioedema
"suggesting that many patients with HAE remain undiagnosed in Japan. Furthermore, in Japan, the mean duration from the first symptoms to diagnosis is 15.6 years [<xref rid=""ref4"" ref-type=""bibr"">4</xref>], which is longer than that in Europe and the United States [<xref rid=""ref5"" ref-type=""bibr"">5</xref>,<xref rid=""ref6"" ref-type=""bibr"">6</xref>]. Early detection of undiagnosed patients is critical for effective treatment of HAE. To overcome this situation in Japan, the Diagnostic Consortium to Advance the",3_2,Early Diagnosis of Hereditary Angioedema in Japan Based on a US Medical Dataset: Algorithm Development and Validation,2024,,Hereditary_Angioedema
"Japan, the Diagnostic Consortium to Advance the Ecosystem for Hereditary Angioedema (DISCOVERY) was established in 2021 [<xref rid=""ref7"" ref-type=""bibr"">7</xref>]; it aimed to identify patients with undiagnosed HAE and provide them with appropriate treatment as early as possible. In this study, we aimed to develop an artificial intelligence (AI) model that can detect suspected patients with HAE using medical history data (claims and electronic medical records [EMRs]) in the United States. We then sought",3_3,Early Diagnosis of Hereditary Angioedema in Japan Based on a US Medical Dataset: Algorithm Development and Validation,2024,,Hereditary_Angioedema
"[EMRs]) in the United States. We then sought to validate the model’s performance in detecting HAE cases. In addition, we conducted a pilot study at Kyoto University Hospital (KUHP) using the EMR data to verify the model’s applicability to medical data obtained from the Japanese population. The main objective of this study was to verify whether this model could identify patients with a history of HAE or related diseases.",3_4,Early Diagnosis of Hereditary Angioedema in Japan Based on a US Medical Dataset: Algorithm Development and Validation,2024,,Hereditary_Angioedema
"A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System Hereditary angioedema (HAE) due to C1 inhibitor (C1-INH) deficiency is an ultra-rare disease that affects 1 in 67,000 people in the world. It is an autosomal dominant inherited disease (<xref rid=""ref1"" ref-type=""bibr"">1</xref>), mostly resulting in decreased production of C1-INH (type I) and/or functional activity of C1-INH (type II), leading to excessive bradykinin",4_0,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"C1-INH (type II), leading to excessive bradykinin production (<xref rid=""ref2"" ref-type=""bibr"">2</xref>). Although HAE is a genetic disease, approximately 25% of the cases are C1-INH <italic toggle=""yes"">de novo</italic> gene mutations (<xref rid=""ref3"" ref-type=""bibr"">3</xref>, <xref rid=""ref4"" ref-type=""bibr"">4</xref>). All types of HAE have similar clinical characteristics and may be triggered by emotional stress, trauma, surgical procedures, infection, and inflammation (<xref rid=""ref5""",4_1,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"infection, and inflammation (<xref rid=""ref5"" ref-type=""bibr"">5</xref>). The manifestations, also called attacks, are based on subcutaneous and submucosal edema due to the bradykinin’s excessive production, usually affecting the face, tongue, body extremities (hands and feet), and genitals (<xref rid=""ref6"" ref-type=""bibr"">6</xref>). The attacks may be triggered by factors such as stress or trauma or no apparent reason and can last from 2 to 5 days without treatment. Laryngeal edema might be present,",4_2,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"treatment. Laryngeal edema might be present, resulting in asphyxia with a high risk of death if not properly managed (<xref rid=""ref7"" ref-type=""bibr"">7</xref>). In the gastrointestinal tract, it generates symptoms such as transient edema of the intestinal walls, partial or total intestinal obstruction, and/or accumulation of fluid in the abdominal cavity (<xref rid=""ref8"" ref-type=""bibr"">8</xref>). HAE-C1-INH types I and II can be diagnosed by measuring serum complement levels including C4 and antigenic",4_3,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"complement levels including C4 and antigenic and functional levels of C1-INH. The clinical diagnosis of HAE-C1-INH is usually based on the appearance of typical clinical manifestations of the disease, such as non-inflammatory subcutaneous angioedema lasting more than 12 h, abdominal pain of undefined organic etiology lasting more than 6 h, swellings not associated with wheals and which do not improve with anti-histaminergic drugs, and recurrent laryngeal edema (<xref rid=""ref3"" ref-type=""bibr"">3</xref>).",4_4,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"(<xref rid=""ref3"" ref-type=""bibr"">3</xref>). The main differential diagnoses of HAE are the other types of angioedema, especially those with chronic or recurrent presentation. The most frequent type of recurrent angioedema is histaminergic, which is usually associated with wheals and can be induced or exacerbated using non-steroidal anti-inflammatory drugs (NSAIDs) (<xref rid=""ref3"" ref-type=""bibr"">3</xref>). The broad and unspecific disease symptoms and unawareness of this rare disease by the treating",4_5,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"unawareness of this rare disease by the treating physician result in long periods of delayed diagnosis and misdiagnosis, leading to mistreatment (<xref rid=""ref9"" ref-type=""bibr"">9</xref>, <xref rid=""ref10"" ref-type=""bibr"">10</xref>). The long time elapsed between the first symptoms and diagnosis and the misdiagnoses is multifactorial (<xref rid=""ref11"" ref-type=""bibr"">11</xref>). Reasons for diagnostic delay include underrecognized cases from the doctor or even lack of knowledge about the disease, and",4_6,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"or even lack of knowledge about the disease, and also the similarity of symptoms with other diseases (<xref rid=""ref12"" ref-type=""bibr"">12</xref>). An international study with HAE-C1-INH patients showed that patients visited an average of 4.4 physicians before the correct diagnosis and took a mean of 8.3 years for diagnosis (<xref rid=""ref13"" ref-type=""bibr"">13</xref>, <xref rid=""ref14"" ref-type=""bibr"">14</xref>), but a Brazilian study found almost double the time, approximately 14–18 years between the",4_7,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"the time, approximately 14–18 years between the initial manifestation and the diagnosis (<xref rid=""ref11"" ref-type=""bibr"">11</xref>, <xref rid=""ref15"" ref-type=""bibr"">15</xref>). Another study also reported a delay in the HEA diagnosis, even in those patients with a familial history (<xref rid=""ref10"" ref-type=""bibr"">10</xref>). In this descriptive, cross-sectional study with prospective data collection of 138 Brazilian patients with HAE, the diagnosis delay was 17.7 ± 12.6 years (<xref rid=""ref10""",4_8,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"delay was 17.7 ± 12.6 years (<xref rid=""ref10"" ref-type=""bibr"">10</xref>). The management of HAE-C1-INH is based on acute attacks and prophylactic treatment (long- or short-term use) aiming to prevent the attack occurrence. The HAE-C1-INH attack treatment is focused on either preventing or treating them by using prophylactic treatment. Acute attacks may be treated with efficient drugs: the replacement of the lacking protein with plasma-derived human C1-INH (pdC1-INH) or icatibant acetate. Attenuated",4_9,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"(pdC1-INH) or icatibant acetate. Attenuated androgens, antifibrinolytics, and pdC1-INH are the most used drugs for long-term prophylactic treatment, although new drugs have been developed in recent years. Conventional treatment for allergic angioedema with adrenaline, antihistamine, and glucocorticoids has not been efficacious as the mechanism is bradykinin-mediated. Since 2010, the specific treatment is incorporated into the Clinical Protocols and Therapeutic Guidelines (PCDT [<italic",4_10,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"and Therapeutic Guidelines (PCDT [<italic toggle=""yes"">Protocolos Clínicos e Diretrizes Terapêuticas</italic>]) of the disease and includes danazol for long-term prophylaxis and fresh frozen plasma for acute attacks (<xref rid=""ref1"" ref-type=""bibr"">1</xref>, <xref rid=""ref16"" ref-type=""bibr"">16</xref>, <xref rid=""ref17"" ref-type=""bibr"">17</xref>). Given the rarity of the disease, real-world evidence (RWE) on the clinical management of patients with HAE-C1-INH is scarce. RWE is the analysis of real-world",4_11,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"is scarce. RWE is the analysis of real-world data (RWD) that generates evidence related to patient health status and/or the delivery of healthcare. This evidence can assist public managers in making informed decisions about the incorporation, exclusion, or change of new medicines, products, and procedures, as well as in the preparation and review of PCDT (<xref rid=""ref18"" ref-type=""bibr"">18</xref>). Considering the lack of information on the clinical management of Brazilian patients with HAE, this study",4_12,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"of Brazilian patients with HAE, this study aims to identify and characterize patients with HAE-C1-INH that used danazol prophylactic treatment in the Brazilian Public Healthcare System (<italic toggle=""yes"">Sistema Único de Saúde</italic> [SUS]).   This database study of the ultra-rare disease, HAE, conducted from January 2011 until December 2021 is the first of its kind to describe the characteristics of patients with HAE-C1-INH treated with danazol within the SUS and yielded interesting findings. During",4_13,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"the SUS and yielded interesting findings. During the follow-up period, our study included 799 patients with a mean age at danazol initiation of 40 years (<xref rid=""ref16"" ref-type=""bibr"">16</xref>). The number of patients with HAE showed a similar distribution over these 10-year period analyzed with the highest number of patients in 2015 (<italic toggle=""yes"">n</italic> = 509) and 2016 (<italic toggle=""yes"">n</italic> = 480). The prevalence of patients with HAE throughout the calendar years showed a",4_14,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"with HAE throughout the calendar years showed a similar distribution and the mean prevalence was approximately 401 patients. Approximately 12% of the patients included in the study had at least one attack per year. In addition, from those patients who had attacks, approximately 54% of the patients had at least one hospital admission with HAE-related ICD-10 codes with a mean hospitalization length of 5 (<xref rid=""ref8"" ref-type=""bibr"">8</xref>) days. Interestingly, the number of patients with attacks",4_15,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"the number of patients with attacks decreased over the years, while the proportion of patients with any HAE-related hospital admission seems to increase over the years. The states with the highest concentration of patients identified with HAE and treated with danazol were São Paulo, Minas Gerais, and Paraná. Indeed, these regions reflect one of the country’s highest population densities, but the cases of HAE found seem not equivalent to the demographic density. Probably, the higher number of patients in",4_16,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"Probably, the higher number of patients in the Southeast and South regions might be related to the fact these regions concentrated the higher number of specialized centers in the country. According to the ABRANGHE, only 3% of patients registered as HAE were located in the North and less than 8% in the Midwest region of Brazil (<xref rid=""ref20"" ref-type=""bibr"">20</xref>). The treatment strategy involving prophylaxis drugs to reduce HAE-related morbidity and mortality is mostly related to laryngeal",4_17,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"and mortality is mostly related to laryngeal angioedema. This type of attacks can be managed following local anaphylaxis which commonly included intubation or cricothyrotomy/tracheotomy (<xref rid=""ref21"" ref-type=""bibr"">21</xref>). Despite the use of danazol, our study showed that 2.8% of the patients had a tracheostomy and 4.7% of the cases had anaphylactic shock treatment, which is directly related to attacks in upper airways. A Chinese study found that 9 of 43 patients had tracheostomy during an upper",4_18,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"9 of 43 patients had tracheostomy during an upper airway episode (<xref rid=""ref22"" ref-type=""bibr"">22</xref>). Although the understanding of the pathophysiology of the disease has led to the launch of new treatments (<xref rid=""ref23"" ref-type=""bibr"">23</xref>), in Brazil the access to novel agents, particularly in the public setting, is still restricted. International guidelines preconize the use of C1-INH concentrate and kallikrein inhibitors as the first-line therapy aiming to reduce the frequency and",4_19,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"therapy aiming to reduce the frequency and severity of the attacks (<xref rid=""ref17"" ref-type=""bibr"">17</xref>). However, these drugs are not currently available in the Brazilian public setting. Up to now, Danazol is the only drug available in SUS for long-term prophylactic treatment (<xref rid=""ref16"" ref-type=""bibr"">16</xref>), and fresh frozen plasma is used for on-demand treatment predominantly in a hospital setting. On-demand therapy seems not to be used frequently by HAE treaters (<xref rid=""ref24""",4_20,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"frequently by HAE treaters (<xref rid=""ref24"" ref-type=""bibr"">24</xref>), in agreement with our results, in which less than 1% of the HAE cohort had at least one claim of fresh frozen plasma over the years. Frozen plasma can be used if specific therapies for HAE-C1-INH are not available. Although fresh frozen plasma treatment can be effective, it is also potentially dangerous to the patient. This is because high-molecular weight kininogen in the presence of other enzymes activated during the attack might",4_21,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"other enzymes activated during the attack might raise the levels of bradykinin and worsen the attack (<xref rid=""ref25"" ref-type=""bibr"">25</xref>). Therefore, the study adopts the use of danazol as an eligibility criterion to enhance the accuracy of identifying HAE patients as danazol is the only drug available in the SUS for long-term treatment (<xref rid=""ref16"" ref-type=""bibr"">16</xref>). In addition, the study sought to further understand the impact of danazol use on the frequency of attacks and the",4_22,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"danazol use on the frequency of attacks and the utilization of healthcare resources. It is not possible to assume that patients who were treated with danazol continued to use it over the years. However, we found that although there was a decrease in trend in the number of patients with at least one claim of danazol over the years, 43–80% of them were using danazol over the years (<xref rid=""tab1"" ref-type=""table"">Table 1</xref>), This allows presuming that most of patients were under prophylactic treatment",4_23,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"of patients were under prophylactic treatment in the present study, since there is no guarantee that patient would continue the treatment throughout the study period. Adding to this, <xref rid=""tab2"" ref-type=""table"">Table 2</xref> shows the ratio claims for prophylactic and on-demand treatment for patients with HAE. The number of claims of prophylactic treatment (danazol) per patient per year varies from 5.35 to 9.84, and the number of claims per patient per year of on-demand treatment (plasma",4_24,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"patient per year of on-demand treatment (plasma transfusion) varies from 1 to 3.67 claims per patient, indicating that although there is variation in the number of claims per patient, they are receiving some treatment (<xref rid=""tab2"" ref-type=""table"">Table 2</xref>). The symptoms of HAE are characterized by recurrent episodes of swelling and attacks that are disabling and potentially life-threatening, and are unpredictable in terms of frequency, severity, and local (<xref rid=""ref6""",4_25,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"frequency, severity, and local (<xref rid=""ref6"" ref-type=""bibr"">6</xref>). A Brazilian cohort study with 98 HAE patients showed that the main sites affected were extremities (98%), face (88%), abdominal (88%), genitalia (57%), larynx (47%), and tongue (37%) (<xref rid=""ref11"" ref-type=""bibr"">11</xref>). This study corroborates findings as our study showed that attacks were more peripheral (47%), followed by abdominal attacks (39%), facial attacks (6.3%), and laryngeal attacks (4.8%). Episodes involving",4_26,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"and laryngeal attacks (4.8%). Episodes involving the intestinal tract cause severe abdominal pain, and as shown by previous studies, approximately 25% of undiagnosed patients might be submitted to an unnecessary surgery, such as abdominal exploratory surgery (<xref rid=""ref13"" ref-type=""bibr"">13</xref>, <xref rid=""ref14"" ref-type=""bibr"">14</xref>). Symptoms involving upper airway swelling are the most dangerous episode of HAE due to the risk of asphyxia (<xref rid=""ref26"" ref-type=""bibr"">26</xref>) that",4_27,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"rid=""ref26"" ref-type=""bibr"">26</xref>) that might affect approximately 25 to 40% of patients not properly treated (<xref rid=""ref11"" ref-type=""bibr"">11</xref>). The present study reported only resources linked to angioedema attacks and the disease itself. Indeed, D84.1 ICD-10 code was not included as attack in the present study to avoid underestimation of attacks since the ICD-10 code was applied as eligibility criteria. We found that the prevalence of patients who had at least one attack during the period",4_28,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"who had at least one attack during the period analyzed was approximately 30% and the annual incidence was approximately 25% per each calendar year. In general, we identified 253 patients with at least one attack with most of them (48%) presenting only one attack within the 11-year study period, and among those patients with attacks, approximately 10% had 8 or more attacks per patient. Although almost half of the patients had only one attack, we found a high variability across patients, ranging from 1 to",4_29,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"variability across patients, ranging from 1 to 126 attacks. A multinational post-marketing study of icatibant with 42 patients from Brazil found a total of 228 icatibant-treated attacks over the course of an average of 4 years of follow-up, and a 1-year prospective cost analysis and survival analysis found that in addition to the significant reduction on attack duration after icatibant and pdC1-INH use, an average of 11 attacks per year were reported (<xref rid=""ref27"" ref-type=""bibr"">27</xref>). A survey",4_30,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"rid=""ref27"" ref-type=""bibr"">27</xref>). A survey study conducted on HAE patients in the United States in 2007 showed that patients experienced an average of 27 swelling attacks per year, most of which were of moderate-to-severe intensity (<xref rid=""ref9"" ref-type=""bibr"">9</xref>). The discrepancy in the outcomes could be explained by the inherent limitation on the database used and the proxy considered as attacks in this study. The types of procedures available on SIGTAP are limited, and the lack of",4_31,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"available on SIGTAP are limited, and the lack of clinical characteristics (signs and symptoms) prevents the capture of mild swelling attacks and/or all cases of attacks, which probably underestimated our outcomes. Data from this study were captured from attacks that generated the use of health resources, as recorded by DATASUS. Even with these limitations, it is possible to note the considerable number of attacks presented by HAE patients. HCRU outcomes of interest were based on hospitalizations, emergency",4_32,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"were based on hospitalizations, emergency department visits, and ambulatory visits. Although it is known that the disease has an important indirect use of resources and a substantial impact on work production due to work/school absenteeism and productivity impairment during and in between attacks (<xref rid=""ref28"" ref-type=""bibr"">28</xref>), this aspect was not assessed and considered in the present study. HCRU was classified as HAE-related as identified by ICD-10 codes or procedures related to the",4_33,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"by ICD-10 codes or procedures related to the disease. Among HAE patients treated with danazol with at least one attack (<italic toggle=""yes"">n</italic> = 253), it was identified that HCRU was higher in hospital settings compared to outpatient settings when considering only resources used to manage attacks. A total of 188 ambulatorial visits and 491 hospital admissions were identified, which represents a mean of 2 and 3 visits per patient over the study period, respectively. Of the 137 patients with at",4_34,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"period, respectively. Of the 137 patients with at least one hospital admission, nearly 15% had 6 or more hospital admissions and 14% of the patients had at least one ICU admission, demonstrating how serious were the attacks and how much the patients demanded from complex health assistance and hospitalization. The most reported procedures across all the years were plasma transfusion, treatment of other diseases of the digestive tract, and tracheostomy. A cross-sectional study from a C1-INH-HAE cohort in",4_35,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"cross-sectional study from a C1-INH-HAE cohort in Brazil from 2010 to 2020 showed that approximately 60% of patients diagnosed with HAE were hospitalized at the <italic toggle=""yes"">Hospital das Clínicas</italic> of the School of Medicine University of São Paulo, and 30% had an ICU admission (<xref rid=""ref11"" ref-type=""bibr"">11</xref>). An international survey with 242 HAE patients from different countries who have had at least one attack in the last 2 years found that almost all patients (97%) reported",4_36,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"found that almost all patients (97%) reported regularly seeing a medical professional to manage the disease in the last year, 37% at least one HAE-related emergency room visit, 19% a hospitalization, and 18% an urgent care visit (<xref rid=""ref29"" ref-type=""bibr"">29</xref>). Similarly, in the present study, we found that approximately 20% of the HAE patients who had attacks had at least one HAE-related hospital admission 1 year after danazol initiation. In subsequent years, the proportion of patients who",4_37,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"subsequent years, the proportion of patients who experienced attack was slightly higher, ranging from 22 to 32% depending on the year. Considering HAE-related hospitalizations, the proportion of patients who had at least one admission ranged from 23 to 56% depending on the year after danazol initiation. In the present study, the proportion of patients with a record of ICU admission ranged from 2 to 8% when considered HAE-related ICU admissions. Although all patients had at least one ambulatory visit in the",4_38,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"patients had at least one ambulatory visit in the first year after danazol, only 15% of the ambulatory care were HAE-related in the first year, with lower proportions across the following years. Several patients with low-to-moderate symptoms (acute swelling) that search for ambulatory assistance might not be detected in the database due to the limitation on registry signs and symptoms and their ICD-10 code related to these types of clinical manifestations. The 2015–2016 Nationwide Emergency Department",4_39,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"The 2015–2016 Nationwide Emergency Department Sample from the United States involving HAE patients shows that 8.2% of HAE patients were hospitalized (<xref rid=""ref24"" ref-type=""bibr"">24</xref>). A real-world study with HAE patients in the United States between 2006 and 2014 under prophylactic or on-demand treatment showed that 15% of patients experienced one or more hospitalizations, and 52% had one or more emergency visits during the study period (<xref rid=""ref30"" ref-type=""bibr"">30</xref>) and other",4_40,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"rid=""ref30"" ref-type=""bibr"">30</xref>) and other evidence showed that HAE accounts for 15,000–30,000 emergency room visits each year in the United States (<xref rid=""ref11"" ref-type=""bibr"">11</xref>). These numbers account for diagnosed patients and could be even higher. Previous studies showed that HAE abdominal pain presents similarly to and is often mistaken for appendicitis, bowel obstruction, or other gastrointestinal diseases resulting in unnecessary image procedures and even surgeries, such as",4_41,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"image procedures and even surgeries, such as appendicectomy, cholecystectomy, and hysterectomy (<xref rid=""ref24"" ref-type=""bibr"">24</xref>). A case report study in Japan mentioned that a woman had a medical history of abdominal attacks at the hospital 2 or 3 times a year with a misdiagnosis of enteritis and endometriosis. The same women also presented 3 episodes of life-threatening laryngeal edema, 2 of which were unsuccessfully treated with steroids and antihistamines (<xref rid=""ref31""",4_42,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"steroids and antihistamines (<xref rid=""ref31"" ref-type=""bibr"">31</xref>). In one study developed in Brazil, 50% of patients had at least one episode of laryngeal edema, and almost 27% were mistakenly submitted to laparotomy (<xref rid=""ref11"" ref-type=""bibr"">11</xref>). Considering these aspects, we may hypothesize that if the proper diagnosis was made, the hospitalization and HCRU would be higher in our study. This database study is the first of its kind and the developed strategy applied to find",4_43,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"kind and the developed strategy applied to find patients with HAE who use danazol for long-term prophylaxis allowed us to describe the characteristics of patients in the SUS and also identify HCRU outcomes of interest such as hospitalizations, inpatient, and outpatient settings. This study also allowed us to assess the frequency of attacks and severe attacks among those who needed to use resources from public institutions conditioned to inpatient and outpatient settings. Our findings also highlighted that",4_44,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"settings. Our findings also highlighted that even with limitations due to the study design, we could capture the attack’s prevalence of more than 30 and 4% of life-threatening severe attack that included asphyxia and edema laryngeal in addition to surgeries and other invasive procedures performed due to attacks. The important number of attacks, hospitalizations, and general resource uses highlights the necessity to increase awareness of new strategies and accurate approaches to treat HAE patients.",4_45,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"and accurate approaches to treat HAE patients. Therefore, our findings are important indicators that our health system and guidelines need to be revised and improved to properly diagnose, treat, and assist patients with HAE. The original contributions presented in the study are included in the article/<xref rid=""SM1"" ref-type=""supplementary-material"">Supplementary material</xref>, further inquiries can be directed to the corresponding author. Ethical approval and written informed consent was not required",4_46,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"and written informed consent was not required for study that only use publicly and anonymized secondary database in accordance with the local legislation and institutional requirements. AR: Conceptualization, Data curation, Formal analysis, Writing – original draft, Investigation, Methodology, Project administration, Resources, Software, Visualization. SS: Conceptualization, Formal analysis, Writing – original draft, Data curation, Investigation, Methodology, Resources, Software, Visualization. RP:",4_47,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"Resources, Software, Visualization. RP: Conceptualization, Writing – review & editing, Funding acquisition, Supervision. JS: Conceptualization, Writing – review & editing, Funding acquisition, Supervision. FC: Conceptualization, Writing – review & editing, Funding acquisition, Project administration, Supervision. TR: Data curation, Formal analysis, Conceptualization, Writing – review & editing, Investigation, Methodology, Resources. SV: Formal analysis, Conceptualization, Writing – review & editing, Data",4_48,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"Writing – review & editing, Data curation, Methodology, Project administration, Resources, Visualization.",4_49,A real-world study of hereditary angioedema patients due to C1 inhibitor deficiency treated with danazol in the Brazilian Public Health System,06 9 2024,,Hereditary_Angioedema
"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema Hereditary angioedema (HAE) is a rare and life-threatening disorder distinguished by recurrent episodes of angioedema that primarily affect subcutaneous or mucosal tissues. HAE exhibits spontaneous resolution with a period of 3–5 days and displays inherent self-recovery properties [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. The occurrence of edema in critical regions",5_0,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"The occurrence of edema in critical regions of HAE always manifests in the face, throat, genital, or peripheral abdomen, posing significant risks and potentially leading to fatalities in up to 28% of affected individuals [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Various pathogenic genes associated with HAE have been reported, including Serine Protease Inhibitor G1 (<italic toggle=""yes"">SERPING1</italic>), Factor XII (<italic toggle=""yes"">F12</italic>), Plasminogen (<italic toggle=""yes"">PLG</italic>),",5_1,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"Plasminogen (<italic toggle=""yes"">PLG</italic>), myoferlin gene mutation (<italic toggle=""yes"">MYOF</italic>), kininogen-1 (<italic toggle=""yes"">KNG1</italic>), heparan sulfate-glucosamine 3-O-sulfotransferase 6 (<italic toggle=""yes"">HS3ST6</italic>), and Angiopoietin 1 (<italic toggle=""yes"">ANGPT 1</italic>) [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Notely, <italic toggle=""yes"">SERPING1</italic> has garnered significant attention, as approximately 85% of HAE patients exhibit <italic",5_2,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"approximately 85% of HAE patients exhibit <italic toggle=""yes"">SERPING1</italic> gene mutations [<xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR5"">5</xref>]. As a member of the serine protease inhibitor superfamily, CI-INH, encoded by <italic toggle=""yes"">SERPING1</italic>, is the only complement inhibitor and has a direct effect on the occurrence of HAE [<xref ref-type=""bibr"" rid=""CR6"">6</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Clinical observations indicate that",5_3,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"Clinical observations indicate that approximately 40% of the normal secretion of C1-INH is sufficient to maintain the stability of the complement system [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. However, when C1-INH secretion falls below 30% [<xref ref-type=""bibr"" rid=""CR9"">9</xref>–<xref ref-type=""bibr"" rid=""CR11"">11</xref>], complement disorder occurs. Recent research has identified three reasons for the insufficient secretion of C1-INH. Firstly, the coexistence of normal and mutant C1-INH proteins",5_4,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"coexistence of normal and mutant C1-INH proteins leads to inadequate secretion of C1-INH [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. Secondly, the secretion of mutant C1-INH is accompanied by an additional oligosaccharide [<xref ref-type=""bibr"" rid=""CR13"">13</xref>] disrupting its original function. Alternatively, certain mutants induce C1-INH polymerization in vitro, rendering it incapable of fulfilling its intended role [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. The gradual decline in C1-INH",5_5,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"The gradual decline in C1-INH secretion over a prolonged period, ultimately leads to the manifestation of HAE disease primarily. Therefore, studying the function of SERPING1 gene, particularly the C1-INH protein, may also be one of the best entry points for exploring the occurrence of HAE. In this study, a new <italic toggle=""yes"">SERPING1</italic> gene mutation was found in the previously collected HAE family, and the accumulation of C1-INH protein in cells caused by the mutation and its effect on cell",5_6,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"caused by the mutation and its effect on cell homeostasis was clarified by cell experiments, which is intended to find a new marker for early diagnosis and treatment of HAE.   HAE is a rare hereditary disease primarily attributed to abnormal C1-INH concentration or function resulting from genetic variation in the <italic toggle=""yes"">SERPING1</italic> gene. To date, over 500 variants of the <italic toggle=""yes"">SERPING1</italic> gene associated with HAE have been identified, although their underlying",5_7,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"have been identified, although their underlying mechanisms remain unclear. This study presented the discovery of a novel HAE pathogenic mutation in clinically diagnosed HAE patients, c.708T > G (p. Phe236Leu), which has not been previously reported. Additionally, the study revealed that the c.708T > G mutation shares similarities with c.550G > A and c.566C > A mutations, leading to the accumulation of mutant C1-INH in the endoplasmic reticulum, activation of GRP75, and mediation of calcium overload,",5_8,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"of GRP75, and mediation of calcium overload, mitochondrial damage, and eventually apoptosis (Fig. <xref rid=""Fig6"" ref-type=""fig"">6</xref>D, draw with Biorender, agreement number: JC262J2A8I). In this study, five patients with HAE exhibited typical clinical manifestations and family history and were diagnosed strictly following the international WAO/EAAC1 management guidelines. However, in detecting C1-INH and C4 in patients, the plasma C1-INH and C4 levels in some patients (III-1, III-6, and IV-1) were",5_9,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"in some patients (III-1, III-6, and IV-1) were not lower than those of normal subjects. The analysis of the reasons may be due to the particularity and unpredictability of HAE. As mentioned before, we collected blood samples from HAE families at the same time but not during the acute onset period, and there were significant differences among patients and normal in this HAE family (gender, living area, lifestyle habits, age of onset, and history of medication). The levels of C1-INH and/or C4 are also",5_10,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"The levels of C1-INH and/or C4 are also important reactants in the acute phase, and in the case of infection or inflammation, both the levels of C1-INH and C4 could be altered a lot. When some patients have a history of chronic diseases, colds, and other symptoms, the secretion of immune factors or C1-INH and C4 in the patient’s body may be affected by drugs and inflammatory signals, leading to corresponding changes [<xref ref-type=""bibr"" rid=""CR24"">24</xref>]. In this HAE family, patients have an age span",5_11,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"In this HAE family, patients have an age span of over 30 years and with entirely different long-term chronic inflammation-related diseases (bronchitis pathological myopia, etc.). The proband in this study was previously diagnosed with HAE several years ago and had a prolonged record of using multiple medications to avoid HAE (Danazol). At the same time, patients (III-1, III-6 and III-7, III-11, etc.) and normal (III-3 and III-4) also have different histories of long-term use of different types of drugs",5_12,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"of long-term use of different types of drugs [<xref ref-type=""bibr"" rid=""CR24"">24</xref>]. The administration of different drugs can result in alterations in patient detection indicators. Therefore, in the absence of HAE disease, C1-INH and/or C4 expression is exceptionally prone to various situations. Our results and multiple literature reports mentioned earlier have revealed individual and temporal differences in the levels of C1 INH and C4 in the plasma of different patients under various states [<xref",5_13,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"of different patients under various states [<xref ref-type=""bibr"" rid=""CR15"">15</xref>–<xref ref-type=""bibr"" rid=""CR19"">19</xref>]. Therefore, by solely examining the levels of peripheral blood C1-INH and C4, HAE patients may mistakenly perceive them as “normal”, ultimately leading to a missed diagnosis or delayed diagnosis. Based on our findings and previous literature, we can conclude that the assessment of HAE status based on peripheral blood C1 INH and C4 levels is not entirely reliable. Furthermore,",5_14,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"C4 levels is not entirely reliable. Furthermore, the determination of complement indexes in blood often encounters certain ambiguities. Recent research has indicated that the inclusion of functional diagnosis of complement C1 enhances the reliability of detection [<xref ref-type=""bibr"" rid=""CR25"">25</xref>, <xref ref-type=""bibr"" rid=""CR26"">26</xref>]. In short, the clinical presentations of HAE are intricate and varied, and the existing diagnostic markers should not be solely relied upon for accurate",5_15,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"should not be solely relied upon for accurate disease identification, particularly in patients with a complex medication history [<xref ref-type=""bibr"" rid=""CR27"">27</xref>]. Consequently, the exploration of novel diagnostic indicators for HAE is currently a significant area of research. Recent investigations have revealed that the majority of pathogenic mutations in the <italic toggle=""yes"">SERPING1</italic> gene typically result in the insolubility of C1-INH proteins within the ER [<xref ref-type=""bibr""",5_16,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"proteins within the ER [<xref ref-type=""bibr"" rid=""CR28"">28</xref>, <xref ref-type=""bibr"" rid=""CR29"">29</xref>]. Similarly, our study also observed that the c.708T > G mutation can induce a substantial accumulation of C1-INH within the ER, resulting in a decrease in C1-INH secretion. Prior research has demonstrated that a reduction in the secretion of C1-INH protein to a particular threshold is associated with a substantial increase in the occurrence of HAE [<xref ref-type=""bibr"" rid=""CR10"">10</xref>,",5_17,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"HAE [<xref ref-type=""bibr"" rid=""CR10"">10</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Notably, this process may coincide with the manifestation of prodromal symptoms. Individuals affected by HAE commonly experience prodromal symptoms such as migraines, fever, cognitive alterations, inattention, memory impairment, and other manifestations [<xref ref-type=""bibr"" rid=""CR30"">30</xref>–<xref ref-type=""bibr"" rid=""CR32"">32</xref>]. Consequently, accurate prediction and timely intervention during this",5_18,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"prediction and timely intervention during this prodromal phase can effectively mitigate the risks associated with HAE. The progressive accumulation of C1-INH in cells can be considered a significant indicator of precursor symptoms for HAE and a crucial approach for preventing and managing the onset and progression of HAE. Prior research has primarily concentrated on the activation of bradykinin due to inadequate secretion of C1-INH, leading to the development of several efficacious medications for post-HAE",5_19,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"of several efficacious medications for post-HAE attacks [<xref ref-type=""bibr"" rid=""CR33"">33</xref>, <xref ref-type=""bibr"" rid=""CR34"">34</xref>]. Nonetheless, there is a dearth of studies investigating the prodromal phase of HAE. The period of C1-INH retention is considered to be the initial phase of the disease. To replicate intracellular C1-INH retention in vitro, we utilized the SERPING1-WT/Mut plasmid. The mutant plasmid contained a novel mutation c.708T > G, while two pathogenic <italic",5_20,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"mutation c.708T > G, while two pathogenic <italic toggle=""yes"">SERPING1</italic> mutations (c.550G > A and c.566C > A) previously documented in the literature were employed as positive controls [<xref ref-type=""bibr"" rid=""CR35"">35</xref>]. Our findings indicate that the mutagenic effect of c.708T > G is comparable to that of c.550G > A, resulting in an elevation of Ca<sup>2+</sup> levels and mitochondrial damage, ultimately leading to significant apoptosis. Knocking down the expression of RGP75 protein can",5_21,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"Knocking down the expression of RGP75 protein can significantly alter the aforementioned cellular abnormalities. The disruption of cellular homeostasis resulting from protein accumulation in the ER has been established in numerous diseases. This investigation also revealed that an abundance of mutant C1-INH aggregations on the ER induces excessive Ca<sup>2+</sup> through the GRP75, potentially serving as a noteworthy characteristic during the prodromal phase of HAE. It is crucial to acknowledge the",5_22,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"phase of HAE. It is crucial to acknowledge the limitations of this study. Firstly, although blood samples were obtained from the HAE family and C1-INH levels were assessed, there is a dearth of tissue-C1-INH detection, necessitating further refinement in future research. Secondly, we posit that the assessment of intracellular calcium concentration holds potential as a predictive marker for HAE; however, its clinical validation is currently lacking, necessitating future improvements. Moreover, this study",5_23,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"future improvements. Moreover, this study fails to investigate the interplay between C1-INH and GRP75, which serves as the intermediary in C1-INH accumulation and mitochondrial impairment. Lastly, given the scarcity of HAE cases, the limited size of the clinical sample incorporated in this study warrants a cautious interpretation of the findings. In summary, this study provides a comprehensive analysis of the phenomenon wherein the accumulation of C1-INH in cells triggers intracellular alterations before",5_24,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"cells triggers intracellular alterations before the manifestation of HAE. The findings of this investigation indicate that C1-INH has the potential to modulate and enhance the expression of GRP75, a crucial protein involved in calcium transportation between the ER and mitochondria. Concurrently, the continuous accumulation of C1-INH in the ER leads to disturbances in cellular calcium content, ultimately resulting in the initiation of Ca<sup>2+</sup>-dependent apoptosis. This study has successfully",5_25,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
"apoptosis. This study has successfully identified a novel <italic toggle=""yes"">SERPING1</italic> pathogenic mutation in HAE, c.708T > G. This mutation has been found to induce the accumulation of C1-INH in the endoplasmic reticulum, subsequently activating GRP75 and resulting in Ca<sup>2+</sup> overload and apoptosis. These significant findings hold crucial clinical implications for the prognostication and early intervention of HAE.",5_26,"Uncovering a novel <italic toggle=""yes"">SERPING1</italic> pathogenic variant: insights into the aggregation of C1-INH in hereditary angioedema",13 9 2024,,Hereditary_Angioedema
Hereditary angioedema (HAE) in children and adolescents: New treatment options  Modern management of hereditary angioedema (HAE) due to reduced C1 inhibitor (C1-INH) function or concentration (HAE-C1-INH) focuses on individualized therapeutic strategies to address the specific needs of children and adolescents as well as the severity of the disease. Psychosocial factors such as the burden of disease and therapy on quality of life and participation play an important role. New medications have already,6_0,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"an important role. New medications have already significantly improved the prognosis and health related quality of life in HAE patients, but not all of these therapies have yet been approved for children. Further treatment options that inhibit bradykinin effects are currently being investigated. They target factor XIIa, prekallikrein, plasma kallikrein, or the bradykinin B2 receptor. Modern research focuses on oral options or long-acting parenteral therapy approaches to further optimize care and, in",6_1,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"approaches to further optimize care and, in particular, the needs of children. There are also initial developments in the field of gene therapy, which could represent a causal treatment option for HAE in the future. This article focuses on the presentation and treatment of HAE type I (reduced C1-INH concentration) and HAE type II (impaired C1-INH function) in children and adolescents. Acquired AE and HAE with normal C1-INH are rare in the pediatric age group and are not discussed in detail here.",6_2,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"age group and are not discussed in detail here.  Hereditary angioedema (HAE) is a rare autosomal-dominant inherited disease caused by a deficiency or reduced function of the C1 esterase inhibitor (C1-INH). This leads to uncontrolled swelling (angioedema) of the skin and mucous membranes, which can be disfiguring, painful, and life-threatening (laryngeal swellings). In the last 10 years, therapeutic options for HAE-C1-INH have significantly improved due to a better understanding of the pathomechanisms.",6_3,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"to a better understanding of the pathomechanisms. Treatment goal is to control swelling attacks, minimize disease burden, and improve quality of life. This article is based on the international WAO/EAACI guideline from 2021 [<xref rid=""b1"" ref-type=""bibr"">1</xref>] as well as the revised S1 guideline from 2019 [<xref rid=""b2"" ref-type=""bibr"">2</xref>], and especially on the 2020 update of recommendations for the treatment of HAE in children and adolescents in the German-speaking region [<xref rid=""b3""",6_4,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"in the German-speaking region [<xref rid=""b3"" ref-type=""bibr"">3</xref>]. Modern, individualized therapies have already been established for adults and adolescents. The specific needs of children are increasingly being addressed, with current research focusing on orally available substances or parenteral preparations with long-lasting effects. This article highlights treatment options approved in Germany, considering the privileged healthcare situation in industrialized countries, and provides insights into",6_5,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"countries, and provides insights into current therapeutic approaches based on the latest scientific findings.  HAE is one of the rare bradykinin-mediated angioedemas. About 85% of patients have reduced C1-INH concentration (HAE-C1-INH type I), and about 15% have normal (or elevated) levels with reduced C1-INH activity (type II). Both types exhibit similar symptoms. The disease is inherited in an autosomal-dominant manner in 75 – 80% of affected individuals, while the remaining cases result from de novo",6_6,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"while the remaining cases result from de novo variants. These mutations are located in the SERPING1 gene on chromosome 11 (11q12-q13.1), which encodes C1-INH. C1-INH is primarily produced in the liver and is the main inhibitor of active proteases in the contact activation system, plasma kallikrein, and the coagulation pathway, including activated factor XII. A deficiency of C1-INH leads to dysregulation of the contact and kinin systems, resulting in an overproduction of bradykinin, which primarily",6_7,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"an overproduction of bradykinin, which primarily increases vascular permeability by binding to the bradykinin B2 receptor and promotes the development of angioedema (<xref rid=""Figure1"" ref-type=""fig"">Figure 1</xref>) [<xref rid=""b4"" ref-type=""bibr"">4</xref>].  Men and women are equally affected by HAE-C1-INH and there are no known differences between various ethnic groups. The majority of patients develop first HAE symptoms during childhood or early adolescence with a median age of approximately 11 years",6_8,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"with a median age of approximately 11 years [<xref rid=""b2"" ref-type=""bibr"">2</xref>]. Recently collected retrospective prescription data of HAE medications in children and adolescents in Germany between 2016 and 2021 suggest an HAE prevalence of 2.51 : 100,000 in pediatric patients aged < 12 years in Germany. The overall cohort’s prevalence was 3.35 per 100,000 which is higher than the previously published average prevalence of 1 – 2 : 100,000 but within the range of reported values from",6_9,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"but within the range of reported values from 0.67 – 10 : 100,000 [<xref rid=""b7"" ref-type=""bibr"">7</xref>].  HAE symptoms typically manifest in childhood or adolescence but are extremely rare in newborns and infants. However, early onset often indicates a more severe course. During puberty and adolescence, the frequency and severity of HAE attacks may increase [<xref rid=""b1"" ref-type=""bibr"">1</xref>]. First symptoms often include recurrent abdominal pain accompanied by nausea, vomiting, and/or diarrhea,",6_10,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"accompanied by nausea, vomiting, and/or diarrhea, caused by angioedema of the intestinal mucosa. Other common symptoms include peripheral swelling of the skin, i.e., of the extremities (<xref rid=""Figure2"" ref-type=""fig"">Figure 2</xref>), face (<xref rid=""Figure3"" ref-type=""fig"">Figure 3</xref>), thoracic wall, or genital area, which are localized, doughy-firm, and skin-colored. These swellings can also be painful and differ from histamine-mediated angioedema by the absence of urticaria and itching. In",6_11,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"by the absence of urticaria and itching. In individual cases, angioedema may be preceded by erythema marginatum, a non-itching, sharply defined (not raised!) reddening of the skin (<xref rid=""Figure4"" ref-type=""fig"">Figure 4</xref>). This symptom is more common in children and occurs in about 50% of cases. Misinterpreting it as urticaria may lead to misdiagnosis and ineffective treatment. Other prodromal symptoms of an HAE attack may include fatigue, exhaustion, thirst, aggression, or depressive mood",6_12,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"thirst, aggression, or depressive mood [<xref rid=""b1"" ref-type=""bibr"">1</xref>, <xref rid=""b2"" ref-type=""bibr"">2</xref>, <xref rid=""b3"" ref-type=""bibr"">3</xref>].  HAE swellings develop slowly and are usually self-limiting within 2 – 5 days. Triggers can be trauma, infections, hormonal changes (such as menstruation), medications like ACE inhibitors or estrogen preparations as well as emotional stress. Medical procedures in the mouth or throat can trigger life-threatening swelling of the upper airways,",6_13,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"life-threatening swelling of the upper airways, although this usually does not occur during the procedure itself but with a delay of a few hours [<xref rid=""b1"" ref-type=""bibr"">1</xref>, <xref rid=""b2"" ref-type=""bibr"">2</xref>, <xref rid=""b3"" ref-type=""bibr"">3</xref>]. HAE attacks manifesting with severe abdominal pain only and without skin symptoms can lead to unnecessary surgeries because of suspected acute abdomen [<xref rid=""b2"" ref-type=""bibr"">2</xref>]. The symptoms of HAE-C1-INH are not specific and",6_14,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"The symptoms of HAE-C1-INH are not specific and may be confused with those of more common conditions. However, early diagnosis is crucial to initiate appropriate therapeutic measures and prevent life-threatening complications [<xref rid=""b3"" ref-type=""bibr"">3</xref>].  Patients suspected of having HAE-C1-INH based on clinical symptoms or a positive family history should undergo testing. Early differentiation between HAE and other types of angioedema, such as histamine- or drug-induced angioedema, is",6_15,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"such as histamine- or drug-induced angioedema, is crucial to initiate appropriate treatment [<xref rid=""b1"" ref-type=""bibr"">1</xref>, <xref rid=""b3"" ref-type=""bibr"">3</xref>]. Laboratory diagnostics involve evaluating C1-INH concentration and activity, as well as C4 concentration in plasma. A “screening test” that examines only one of these parameters is insufficient to rule out HAE-C1-INH [<xref rid=""b1"" ref-type=""bibr"">1</xref>, <xref rid=""b2"" ref-type=""bibr"">2</xref>, <xref rid=""b3""",6_16,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"rid=""b2"" ref-type=""bibr"">2</xref>, <xref rid=""b3"" ref-type=""bibr"">3</xref>]. In HAE type I, C1-INH activity and concentration as well as C4 are reduced, while in HAE type II only C1-INH activity and C4 are reduced, while C1-INH concentration is normal or may even be elevated (<xref rid=""Table1"" ref-type=""table"">Table 1</xref>) [<xref rid=""b1"" ref-type=""bibr"">1</xref>, <xref rid=""b2"" ref-type=""bibr"">2</xref>, <xref rid=""b3"" ref-type=""bibr"">3</xref>].  Abnormal test results should ideally be confirmed in",6_17,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"test results should ideally be confirmed in certified laboratories. Genetic testing is not recommended as a routine examination but can support the diagnosis in doubtful cases, atypical presentations, or in very young infants or when distinguishing types of HAE with normal C1-INH levels [<xref rid=""b1"" ref-type=""bibr"">1</xref>, <xref rid=""b2"" ref-type=""bibr"">2</xref>, <xref rid=""b3"" ref-type=""bibr"">3</xref>].  Due to the autosomal-dominant inheritance of HAE-C1-INH, there is a 50% chance that offspring of",6_18,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"there is a 50% chance that offspring of affected individuals will inherit the condition. These children are considered potentially affected until HAE-C1-INH is ruled out and must be monitored closely and tested as early as possible, ideally before clinical symptoms appear. Testing for C1-INH in very young infants should be repeated at the age of 1 year [<xref rid=""b1"" ref-type=""bibr"">1</xref>].  Diagnosing HAE for the first time in children is challenging, as symptoms such as abdominal pain often resemble",6_19,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"as symptoms such as abdominal pain often resemble those of other, more common pediatric conditions. An abdominal ultrasound during the acute phase of an HAE attack may show intestinal wall thickening, but a normal abdominal ultrasound does not necessarily exclude HAE [<xref rid=""b3"" ref-type=""bibr"">3</xref>]. Recurrent abdominal pain and peripheral swelling, particularly with a positive family history, may indicate HAE [<xref rid=""b1"" ref-type=""bibr"">1</xref>, <xref rid=""b3"" ref-type=""bibr"">3</xref>].",6_20,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<xref rid=""b3"" ref-type=""bibr"">3</xref>].  Children and adolescents with HAE-C1-INH should be treated by medical personnel experienced in HAE management or in specialized centers. Like adults, they require an emergency document and a regularly updated treatment plan tailored to the child’s life circumstances and medical needs. Medical decisions are made together with the families and consider the child’s needs. Treatment includes both on-demand therapy for acute attacks as well as prophylactic strategies,",6_21,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"acute attacks as well as prophylactic strategies, with various medications available for different indications and ways of application, although not all are approved for every age group (<xref rid=""Table2"" ref-type=""table"">Tables 2</xref>, <xref rid=""Table3"" ref-type=""table"">3</xref>, <xref rid=""Table4"" ref-type=""table"">4</xref>) [<xref rid=""b3"" ref-type=""bibr"">3</xref>].  Patients and their caregivers should be well informed about HAE, possible triggers (such as certain medications), and should be",6_22,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"(such as certain medications), and should be equipped with emergency documents. It is recommended that a swelling calendar (or app) be kept to document HAE attacks, prodromal symptoms, triggers, and the administered medication. The therapeutic options described in this article provide modern and effective ways for children and adolescents with HAE for both on-demand treatment and prophylaxis. In cases of bradykinin-mediated HAE attacks, ineffective medications such as corticosteroids, antihistamines, and",6_23,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"such as corticosteroids, antihistamines, and epinephrine, which are effective in histamine-mediated angioedema only, should not be used [<xref rid=""b3"" ref-type=""bibr"">3</xref>]. Regular medical check-ups are necessary to monitor the frequency and severity of attacks, assess treatment efficacy, and detect potential side effects early. The treatment plan should be continuously reviewed and updated. The possibility of home therapy should also be pointed out and appropriate training provided. Medication",6_24,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"out and appropriate training provided. Medication dosages in children are regularly adjusted based on weight and/or age. Precise written advice concerning short-term prophylaxis should also be provided [<xref rid=""b1"" ref-type=""bibr"">1</xref>, <xref rid=""b3"" ref-type=""bibr"">3</xref>, <xref rid=""b15"" ref-type=""bibr"">15</xref>].  Therapeutic success and quality of life should regularly be recorded and evaluated. Validated questionnaires such as the Angioedema Control Test (AECT) [<xref rid=""b16""",6_25,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"Angioedema Control Test (AECT) [<xref rid=""b16"" ref-type=""bibr"">16</xref>] and the Angioedema Quality of Life Instrument (AE-QoL) [<xref rid=""b17"" ref-type=""bibr"">17</xref>] are available for adults, but there are no validated instruments for children or adolescents yet. HAE can have significant emotional and social impact on affected children and adolescents. Fear of attacks or pain, as well as daily limitations or embarrassment due to disfiguring angioedema, can lead to psychological stress [<xref",6_26,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"can lead to psychological stress [<xref rid=""b18"" ref-type=""bibr"">18</xref>]. A strong patient organization, such as Hereditary Angioedema e.V. (HAE e.V.), supports individuals with HAE and their families in Germany and can be found at https://hae-online.de/. A holistic, multidisciplinary approach is recommended for treating HAE patients, which should include psychological support and counseling for the entire family by medical professionals experienced in HAE diagnosis and treatment [<xref rid=""b3""",6_27,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"in HAE diagnosis and treatment [<xref rid=""b3"" ref-type=""bibr"">3</xref>].  New drugs have also recently been approved for pediatric HAE patients. However, there is still a need for oral therapies or parenteral options with longer dosing intervals in HAE treatment for children. Several novel agents for on-demand treatment, but also for long-term prophylaxis, are currently being investigated regarding these questions. The improved understanding of HAE pathogenesis is currently enabling the rapid development",6_28,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"is currently enabling the rapid development of new therapeutic strategies aimed at inhibiting bradykinin effects. These therapies target factor XIIa, prekallikrein, plasma kallikrein, or the bradykinin B2 receptor (<xref rid=""Figure1"" ref-type=""fig"">Figure 1</xref>, marked with **) [<xref rid=""b6"" ref-type=""bibr"">6</xref>].  MF writing original draft, review and editing. BW review and editing.  None.  MF: personal: no conflicts of interest; institutional: IDCL participates in NIS PIQHAR (Prophylaxis Impact",6_29,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"participates in NIS PIQHAR (Prophylaxis Impact on Quality of life Impairment of HAE Patients with Lower Annual Base Attack Rates)  BW: Lecture fees (mostly paid) from Ärztekammer Niedersachsen, ALK-Abelló, Bencard, Cogitando, BVDD, CSL Behring, DDG, DGA, DGAKI, DGP, fg-hno-aerzte, FOMF, NDG, NEDH e.V., Novartis, Roche Posay, Streamed Up, Takeda, ThermofisherScientific sowie Advisory Board (honoriert) von Biocryst, Biomarin, CSL Behring, Kalvista, Novartis, Sanofi-Aventis, Takeda.",6_30,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<table-wrap position=""float"" id=""Table1""><label>Table 1.</label><caption><title>Diagnosing hereditary angioedema. </title></caption><table frame=""box"" rules=""all""><tbody><tr><td rowspan=""3"" colspan=""1"">Clinical symptoms/medical history</td><td colspan=""4"" rowspan=""1"">Recurrent peripheral swelling of the skin without urticaria/itching and no response to corticosteroids, epinephrine, or antihistamines</td></tr><tr><td colspan=""4"" rowspan=""1"">Abdominal pain attacks</td></tr><tr><td colspan=""4""",6_31,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"pain attacks</td></tr><tr><td colspan=""4"" rowspan=""1"">Possible laryngeal swelling</td></tr><tr><td rowspan=""1"" colspan=""1"">Family history</td><td colspan=""4"" rowspan=""1"">Possibly positive family history for HAE</td></tr><tr><td rowspan=""4"" colspan=""1"">Laboratory findings</td><td colspan=""4"" rowspan=""1"">Reduced C4 and reduced C1-INH activity, with or without reduced C1-INH concentration in plasma</td></tr><tr><td rowspan=""1"" colspan=""1""></td><td rowspan=""1"" colspan=""1"">",6_32,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<bold>C1-INH activity</bold>
</td><td rowspan=""1"" colspan=""1"">
<bold>C1-INH concentration</bold>
</td><td rowspan=""1"" colspan=""1"">
<bold>C4 concentration</bold>",6_33,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<bold>C4 concentration</bold>
</td></tr><tr><td rowspan=""1"" colspan=""1"">HAE type I</td><td rowspan=""1"" colspan=""1"">↓</td><td rowspan=""1"" colspan=""1"">↓</td><td rowspan=""1"" colspan=""1"">↓</td></tr><tr><td rowspan=""1"" colspan=""1"">HAE type II</td><td rowspan=""1"" colspan=""1"">↓</td><td rowspan=""1"" colspan=""1"">N/↑</td><td rowspan=""1"" colspan=""1"">↓</td></tr></tbody></table><table-wrap-foot><fn><p>HAE = hereditary angioedema; C1-INH = C1 inhibitor; N = normal.</p></fn></table-wrap-foot></table-wrap>",6_34,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<table-wrap position=""float"" id=""Table2""><label>Table 2.</label><caption><title>On-demand treatment of acute hereditary angioedema attacks. </title></caption><table frame=""box"" rules=""all""><thead><tr><th rowspan=""1"" colspan=""1"">
<bold>Active ingredient/mode of action </bold>
<break></break>
<bold>(approved in Germany)</bold>
</th><th rowspan=""1"" colspan=""1"">
<bold>Way of administration</bold>
</th><th rowspan=""1"" colspan=""1"">
<bold>Dosage for children </bold>
<break></break>
<bold>by age or BW</bold>",6_35,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<break></break>
<bold>by age or BW</bold>
</th><th rowspan=""1"" colspan=""1"">
<bold>Dosage for adolescents/adults</bold>
</th><th rowspan=""1"" colspan=""1"">
<bold>Special features</bold>
</th></tr></thead><tbody><tr><td rowspan=""1"" colspan=""1"">
<bold>pdC1-INH (500/1,500) </bold>",6_36,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<bold>pdC1-INH (500/1,500) </bold>
<break></break>Berinert <break></break>Plasma-derived C1-INH</td><td rowspan=""1"" colspan=""1"">IV</td><td rowspan=""1"" colspan=""1"">≥ 0 years: 20 IU/kg BW</td><td rowspan=""1"" colspan=""1"">20 IU/kg BW</td><td rowspan=""1"" colspan=""1"">Plasma product <break></break>Reconstitution <break></break>Home therapy/self-application <break></break>Batch documentation</td></tr><tr><td rowspan=""1"" colspan=""1"">
<bold>pdC1-INH (500) </bold>",6_37,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<bold>pdC1-INH (500) </bold>
<break></break>Cinryze <break></break>Plasma-derived C1-INH</td><td rowspan=""1"" colspan=""1"">IV</td><td rowspan=""1"" colspan=""1"">2 – 11 years (10 – 25 kg): 500 IU <break></break>2 – 11 years (> 25 kg): 1,000 IU</td><td rowspan=""1"" colspan=""1"">≥ 12 years (> 25 kg): 1,000 IU</td><td rowspan=""1"" colspan=""1"">Plasma product <break></break>Reconstitution <break></break>Home therapy/self-application <break></break>Batch documentation</td></tr><tr><td rowspan=""1"" colspan=""1"">",6_38,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<bold>rhC1-INH (2100) Conestat α</bold>
<break></break>Recombinant analogue <break></break>of the human C1-INH</td><td rowspan=""1"" colspan=""1"">IV</td><td rowspan=""1"" colspan=""1"">≥ 2 years (< 84 kg): 50 IU/kg BW</td><td rowspan=""1"" colspan=""1"">< 84kg: 50 IU/kg <break></break>≥ 84kg: 4,200 IU</td><td rowspan=""1"" colspan=""1"">Contains traces of rabbit protein <break></break>Reconstitution <break></break>Home therapy/self-application</td></tr><tr><td rowspan=""1"" colspan=""1"">
<bold>Icatibant </bold>",6_39,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<break></break>Selective, competitive bradykinin type 2 receptor antagonist</td><td rowspan=""1"" colspan=""1"">SC</td><td rowspan=""1"" colspan=""1"">2 – 17 years <break></break>• 12 – 25 kg: 10 mg (1 mL) <break></break>• 26 – 40 kg: 15 mg (1.5 mL) <break></break>• 41 – 50 kg: 20 mg (2 mL) <break></break>• 51 – 65 kg: 25 mg (2.5 mL) <break></break>• > 65 kg: 30 mg (3 mL)</td><td rowspan=""1"" colspan=""1"">≥ 18 years (> 65 kg): 30 mg (3 mL)</td><td rowspan=""1"" colspan=""1"">Prefilled syringe <break></break>Home",6_40,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"colspan=""1"">Prefilled syringe <break></break>Home therapy/self-application</td></tr></tbody></table><table-wrap-foot><fn><p>C1-INH = C1 inhibitor; IV = intravenously; SC = subcutaneously; BW = body weight. According to German product information. Of note (according to [<xref rid=""b3"" ref-type=""bibr"">3</xref>]): – Every attack in the head and neck area should be treated at any age! – Initiate therapy as early as possible! On-demand medication should always be readily available! – Treatment of children",6_41,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"be readily available! – Treatment of children younger than 6 years of age should also include abdominal and peripheral attacks. – Consider treatment of attacks (outside the head and neck area, depending on severity) in children older than 6 years of age.</p></fn></table-wrap-foot></table-wrap>",6_42,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<table-wrap position=""float"" id=""Table3""><label>Table 3.</label><caption><title>Short-term prophylaxis prior to invasive medical procedures. </title></caption><table frame=""box"" rules=""all""><thead><tr><th rowspan=""1"" colspan=""1"">
<bold>Active ingredient/mode of action (approved in Germany)</bold>
</th><th rowspan=""1"" colspan=""1"">
<bold>Way of administration</bold>
</th><th rowspan=""1"" colspan=""1"">
<bold>Dosage for children by age or BW</bold>
</th><th rowspan=""1"" colspan=""1"">",6_43,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"</th><th rowspan=""1"" colspan=""1"">
<bold>Dosage for adolescents/adults</bold>
</th><th rowspan=""1"" colspan=""1"">
<bold>Special features</bold>
</th></tr></thead><tbody><tr><td rowspan=""1"" colspan=""1"">
<bold>pdC1-INH (500/1,500) </bold>",6_44,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<bold>pdC1-INH (500/1,500) </bold>
<break></break>Berinert <break></break>Plasma-derived C1-INH</td><td rowspan=""1"" colspan=""1"">IV</td><td rowspan=""1"" colspan=""1"">0 – < 18 years: 15 – 30 IU/kg BW</td><td rowspan=""1"" colspan=""1"">< 18 years: 15 – 30 IU/kg bw <break></break>≥ 18 years: 1,000 IU</td><td rowspan=""1"" colspan=""1"">Plasma product <break></break>Reconstitution <break></break>Home therapy/self-application <break></break>Within 6 hours before the procedure</td></tr><tr><td rowspan=""1"" colspan=""1"">",6_45,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
<bold>pdC1-INH (500) </bold>,6_46,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<break></break>Cinryze <break></break>Plasma-derived C1-INH</td><td rowspan=""1"" colspan=""1"">IV</td><td rowspan=""1"" colspan=""1"">2 – 11 years (10 – 25 kg): 500 IU <break></break>2 – 11 years (> 25 kg): 1,000 IU</td><td rowspan=""1"" colspan=""1"">≥ 12 years (> 25 kg): 1,000 IU</td><td rowspan=""1"" colspan=""1"">Plasma product <break></break>Reconstitution <break></break>Home therapy/self-application <break></break>Within 24 hours prior to the procedure</td></tr></tbody></table><table-wrap-foot><fn><p>C1-INH = C1",6_47,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"= C1 inhibitor; IV = intravenously; BW = body weight. According to German product information. Of note (according to [<xref rid=""b3"" ref-type=""bibr"">3</xref>]): – Administration prior to all invasive medical procedures in the head/neck area, and as close as possible to the procedure! – If short-term prophylaxis is not used, on-demand therapy with C1-INH concentrate should be readily available.</p></fn></table-wrap-foot></table-wrap>",6_48,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<table-wrap position=""float"" id=""Table4""><label>Table 4.</label><caption><title>Long-term prophylaxis for the prevention of hereditary angioedema attacks. </title></caption><table frame=""box"" rules=""all""><thead><tr><th rowspan=""1"" colspan=""1"">
<bold>Active ingredient/mode of action (Approved in Germany)</bold>
</th><th rowspan=""1"" colspan=""1"">
<bold>Way of administration</bold>
</th><th rowspan=""1"" colspan=""1"">
<bold>Dosage for children by age or BW</bold>
</th><th rowspan=""1"" colspan=""1"">",6_49,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"</th><th rowspan=""1"" colspan=""1"">
<bold>Dosage for adolescents/adults</bold>
</th><th rowspan=""1"" colspan=""1"">
<bold>Special features</bold>
</th></tr></thead><tbody><tr><td rowspan=""1"" colspan=""1"">
<bold>pdC1-INH (2000/3000) </bold>",6_50,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<bold>pdC1-INH (2000/3000) </bold>
<break></break>Berinert <break></break>Plasma-derived C1-INH</td><td rowspan=""1"" colspan=""1"">SC</td><td rowspan=""1"" colspan=""1"">/</td><td rowspan=""1"" colspan=""1"">≥ 12 years: 60 IU/kg BW 2×/week</td><td rowspan=""1"" colspan=""1"">Plasma product <break></break>Reconstitution <break></break>Home therapy/self-application <break></break>Batch documentation</td></tr><tr><td rowspan=""1"" colspan=""1"">",6_51,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<bold>pdC1-INH (500</bold>) <break></break>Cinryze <break></break>Plasma-derived C1-INH</td><td rowspan=""1"" colspan=""1"">IV</td><td rowspan=""1"" colspan=""1"">6 – 11 years: 500 IU every 3 – 4 days</td><td rowspan=""1"" colspan=""1"">≥ 12 years: 1,000 IU every 3 – 4 days</td><td rowspan=""1"" colspan=""1"">Plasma product <break></break>Reconstitution <break></break>Home therapy/self-application <break></break>Batch documentation</td></tr><tr><td rowspan=""1"" colspan=""1"">
<bold>Lanadelumab </bold>",6_52,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<break></break>(Recombinant human monoclonal antibody) <break></break>Plasma kallikrein inhibitor</td><td rowspan=""1"" colspan=""1"">SC</td><td rowspan=""1"" colspan=""1"">2 – 11 years <break></break>• 10 – ≤ 20 kg: 150 mg every 4 weeks <break></break>• 20 – ≤ 40 kg: 150 mg every 2 weeks <break></break>• ≥ 40 kg: 300 mg every 2 weeks</td><td rowspan=""1"" colspan=""1"">≥ 12 years: 300 mg every 2 weeks</td><td rowspan=""1"" colspan=""1"">Prefilled syringe <break></break>Home therapy/self-application <break></break>Dose",6_53,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"therapy/self-application <break></break>Dose adjustment possible <break></break>Batch documentation</td></tr><tr><td rowspan=""1"" colspan=""1"">",6_54,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
<bold>Berotralstat </bold>,6_55,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"<break></break>(Small molecule) <break></break>Synthetic oral plasma kallikrein inhibitor</td><td rowspan=""1"" colspan=""1"">PO</td><td rowspan=""1"" colspan=""1"">/</td><td rowspan=""1"" colspan=""1"">≥ 12 years (≥ 40 kg): 150 mg 1 × daily</td><td rowspan=""1"" colspan=""1"">Hard capsule <break></break>Home therapy/self-application <break></break>Consumption with a meal</td></tr></tbody></table><table-wrap-foot><fn><p>C1-INH = C1 inhibitor; IV = intravenously; SC = subcutaneously; PO = orally; BW = body weight.",6_56,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"= subcutaneously; PO = orally; BW = body weight. According to German product information. Of note (according to [<xref rid=""b1"" ref-type=""bibr"">1</xref>, <xref rid=""b3"" ref-type=""bibr"">3</xref>]): Consideration of the attack frequency (generally > 2 attacks per month), individual disease burden, as well as limitations in health-related quality of life and participation due to HAE, when deciding on long-term prophylaxis.</p></fn></table-wrap-foot></table-wrap>",6_57,Hereditary angioedema (HAE) in children and adolescents: New treatment options ,2024,,Hereditary_Angioedema
"Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study Hereditary angioedema (HAE) resulting from the genetic defect of C1 inhibitor (C1INH) is a rare autosomal dominant disease characterized by recurrent attacks of submucosal and cutaneous edema: angioedema attacks can potentially involve any site and generally are self-limiting within 72 hours (<xref rid=""B1"" ref-type=""bibr"">1</xref>,",7_0,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"hours (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B2"" ref-type=""bibr"">2</xref>). The defect of C1INH can be either a quantitative deficiency (type I C1INH-HAE) or a qualitative dysfunction (type II C1INH-HAE) of the protein: the overproduction of bradykinin (BK) related to the lack of activity of C1INH leads to a consequent abnormal activation of the BK-B2 receptors (<xref rid=""B3"" ref-type=""bibr"">3</xref>) resulting in an increased vascular permeability and, thus, angioedema attacks (<xref",7_1,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"permeability and, thus, angioedema attacks (<xref rid=""B2"" ref-type=""bibr"">2</xref>). In disorders due to deficiencies of complement system (CS) components and related regulatory proteins, immune complexes (IC) mediated diseases could be promoted because of the defect of early components like C1q, C1r, C1s, C4, and C2 (<xref rid=""B4"" ref-type=""bibr"">4</xref>, <xref rid=""B5"" ref-type=""bibr"">5</xref>). That network could lead to lupus-like syndromes as occur in patients with primary genetic deficiencies of",7_2,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"in patients with primary genetic deficiencies of C2, C4, and other complement components (<xref rid=""B6"" ref-type=""bibr"">6</xref>, <xref rid=""B7"" ref-type=""bibr"">7</xref>). Along with the constitutively reduced levels of C4 and C1INH, sex hormones, mainly estrogens, pathogenetically link autoimmune diseases and C1INH-HAE (<xref rid=""B8"" ref-type=""bibr"">8</xref>–<xref rid=""B11"" ref-type=""bibr"">11</xref>). As known, systemic autoimmune diseases have a clear female preponderance and can mainly arise following",7_3,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"preponderance and can mainly arise following pubertal onset strengthening the key role for sex hormones in autoimmunity (<xref rid=""B10"" ref-type=""bibr"">10</xref>, <xref rid=""B11"" ref-type=""bibr"">11</xref>). In addition, C1INH-HAE women experience a stronger disease severity with poorer quality of life than males (<xref rid=""B12"" ref-type=""bibr"">12</xref>–<xref rid=""B16"" ref-type=""bibr"">16</xref>) as occur in patients affected by systemic autoimmune diseases including Systemic Lupus Erythematosus (SLE) and",7_4,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"including Systemic Lupus Erythematosus (SLE) and antiphospholipid syndrome (APS) (<xref rid=""B17"" ref-type=""bibr"">17</xref>–<xref rid=""B21"" ref-type=""bibr"">21</xref>). Occasional reports describe potential links between autoimmune conditions and C1INH-HAE (<xref rid=""B22"" ref-type=""bibr"">22</xref>–<xref rid=""B25"" ref-type=""bibr"">25</xref>). Although several immunoregulatory disorders have been documented, the specific prevalence of autoimmune diseases in patients with HAE remains debated (<xref rid=""B9""",7_5,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"patients with HAE remains debated (<xref rid=""B9"" ref-type=""bibr"">9</xref>, <xref rid=""B26"" ref-type=""bibr"">26</xref>, <xref rid=""B27"" ref-type=""bibr"">27</xref>). To date, no studies have specifically focused on the occurrence of rare connective tissue diseases (RCTDs) in C1INH-HAE (<xref rid=""B23"" ref-type=""bibr"">23</xref>). Therefore, we aim at evaluating distribution of RCTDs including SLE, primary Sjögren’s syndrome (SjS), primary APS, Systemic Sclerosis (SSc), and mixed connective tissue disease",7_6,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"(SSc), and mixed connective tissue disease (MCTD) in C1INH-HAE patients providing first evidence from a large Italian cohort study. A multicenter observational study includes C1INH-HAE patients from ITACA Centers throughout Italy (time frame Sept 2023-March 2024). Inclusion criteria are i. a defined diagnosis of type I or type II C1INH-HAE (<xref rid=""B2"" ref-type=""bibr"">2</xref>); ii. age ≥15 years (puberty already occurred); iii. enrollment in the ITACA Registry, approved by the ethics committee of the",7_7,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"Registry, approved by the ethics committee of the coordinating center (Comitato etico Milano area 1) on 5 May 2017 (<xref rid=""B28"" ref-type=""bibr"">28</xref>). Data from patients comprise: HAE disease history (age at onset, familiar history, disease activity, treatments’ regimens); demographic and biochemical data (including autoantibodies); the occurrence of a defined diagnosis of RCTDs performed from expert Immunologists/Rheumatologists according to international classification criteria (<xref rid=""B23""",7_8,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"classification criteria (<xref rid=""B23"" ref-type=""bibr"">23</xref>). RCTDs include: SLE (<xref rid=""B29"" ref-type=""bibr"">29</xref>), primary SjS (<xref rid=""B30"" ref-type=""bibr"">30</xref>), primary APS (<xref rid=""B31"" ref-type=""bibr"">31</xref>), SSc (<xref rid=""B32"" ref-type=""bibr"">32</xref>), and MCTD (<xref rid=""B33"" ref-type=""bibr"">33</xref>). All patients provide written consent to be included in the registry; for patients younger than 18 years, consents are obtained in the presence and with the",7_9,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"are obtained in the presence and with the consent of parents. Data are collected from a dedicated electronic database for the analyses: patients with relevant clinical missing data (over 20% data missing) are excluded from the study. Data are collected from 15 ITACA Centers: 92.5% of patients (n=855) are included in the study while 7.5% are excluded for clinical missing data. No significant gender prevalence results in the whole cohort with F:M ratio 1.5 (<xref rid=""T1"" ref-type=""table"">",7_10,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"<bold>Table 1</bold>
</xref>). Type I C1INH-HAE diagnosis is prevalent (87.2%); most of patients have positive familial history while <italic toggle=""yes"">de novo</italic> mutations are registered in 14% of cases (n=120). A third of cohort at the enrollment results on LTP regimen (<xref rid=""T1"" ref-type=""table"">
<bold>Table 1</bold>",7_11,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"</xref>). Our findings provide the first evidence of the prevalence and distribution of RCTDs in a large cohort of C1INH-HAE patients from Italian HAE Centers. The estimated prevalence of RCTDs results to be 2.1%: however, a single RCTD occurs in 0.4-0.5% (SjS, primary APS) and 0.9-1% (SLE) of the study population. Extremely rare diseases such as SSc and MCTD have been registered in 0.2% of cases. The rarity of the aforementioned RCTDs does not allow accurate estimations: results from epidemiological",7_12,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"estimations: results from epidemiological studies are variable due mainly to the heterogeneity of the patients’ populations and/or inclusion criteria (<xref rid=""B34"" ref-type=""bibr"">34</xref>, <xref rid=""B35"" ref-type=""bibr"">35</xref>). Previous evidence reports a prevalence of 12% for autoimmune disease out of 157 individuals with C1INH-HAE but a wide range of diagnoses are included such as glomerulonephritis, inflammatory bowel disease, thyroiditis, inflammatory arthritis, and several CTDs (<xref",7_13,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"inflammatory arthritis, and several CTDs (<xref rid=""B36"" ref-type=""bibr"">36</xref>). Furthermore, Authors reports six cases out of 143 Italian C1INH-HAE patients having a systemic autoimmune disease (4.2%) but both CTDs and inflammatory arthritis are considered (<xref rid=""B34"" ref-type=""bibr"">34</xref>). In general, the worldwide SLE prevalence is estimated to be at least 0.04% with the highest prevalence observed in females (<xref rid=""B37"" ref-type=""bibr"">37</xref>, <xref rid=""B38""",7_14,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"ref-type=""bibr"">37</xref>, <xref rid=""B38"" ref-type=""bibr"">38</xref>). Specifically, in C1INH-HAE patients, lupus prevalence has been estimated at 2.2% by Donaldson (<xref rid=""B6"" ref-type=""bibr"">6</xref>, <xref rid=""B39"" ref-type=""bibr"">39</xref>). More recently, the French prevalence of lupus among C1INH-HAE patients results between 0.4% and 0.9% of patients: however, authors retrospectively document six cases of type I C1INH-HAE patients with SLE-like or unspecified cutaneous lupus while no cases of",7_15,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"or unspecified cutaneous lupus while no cases of defined SLE are described (<xref rid=""B26"" ref-type=""bibr"">26</xref>). As known, SLE can occur at any age, although it is rare during the first decade of life: however, the risk is particularly high in women of childbearing age (<xref rid=""B40"" ref-type=""bibr"">40</xref>). Age is thus an independent factor in the onset and diagnosis of SLE: our findings describe a slightly younger mean age at SLE diagnosis with the respect to evidence from the literature",7_16,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"with the respect to evidence from the literature (<xref rid=""B41"" ref-type=""bibr"">41</xref>). Even though adequate comparisons are challenging due to differences in study populations as well as data sources, various hypotheses can explain the difference in mean age at SLE diagnosis. This may be related to factors involved in the pathogenesis of SLE, such as the consumption of complement C4 which occurs in C1INH-HAE with consequent impaired clearance of apoptotic cells (<xref rid=""B9""",7_17,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"clearance of apoptotic cells (<xref rid=""B9"" ref-type=""bibr"">9</xref>). Therefore, hypocomplementemia in C1INH-HAE might reduce the age of disease onset of secondary SLE in such patients. In addition to pathogenetic factors, another possible explanation could be the increased likelihood of early detection and diagnosis of SLE in C1INH-HAE patients who are adequately and regularly managed in Tertiary Immunologic settings (<xref rid=""B41"" ref-type=""bibr"">41</xref>). According to data from the literature, the",7_18,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"According to data from the literature, the overall prevalence of SjS is assumed to be at least 0.4%, including the more common secondary SjS (<xref rid=""B42"" ref-type=""bibr"">42</xref>). This is in the order of magnitude of our current study (0.46%): however, in our research, we include only the primary form of SjS which is the less prevalent (<xref rid=""B42"" ref-type=""bibr"">42</xref>). Likewise, the overall estimated prevalence of APS is 0.05% and includes both the primary form and the one associated with",7_19,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"both the primary form and the one associated with other autoimmune diseases, particularly SLE (<xref rid=""B43"" ref-type=""bibr"">43</xref>, <xref rid=""B44"" ref-type=""bibr"">44</xref>). Results from our current study describe a prevalence of 0.35% and refer only to primary APS. In the literature, no data on primary APS in C1INH-HAE have been documented while reports describe APS related to acquired conditions of C1INH deficiency (<xref rid=""B45"" ref-type=""bibr"">45</xref>, <xref rid=""B46""",7_20,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"ref-type=""bibr"">45</xref>, <xref rid=""B46"" ref-type=""bibr"">46</xref>). The global prevalence of SSc has been reported to be 0.023% (<xref rid=""B47"" ref-type=""bibr"">47</xref>, <xref rid=""B48"" ref-type=""bibr"">48</xref>). We describe two cases of SSc-C1INH-HAE who show a different clinical spectrum being classified as limited cutaneous and diffuse cutaneous SSc. Evidence from the literature suggests that CS activation might be involved in the pathophysiology of SSc: abnormal local complement activation has",7_21,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"of SSc: abnormal local complement activation has been described in skin lesions of SSc patients, and C3 and/or C4 hypocomplementemia is present in ∼15% of patients with SSc (<xref rid=""B49"" ref-type=""bibr"">49</xref>, <xref rid=""B50"" ref-type=""bibr"">50</xref>). Although it is intriguing to speculate that dysfunctional innate and adaptive immune responses and/or IC might be responsible for CS activation in SSc, evidence from the literature is still debated (<xref rid=""B51"" ref-type=""bibr"">51</xref>). In our",7_22,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"rid=""B51"" ref-type=""bibr"">51</xref>). In our SSc patients, the coexistence of intense C4 consumption related to the congenital C1INH deficiency seems to not correlate with a worse clinical phenotype. However, it must still be considered that these are only two cases for which generalized conclusions cannot be drawn. MCTD has certainly the lowest prevalence among RCTDs: the reported prevalence estimates are similar across the different criteria sets of MCTD and range from 0.0002% to 0.002% (<xref rid=""B47""",7_23,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"and range from 0.0002% to 0.002% (<xref rid=""B47"" ref-type=""bibr"">47</xref>, <xref rid=""B52"" ref-type=""bibr"">52</xref>). From our findings, the registered MCTD C1INH-HAE patient is a female young adult who shows a defined serological (-U1RNP) and clinical profile also including pulmonary arterial hypertension. As known, women are more likely to develop RCTDs: accordingly, we report a higher F:M ratio among C1INH-HAE with concomitant RCTDs, mainly in SLE and SjS cases. Moreover, the single case of MCTD is a",7_24,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"SjS cases. Moreover, the single case of MCTD is a woman. In C1INH-HAE patients with RCTDs, LTP occurs in a significantly higher prevalence compared with that from HAE patients without RCTDs, suggesting an association between HAE disease activity and systemic autoimmune diseases. However, the rate of patients already in LTP at the time of RCTDs diagnosis is similar to that of patients who start LTP after the RCTD diagnosis. It is plausible to assume that the relation between HAE disease activity and the",7_25,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"the relation between HAE disease activity and the occurrence of autoimmune diseases in C1INH-HAE might be bidirectional since a higher HAE disease activity can concur to autoimmunity thus increasing the risk of autoimmune diseases by the unregulated consumption of complement C4 (<xref rid=""B9"" ref-type=""bibr"">9</xref>, <xref rid=""B34"" ref-type=""bibr"">34</xref>). Therefore, it is conceivable that more severe forms of HAE, requiring LTP, could be associated with an increased risk of autoimmune diseases. A",7_26,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"with an increased risk of autoimmune diseases. A limitation of the study is represented by the lack of a regression analysis of factors associated to RCTDs that might be useful to describe possible risk factors associated to the development of RCTDs: regression analysis had not been done because of the small sample size that could lead to low accurate estimates and informative results. In conclusion, we provide the first evidence of distribution of RCTDs in a large cohort of adult Italian patients with",7_27,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"in a large cohort of adult Italian patients with C1INH-HAE, documenting that the prevalence of RCTDs - SLE, APS, and SSc - is approximately 5 to 10 times higher in C1INH-HAE patients compared to the general population as reported in the literature. However, in studies on rare diseases, making adequate comparisons is challenging due to potential discrepancies in study populations, data sources, healthcare management, and regional factors. The multicentric design of our study helps to minimize potential bias",7_28,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"of our study helps to minimize potential bias related to geographic differences, with the aim of providing representative and high-quality data. According to our results, a greater proportion of patients on LTP occurs among RCTDs patients compared with patients without RCTDs. Elevated HAE activity could promote autoimmunity, increasing the chance of autoimmune conditions by depleting complement C4, which in turn leads to defective clearance of IC. Considering these findings, it’s possible to suggest that",7_29,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"these findings, it’s possible to suggest that the link between HAE and autoimmune diseases might be reciprocal.",7_30,Rare connective tissue diseases in patients with C1-inhibitor deficiency hereditary angioedema: first evidence on prevalence and distribution from a large Italian cohort study,18 10 2024,,Hereditary_Angioedema
"Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report C1-inhibitor (C1INH) deficiency due to a mutation in the <italic toggle=""yes"">SERPING1</italic> gene is the most common cause of hereditary angioedema (HAE) (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B2"" ref-type=""bibr"">2</xref>). Hereditary angioedema due to C1-inhibitor deficiency (HAE-C1INH) occurs worldwide, with an estimated prevalence in Italy of",8_0,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"with an estimated prevalence in Italy of 1:64,000 (<xref rid=""B3"" ref-type=""bibr"">3</xref>). Clinical presentation usually consists of self-limiting, subcutaneous edema of the extremities, face, or genitals without wheals. Gastrointestinal and upper airway mucosa may also be involved with symptoms mimicking an acute abdomen or with the risk of asphyxiation, respectively (<xref rid=""B4"" ref-type=""bibr"">4</xref>). The mortality rate of HAE-C1INH is affected by the diagnostic delay and the availability of",8_1,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"by the diagnostic delay and the availability of on-demand and prophylaxis treatment. However, in a retrospective study, asphyxiation in Italian HAE-C1INH families was less common than previously reported, with malignancy and cardiovascular disease representing the leading cause of death (<xref rid=""B5"" ref-type=""bibr"">5</xref>). Until 2020, when the kallikrein antagonist lanadelumab became available, the most common treatment for HAE-C1INH long-term prophylaxis (LTP) in Italy was danazol and stanazolol,",8_2,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"(LTP) in Italy was danazol and stanazolol, two synthetic attenuated androgens (AA), which can predispose to cardiovascular and metabolic complaints (<xref rid=""B1"" ref-type=""bibr"">1</xref>). In January 2023, subcutaneous plasma-derived C1INH also arrived on the market and berotralstat in March 2024. Zanichelli et al. recently found a greater incidence of hypertension (22.8% vs. 10.8%; OR 2.02), hypercholesterolemia (19.5% vs. 5.3%; OR 3.97), and diabetes mellitus (5% vs. 1.4%; OR 3.21) in HAE-C1INH",8_3,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"mellitus (5% vs. 1.4%; OR 3.21) in HAE-C1INH patients on AA as LTP from a large cohort of the Italian network for Hereditary and Acquired Angioedema (ITACA). Renal failure was reported as a comorbidity in 3.8% of cases, with AA as a risk factor (OR 1.58 from 0.59 to 4.24) (<xref rid=""B6"" ref-type=""bibr"">6</xref>). For this reason, especially in uremic patients in whom cardiovascular diseases represent the first cause of death (<xref rid=""B7"" ref-type=""bibr"">7</xref>), it is essential to discontinue AA",8_4,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"it is essential to discontinue AA treatment. Here, we report a case of an immunosuppressed kidney transplant patient with HAE-C1INH who discontinued AA prophylaxis and switched to Lanadelumab LTP. A male patient, 57 years old, presented in 1984, at the age of 17, to the Emergency Room for his first episode of angioedema, affecting one arm (<xref rid=""f1"" ref-type=""fig"">",8_5,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
<bold>Figure 1</bold>,8_6,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"</xref>). Blood analysis showed evidence of previously unknown acute renal failure, and soon after, he started immunosuppressive therapy with steroids and cyclosporin. Unfortunately, disease progression led the patient to hemodialysis in the next year, and at that time, no clear definition of nephropathy was provided. In the following five years, he continued to experience a mean of two attacks per month of angioedema with localization on the face or limbs that were treated with standard therapy",8_7,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"or limbs that were treated with standard therapy (corticosteroids and antihistamines) without regression of symptoms. Finally, on January 1989 he was diagnosed as HAE-C1INH type I (C1-INH antigen: 0.02 g/L; normal range: 0.21-0.38 g/L; Functional C1INH activity:10%; normal range: 70-130%; C4: 0.03g/L; normal range 0. 1-0.4 g/L). C1q plasma level was normal (0.23 g/L; referral range: 0.1-0.25 g/L), a common finding in hereditary angioedema. Family screening tested negative and classified the patient as a",8_8,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"tested negative and classified the patient as a <italic toggle=""yes"">de novo</italic> mutation. Unfortunately, his children would have been later affected by angioedema, thus confirming the diagnosis of HAE-C1INH type I. The patient was treated with on-demand plasma-derived C1INH concentrate administered intravenously in case of an acute attack with rapid regression of angioedema symptoms. However, the frequency of episodes prompted us to prescribe LTP with stanozolol 4 mg QD in March 1989. Before AA",8_9,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"with stanozolol 4 mg QD in March 1989. Before AA treatment, he discovered an HCV infection serotype 2a/2c. This liver disease was considered, but due to the high number of angioedema attacks, AA therapy was started with strict control of liver functional exams and ultrasound evaluation every six months. The attenuated androgen was well tolerated and effective in preventing recurrences of angioedema, reduced to only one attack per year. After one year of treatment, the dose of stanozolol was reduced to 1 mg",8_10,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"the dose of stanozolol was reduced to 1 mg with sustained control of attacks. In October 1991, the patient underwent a kidney transplant, and therapy with steroids and cyclosporine was reintroduced. Shortly after, he developed arterial hypertension treated with beta-blockers. In 1994, he changed AA prophylaxis, switching to Danazol at 100 mg due to the lack of stanazolol on the market. This change didn’t affect the efficacy of AA prophylaxis. Due to the development of concentric myocardial hypertrophy, a",8_11,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"of concentric myocardial hypertrophy, a steroid-sparing immunosuppressive treatment with mycophenolate was started in 2002 when the patient was 35 years old. Doxazosin and amlodipine were added as antihypertensive drugs, and the clinical situation remained stable until 2012, when he developed cyclosporin nephropathy, leading to transplant failure with the need for peritoneal dialysis. This procedure, probably together with psychological stress, resulted in a recrudescence of HAE attacks, and the dose of",8_12,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"a recrudescence of HAE attacks, and the dose of Danazol was increased to 100 mg BID – despite comorbidities - to obtain disease control. After bacterial peritonitis in 2015, hemodialysis through a central venous catheter three times per week was recommended. Finally, after the onset of severe anemia requiring alpha erythropoietin administration, two catheter-related systemic infections, and the exclusion of active HCV infection, he performed a second kidney transplant in 2018. Histopathology from the",8_13,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"in 2018. Histopathology from the removed kidney was consistent with IgA nephropathy. Since then, immunosuppressive treatment with mycophenolate 1000 mg, tacrolimus 1 mg, and prednisone 5mg QD is still ongoing together with calcium-mimetic therapy (Cinacalcet 30 mg) for persistent, post-transplant hyperparathyroidism. In June 2023, when the patient was 56 years old, we calculated the cardiovascular risk during a follow-up visit, according to the Matsushita et al. score incorporating kidney disease measures",8_14,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"score incorporating kidney disease measures into cardiovascular risk prediction (<xref rid=""B8"" ref-type=""bibr"">8</xref>), resulting in 13.2% at ten years (<xref rid=""B9"" ref-type=""bibr"">9</xref>). Furthermore, the patient reported weight gain (BMI 31.2 kg/m2) as an adverse event of AA. Therefore, although HAE-C1INH symptoms were well controlled with Danazol 100 mg BID effect. A novel prophylactic treatment for HAE-C1INH was proposed to reduce cardiovascular risk. After careful evaluation of the patient’s",8_15,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"risk. After careful evaluation of the patient’s need and extensive discussion with him, he gradually reduced the posology of danazol 50 mg every two weeks until discontinuation in 8 weeks. Then, he started lanadelumab 300 mg SC every two weeks. After a six-month attack-free period, the dosing interval of lanadelumab was extended to four weeks. The patient is still asymptomatic for angioedema; he lost 4 kg in weight, and the cardiovascular risk is now 9.3% at ten years, thanks to improved lipid metabolism",8_16,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"at ten years, thanks to improved lipid metabolism (<xref rid=""T1"" ref-type=""table"">",8_17,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
<bold>Table 1</bold>,8_18,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"</xref>). According to the latest WAO-EAACI 2022 guidelines for hereditary angioedema, four treatments are indicated for LTP in patients with HAE-C1INH: berotralstat, lanadelumab, and subcutaneous or intravenous plasma-derived C1INH concentrates. All these drugs show a safe cardiovascular profile. At the same time, attenuated androgens are now considered a second-choice treatment to be used only if specific medications are not available, as they may induce several side effects resulting in increased",8_19,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"several side effects resulting in increased cardiovascular risk (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B5"" ref-type=""bibr"">5</xref>, <xref rid=""B6"" ref-type=""bibr"">6</xref>). While there are no consensus guidelines on how best to stop AAs, several real-world strategies have been described for transitioning from AAs to first-line LTP. These strategies are based on tapering, overlapping treatments, or an immediate switch (<xref rid=""B10"" ref-type=""bibr"">10</xref>). The latter approach has",8_20,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"The latter approach has raised concerns regarding an increase in HAE attacks and other adverse events (<xref rid=""B10"" ref-type=""bibr"">10</xref>). It is recommended to avoid abrupt withdrawal of AAs when transitioning to novel prophylaxis to minimize side effects from AA withdrawal. In our case, we decided to taper the androgen dose with reliable access to on-demand medication to treat HAE symptoms to reduce the anxiety related to androgen discontinuation in a patient with thirty-four years of AA",8_21,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"in a patient with thirty-four years of AA treatment. This approach can be individualized based on the duration of androgen therapy, adverse effects experienced, transition plans to another treatment and patient anxiety related to androgen discontinuation. Our patient didn’t experience increased HAE attacks during the eight weeks of AA tapering. However, we decided to start the new LTP to minimize the patient’s burden of disease, who experienced a lot of medical procedures and complications in his whole",8_22,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"medical procedures and complications in his whole life. The plasma kallikrein inhibitor Berotralstat might theoretically represent, given the oral route of administration, the most practical alternative to attenuated androgens. However, adverse effects include urinary tract infection and diarrhea (APEX study, 9.9% and 6.2% of patients, respectively) (<xref rid=""B11"" ref-type=""bibr"">11</xref>) that could lead to a worsening of renal failure, especially in kidney transplanted patients. Moreover, Berotralstat",8_23,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"transplanted patients. Moreover, Berotralstat presents some relevant drug-to-drug interference (<xref rid=""T2"" ref-type=""table"">",8_24,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
<bold>Table 2</bold>,8_25,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"</xref>), which suggests not considering this drug, available in Italy only since March 2024, as the best option to replace attenuated androgens in patients such as the current case report. Subcutaneous and intravenous plasma-derived C1-INH concentrates represent another approach for LTP in C1INH deficiency. This LTP aims to replace the lacking protein without any potential drug interactions. However, local adverse events may occur (site of injection-related pain, hematoma, bleeding, induration, bruising)",8_26,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"pain, hematoma, bleeding, induration, bruising) mostly in older HAE-C1INH patients (<xref rid=""B12"" ref-type=""bibr"">12</xref>), and there is a relevant burden of treatment mainly related to the interval of administration, which is every 3-4 days for both the available formulations. Moreover, our patient used to travel to foreign countries for at least one month every year; thus, carrying a high number of vials for LTP results with him during his travel is unfeasible (<xref rid=""B12""",8_27,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"during his travel is unfeasible (<xref rid=""B12"" ref-type=""bibr"">12</xref>). Lanadelumab, a human monoclonal antibody targeting plasma kallikrein, effectively prevents angioedema attacks in patients with HAE-C1INH. Minor injection site reactions, such as pain, redness, and bruising, are present in 42.9% of patients but do not represent a relevant complaint nor a cause of discontinuation in real life (<xref rid=""B13"" ref-type=""bibr"">13</xref>). Subcutaneous Lanadelumab must be injected every 14 days at 300",8_28,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"Lanadelumab must be injected every 14 days at 300 mg (1 vial sc) for the first six months. The interval can be extended to every four weeks if adequate control is achieved. No dedicated studies have been conducted to evaluate the pharmacokinetics of Lanadelumab in patients with renal failure, but based on pharmacokinetic analysis, renal impairment (estimated GFR: 60 to 89 mL/min/1.73m2, [mild, N=98] and 30 to 59 mL/min/1.73m2, [moderate, N=9]) does not affect the clearance or volume of distribution of",8_29,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"affect the clearance or volume of distribution of Lanadelumab. Our patient’s GFR was over 30mL/min/1.73m2, thus satisfying this inclusion criterion. Concomitant medications such as analgesic, antibacterial, antihistamine, anti-inflammatory, and anti-rheumatic medications did not affect the clearance and volume of distribution of Lanadelumab during the Randomized control trial. Moreover, Cytochrome P450 enzymes, efflux pumps, and protein binding mechanisms are not involved in the clearance of human",8_30,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"are not involved in the clearance of human monoclonal antibodies, thus limiting potential interactions (<xref rid=""B14"" ref-type=""bibr"">14</xref>) in patients on multiple therapies, as in our case. The concern we had when the patient was switched from androgens to lanadelumab was the potential effect of adding lanadelumab to the ongoing immunosuppressive treatment, as a higher rate of upper respiratory infection had been reported compared with placebo (44% vs. 32%) in the loading dose period of 300 mg",8_31,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"vs. 32%) in the loading dose period of 300 mg every two weeks (<xref rid=""B13"" ref-type=""bibr"">13</xref>). During the 13-month follow-up period, our patient showed no evidence of infections or adverse side effects. Lanadelumab was effective and safe as LTP for HAE-C1INH in an immunosuppressed patient, kidney transplant recipient, and with multiple comorbidities. Replacing attenuated androgens with lanadelumab has also improved metabolic control and reduced cardiovascular risk.",8_32,Lanadelumab in a kidney transplant patient with hereditary angioedema due to C1-inhibitor deficiency and high cardiovascular risk - a case report,27 9 2024,,Hereditary_Angioedema
"A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema The plasma kallikrein-kinin system (KKS) lies at an interface between <italic toggle=""yes"">coagulation</italic> through the activation of the intrinsic coagulation pathway, and <italic toggle=""yes"">inflammation</italic> via its ability to generate bradykinin, a potent mediator of vascular permeability, inflammation, and pain (<xref rid=""B1"" ref-type=""bibr"">1</xref>). The KKS consists of prekallikrein (PK),",9_0,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"The KKS consists of prekallikrein (PK), high-molecular-weight kininogen (HK), and coagulation factor XII (FXII) and is activated by FXII autoactivation upon exposure to negatively charged surfaces, the exact endogenous identity of which remains elusive (<xref rid=""B2"" ref-type=""bibr"">2</xref>). KKS activation can also involve membrane-associated prolylcarboxypeptidase or a complex of PK, HK, and heat shock protein 90 (HSP90) on endothelial cells (<xref rid=""B2"" ref-type=""bibr"">2</xref>). The initial",9_1,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"rid=""B2"" ref-type=""bibr"">2</xref>). The initial generation of plasma kallikrein (PKa) promotes a rapid burst of localized KKS activation through the PKa-catalyzed conversion of FXII to its active form (FXIIa), which generates additional PKa (<xref rid=""B3"" ref-type=""bibr"">3</xref>). FXIIa can initiate the intrinsic coagulation pathway through the generation of FXIa, and inhibitors of FXIIa and FXIa have been proposed as novel anti-thrombotic agents, as they have the potential to be anti-thrombotic without",9_2,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"have the potential to be anti-thrombotic without increasing the risk of bleeding (<xref rid=""B4"" ref-type=""bibr"">4</xref>). PKa also cleaves HK to liberate bradykinin, a 9-amino acid peptide, and cleaved HK (HKa). Bradykinin-mediated edema occurs through the activation of the constitutively expressed B2 receptor or the inducible B1 receptor (<xref rid=""B5"" ref-type=""bibr"">5</xref>). Endogenous KKS activation is regulated through protease inhibitors, including <italic toggle=""yes"">α</italic>2-macroglobulin",9_3,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"<italic toggle=""yes"">α</italic>2-macroglobulin and C1 inhibitor (C1INH) (<xref rid=""B6"" ref-type=""bibr"">6</xref>). A genetic deficiency in C1INH leads to dysregulated KKS activation, excess bradykinin production, and the debilitating disease of hereditary angioedema due to C1INH deficiency (HAE-C1INH) (<xref rid=""B3"" ref-type=""bibr"">3</xref>). HAE-C1INH is an autosomal dominant disease manifesting as intermittent edematous attacks at locations that include the gastrointestinal tract, facial tissue, the",9_4,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"the gastrointestinal tract, facial tissue, the upper airway, oropharynx, urogenital region, and/or extremities. Patients with HAE-C1INH type I have mutations in the <italic toggle=""yes"">SERPING1</italic> gene that lead to a deficiency in the total amount of C1INH protein, whereas HAE-C1INH type II patients have a dysfunctional C1INH (<xref rid=""B7"" ref-type=""bibr"">7</xref>). The role of excess KKS activation in HAE-C1INH pathophysiology has been validated by the approval of therapies that include C1INH",9_5,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"by the approval of therapies that include C1INH protein replacement products, a bradykinin B2 receptor antagonist (icatibant), and PKa inhibitors (ecallantide, lanadelumab, and berotralstat). HKa has previously been shown to be a disease state biomarker of KKS activation and is elevated in plasma from HAE-C1INH patients and other disease states (<xref rid=""B8"" ref-type=""bibr"">8</xref>–<xref rid=""B18"" ref-type=""bibr"">18</xref>). We describe the development of a novel enzyme-linked immunosorbent assay",9_6,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"of a novel enzyme-linked immunosorbent assay (ELISA) to specifically detect HKa in human plasma and demonstrate the utility of the assay in comparing the <italic toggle=""yes"">in vitro</italic> potency of PKa inhibitors.  A human antibody phage display library (<xref rid=""B19"" ref-type=""bibr"">19</xref>) was depleted against HK and panned against HKa, from which over 6,700 putative positive phage colonies were obtained. Phage clones positive for binding to immobilized HKa were selected, sub-cloned for",9_7,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"to immobilized HKa were selected, sub-cloned for soluble Fab fragment expression, and further screened for HKa specificity by an ELISA. As target immobilization could mask epitope(s) present in HKa as opposed to HK, and as the goal was to develop an ELISA to detect soluble HKa in plasma, subsequent screening was performed using purified Fabs immobilized on 384-well or 96-well plates with the detection of either biotinylated HK, LK, or HKa binding via streptavidin-HRP. The specificity of 190 anti-kininogen",9_8,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"The specificity of 190 anti-kininogen binding Fabs is shown in <xref rid=""F1"" ref-type=""fig"">Figure 1</xref> where the Fab M4-B4 (aka M004-B04) exhibited the highest specificity for HKa vs. HK or LK (see <xref rid=""s10"" ref-type=""sec"">Supplementary Figure S1</xref> for the specificity of two other Fabs and <xref rid=""s10"" ref-type=""sec"">Supplementary Figure S8</xref> for the amino acid sequence of the M4-B4 Fab). The ability of the M4-B4 antibody to detect HKa was investigated in human plasma treated with",9_9,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"HKa was investigated in human plasma treated with the KKS activator ellagic acid (<xref rid=""B21"" ref-type=""bibr"">21</xref>), purified FXIIa, or purified PKa (<xref rid=""F2"" ref-type=""fig"">Figure 2</xref>). KKS activation was assessed by WBA (<xref rid=""F2"" ref-type=""fig"">Figure 2A</xref>) using a mouse monoclonal antibody (11H05) that binds intact HK as well as the 56- and 46-kDa forms of the HKa light chain. With WBA, activated human plasma showed a reduction in the band corresponding to intact HK and",9_10,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"in the band corresponding to intact HK and increases in the two bands corresponding to light chain (<xref rid=""F2"" ref-type=""fig"">Figure 2A</xref>). Activated plasma displayed an increased HKa ELISA signal (<xref rid=""F2"" ref-type=""fig"">Figure 2B</xref>). Of note, our ELISA did not detect endogenous HKa in plasma from cynomolgus monkeys, mice, or rats after activation with ellagic acid (data not shown). FXII- and PK-deficient plasma demonstrated the specificity of M4-B4 for HKa. As expected, HKa was not",9_11,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"of M4-B4 for HKa. As expected, HKa was not generated in FXII-deficient plasma treated with ellagic acid (lane 10 of <xref rid=""F2"" ref-type=""fig"">Figure 2A</xref> and the solid gray bar in <xref rid=""F2"" ref-type=""fig"">Figure 2B</xref>), but was produced after the addition of FXIIa (lane 11 of <xref rid=""F2"" ref-type=""fig"">Figure 2A</xref> and the hatched bar in <xref rid=""F2"" ref-type=""fig"">Figure 2B</xref>) or PKa (lane 9 of <xref rid=""F2"" ref-type=""fig"">Figure 2A</xref> and the dotted bar in <xref",9_12,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"and the dotted bar in <xref rid=""F2"" ref-type=""fig"">Figure 2B</xref>). Ellagic acid activates the KKS through the formation of an insoluble metal ion complex that serves as a charged surface to promote FXII autoactivation to FXIIa (<xref rid=""B22"" ref-type=""bibr"">22</xref>). It was therefore expected that ellagic acid would be unable to activate the KKS in FXII-deficient or PK-deficient plasma. PK-deficient plasma was only activated by the addition of PKa. Human plasma collected using EDTA as an",9_13,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"of PKa. Human plasma collected using EDTA as an anticoagulant was activated similarly to sodium citrate plasma, as shown by HKa generation using WBA (<xref rid=""F2"" ref-type=""fig"">Figure 2A</xref>), supporting the previous observation that metal ions are not required for KKS activation (<xref rid=""B6"" ref-type=""bibr"">6</xref>). Interestingly, despite HKa formation in activated EDTA plasma by WBA (<xref rid=""F2"" ref-type=""fig"">Figure 2B</xref>), HKa was not detected by an ELISA (<xref rid=""F2""",9_14,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"HKa was not detected by an ELISA (<xref rid=""F2"" ref-type=""fig"">Figure 2B</xref>), suggesting that M4-B4 binding to HKa may be metal ion-dependent, which was restored by the addition of zinc chloride at concentrations that exceeded the EDTA concentration in the blood collection tube (<xref rid=""s10"" ref-type=""sec"">Supplementary Figure S2</xref>). Surface plasmon resonance analyses demonstrated that M4-B4 bound HKa with approximately a sixfold higher affinity in the presence of zinc chloride",9_15,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"higher affinity in the presence of zinc chloride (K<sub>D</sub> = 1.06 ± 0.25 nM) than in its absence (K<sub>D</sub> = 6.08 ± 0.26 nM) (<xref rid=""s10"" ref-type=""sec"">Supplementary Figure S3</xref> and <xref rid=""s10"" ref-type=""sec"">Supplementary Table S2</xref>). Zinc has been previously shown to induce conformational changes in HK (<xref rid=""B23"" ref-type=""bibr"">23</xref>, <xref rid=""B24"" ref-type=""bibr"">24</xref>). HK and LK are cleaved by tissue kallikrein 1 (KLK1) (<xref rid=""B25""",9_16,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"by tissue kallikrein 1 (KLK1) (<xref rid=""B25"" ref-type=""bibr"">25</xref>), as confirmed by WBA (<xref rid=""F3"" ref-type=""fig"">Figure 3A</xref>). Although the form of HKa generated by KLK1 was detected by the ELISA, KLK1-cleaved LK was not detected (<xref rid=""F3"" ref-type=""fig"">Figure 3B</xref>). KLK1-cleaved HK consists mainly of the 56-kDa light chain (lanes 4 and 5 of <xref rid=""F3"" ref-type=""fig"">Figure 3A</xref>), whereas the purified HKa standard protein mainly consists of the 46-kDa light chain (see",9_17,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"mainly consists of the 46-kDa light chain (see lane 2 of <xref rid=""F3"" ref-type=""fig"">Figure 3A</xref>), which suggests that M4-B4 binds HKa at either light chain variant. Standard curves prepared by spiking HKa into citrated plasma from HVs demonstrated a lower limit of quantitation of approximately 156 ng/ml at a dilution of 1:320 (<xref rid=""s10"" ref-type=""sec"">Supplementary Figure S4</xref>). HKa levels in citrated and SCAT169 plasma from HVs and HAE-C1INH patients were compared using a WBA and an",9_18,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"patients were compared using a WBA and an ELISA (<xref rid=""F4"" ref-type=""fig"">Figure 4</xref>, <xref rid=""s10"" ref-type=""sec"">Supplementary Table S1</xref>). HKa levels were higher (<italic toggle=""yes"">p </italic>< 0.05) in both plasma types from HAE-C1INH patients collected either during an attack or in a basal state of disease quiescence than from HVs, using either assay (<xref rid=""s10"" ref-type=""sec"">Supplementary Table S3</xref>). Although the percentage of HKa by WBA was higher during an attack",9_19,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"of HKa by WBA was higher during an attack than under the basal disease state, it did not reach statistical significance (<italic toggle=""yes"">p </italic>< 0.05). In contrast, a statistical difference in HKa plasma levels between the basal and attack disease states was observed by an ELISA. ROC analysis of WBA data demonstrated that HKa levels in citrated plasma can differentiate HAE-C1INH from HVs with an area under the curve (AUC) value of 0.977 for the comparison of basal with HVs or 1.0 for the",9_20,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"the comparison of basal with HVs or 1.0 for the comparison of attack with HVs (<xref rid=""s10"" ref-type=""sec"">Supplementary Table S3</xref>, <xref rid=""s10"" ref-type=""sec"">Supplementary Figure S5</xref>). Plasma HKa levels for HAE-C1INH patients in citrated plasma collected between attacks (i.e., basal samples) were less differentiated from attack samples (AUC = 0.625). Similarly, ROC analysis of WBA data demonstrated that HKa levels in SCAT169 plasma differentiates HAE-C1INH from HVs, with an AUC value of",9_21,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"HAE-C1INH from HVs, with an AUC value of 0.915 for the comparison of basal with HVs or 0.967 for the comparison of attack with HVs (<xref rid=""s10"" ref-type=""sec"">Supplementary Table S3</xref>, <xref rid=""s10"" ref-type=""sec"">Supplementary Figure S5</xref>). Plasma HKa levels for HAE-C1INH patients in SCAT169 plasma collected between attacks were less differentiated from attack samples (AUC = 0.597). ROC analysis of HKa ELISA data in citrated plasma also differentiated HAE-C1INH from HVs, with an AUC value",9_22,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"HAE-C1INH from HVs, with an AUC value of 0.915 for the comparison of basal with HVs or 0.866 for the comparison of attack with HVs (<xref rid=""s10"" ref-type=""sec"">Supplementary Table S3</xref>, <xref rid=""s10"" ref-type=""sec"">Supplementary Figure S5</xref>). HAE-C1INH basal citrated plasma samples were better differentiated from attack samples (AUC = 0.709) by an ELISA than by a WBA. ROC analysis suggests that the ELISA with SCAT169 plasma may be best suited for differentiating HAE-C1INH from HVs, as shown",9_23,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"for differentiating HAE-C1INH from HVs, as shown by ROC analysis, with an AUC value of 0.999 for the comparison of basal with HV or 1.0 for the comparison of attack with HV. Finally, the ELISA with SCAT169 plasma appeared best suited for the differentiation of HAE-C1INH basal from attack samples (AUC = 0.818). HKa levels assessed by an ELISA in plasma collected using P100 tubes (BD Biosciences), which contain protease inhibitors, were lower than in citrated plasma from the same 30 individual HVs (<xref",9_24,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"plasma from the same 30 individual HVs (<xref rid=""s10"" ref-type=""sec"">Supplementary Figure S6</xref>). When the plasma was subjected to five freeze/thaw cycles, there was an apparent reduction in the ELISA signal after four cycles in citrated plasma and in P100 plasma collected in 8-ml tubes that contained a serum separator, but the ELISA signal appeared more stable in freeze/thaw cycles in P100 plasma collected in 2-ml tubes (<xref rid=""s10"" ref-type=""sec"">Supplementary Figure S7</xref>). The complete",9_25,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"Figure S7</xref>). The complete inhibition of the HKa ELISA signal by the specific antibody inhibitor of PKa, lanadelumab (<xref rid=""B26"" ref-type=""bibr"">26</xref>, <xref rid=""B27"" ref-type=""bibr"">27</xref>), with an IC<sub>50</sub> of approximately 0.044 µM, or BD-105294, a novel small-molecule PKa inhibitor [the synthesis (<xref rid=""B28"" ref-type=""bibr"">28</xref>) of which is described in the supplementary methods] with an IC<sub>50</sub> = 0.082 µM, indicates that the ELISA signal is PKa mediated",9_26,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"indicates that the ELISA signal is PKa mediated (<xref rid=""F5"" ref-type=""fig"">Figure 5</xref>). The observation that other reported PKa inhibitors were less effective in reducing HKa generation in activated plasma requires further investigation (<xref rid=""s10"" ref-type=""sec"">Supplementary Table S4</xref>). However, confirmation that the HKa signal does indeed originate from PKa activity in activated plasma was obtained by multiple small-molecule PKa inhibitors screened at Takeda in the HKa ELISA and",9_27,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"screened at Takeda in the HKa ELISA and assessed for oral bioavailability in the rat (<xref rid=""s10"" ref-type=""sec"">Supplementary Figure S9</xref>) and by EPI-KAL-2, a recombinant Kunitz domain PKa inhibitor previously discovered using phage display (<xref rid=""B29"" ref-type=""bibr"">29</xref>), which was also a potent inhibitor in the HKa ELISA with FXIIa activation (IC<sub>50</sub> = 0.15 µM). The HKa-specific antibody M4-B4 was identified from a phage display library (<xref rid=""B19""",9_28,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"from a phage display library (<xref rid=""B19"" ref-type=""bibr"">19</xref>). The specificity of M4-B4 suggests that the antibody binds a neo-epitope(s) on HKa not present on HK or LK that is dependent on PKa or KLK1 activity. HK is a 626 amino acid glycoprotein that consists of six domains, and PKa or KLK1 cleave within domain four to release bradykinin or Lys-bradykinin, respectively, and generate HKa, which consists of two polypeptide chains linked by a disulfide (<xref rid=""B30"" ref-type=""bibr"">30</xref>).",9_29,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"(<xref rid=""B30"" ref-type=""bibr"">30</xref>). HKa has bioactivities (e.g., induction of endothelial cell apoptosis and inhibition of angiogenesis) not exhibited by HK (<xref rid=""B31"" ref-type=""bibr"">31</xref>), which is consistent with HKa having a distinct conformation from HK that is recognized by M4-B4. The increased binding affinity of M4-B4 for HKa in the presence of zinc suggests that the epitope may be near, or influenced by, the zinc-binding site on domain five of the light chain, which mediates",9_30,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"on domain five of the light chain, which mediates the assembly of the KKS on cell surface receptors (<xref rid=""B32"" ref-type=""bibr"">32</xref>). The importance of plasma collection methods and stabilization against proteolytic degradation has been described previously for the analysis of KKS activation (<xref rid=""B11"" ref-type=""bibr"">11</xref>). Contact of plasma with glass or other surfaces can result in extensive <italic toggle=""yes"">ex vivo</italic> KKS activation (<xref rid=""B6""",9_31,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"vivo</italic> KKS activation (<xref rid=""B6"" ref-type=""bibr"">6</xref>). Consequently, plasma obtained in this study relied on a blood collection protocol to minimize <italic toggle=""yes"">ex vivo</italic> KKS activation. <italic toggle=""yes"">Ex vivo</italic> KKS activation can be further minimized using an anticoagulant mixture that includes protease inhibitors (<xref rid=""B11"" ref-type=""bibr"">11</xref>, <xref rid=""B13"" ref-type=""bibr"">13</xref>). In this study, <italic toggle=""yes"">ex vivo</italic> KKS",9_32,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"study, <italic toggle=""yes"">ex vivo</italic> KKS activation, as measured by the concentration of HKa, was higher in citrated plasma from HVs and HAE-C1INH patients than in plasma collected in blood collection tubes that contained protease inhibitors (SCAT169 or P100 tubes). The amount of HKa in citrated plasma by WBA during HAE-C1INH attacks was approximately 61.5% (<xref rid=""s10"" ref-type=""sec"">Supplementary Table S1</xref>), which is similar to previous estimates (<xref rid=""B11""",9_33,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"is similar to previous estimates (<xref rid=""B11"" ref-type=""bibr"">11</xref>, <xref rid=""B33"" ref-type=""bibr"">33</xref>). An HKa ELISA in SCAT169 may provide estimates of the amount of HKa generated during an HAE-C1INH attack (4.4% or 32.7 nM), in basal HAE-C1INH conditions (2.2% or 16.2 nM), or in healthy controls (0.5% or 3.4 nM) (<xref rid=""s10"" ref-type=""sec"">Supplementary Table S1</xref>). HKa concentrations should match the concentration of bradykinin generated during an attack, and the following",9_34,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"generated during an attack, and the following evidence indicates that an approximately equivalent amount of PKa is generated during an HAE-C1INH attack: (1) the concentration of covalent PKa-α-macroglobulin complex (30–110 nM) during an attack (<xref rid=""B34"" ref-type=""bibr"">34</xref>) and (2) PKa estimates calculated from the extent of PK consumption during an attack (<xref rid=""B35"" ref-type=""bibr"">35</xref>, <xref rid=""B36"" ref-type=""bibr"">36</xref>) and (3) from the maximum concentration",9_35,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"and (3) from the maximum concentration (C<sub>max</sub> = 83 nM) of ecallantide, which is a PKa inhibitor approved for treating an HAE-C1INH attack (<xref rid=""B37"" ref-type=""bibr"">37</xref>). Comparable concentrations of PKa and HKa suggest that when the KKS is activated at angioedema attack locations, the generated PKa cleaves HK with approximately equimolar stoichiometry (i.e., single turnover catalytic conditions). Therefore, KKS activation occurring <italic toggle=""yes"">in vivo</italic> during an",9_36,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"<italic toggle=""yes"">in vivo</italic> during an HAE-C1INH attack involves approximately equal concentrations of PKa protease and HK natural protein substrate and are expected to undergo fewer catalytic turnovers than <italic toggle=""yes"">in vitro</italic> reactions using a high concentrations of a synthetic peptide PKa substrate (e.g., 100 μM) that is at least 1000-fold higher than the concentration of PKa in undiluted activated plasma (∼100 nM) or in purified protein assays (∼1 nM). The higher catalytic",9_37,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"protein assays (∼1 nM). The higher catalytic turnovers expected with synthetic peptide substrates may contribute to the higher observed potency of certain reported PKa inhibitors measured using a fluorogenic synthetic peptide in minimally diluted plasma activated with FXIIa than with our HKa ELISA (see <xref rid=""s10"" ref-type=""sec"">Supplementary Table S4</xref>). Furthermore, the use of 90% plasma in our HKa ELISA, as opposed to higher dilutions of plasma, may better predict endogenous PKa inhibition as",9_38,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"may better predict endogenous PKa inhibition as the effects of interfering substances in the plasma (e.g., plasma protein binding) can be minimized at higher plasma dilutions and thereby artifactually increase the observed potency. The use of different KKS activators may also contribute to different observed potencies for PKa inhibitors; ellagic acid or dextran sulfate activates through inducing FXII autoactivation, the kinetics of which are not as immediate as directly adding FXIIa (<xref rid=""B38""",9_39,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"as directly adding FXIIa (<xref rid=""B38"" ref-type=""bibr"">38</xref>). Therefore, KKS activation induced by FXIIa addition may be expected to generate PKa more rapidly than other reported activators and thereby require higher inhibitor concentrations than KKS activators that act via FXII autoactivation. Consequently, our HKa ELISA may be a useful <italic toggle=""yes"">in vitro</italic> assay for helping to predict <italic toggle=""yes"">in vivo</italic> efficacy for PKa inhibitors in development for HAE-C1INH",9_40,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"for PKa inhibitors in development for HAE-C1INH and other indications potentially mediated by PKa, such as bradykinin-mediated angioedema (<xref rid=""B39"" ref-type=""bibr"">39</xref>), diabetic macular edema (<xref rid=""B40"" ref-type=""bibr"">40</xref>), Alzheimer's disease (<xref rid=""B15"" ref-type=""bibr"">15</xref>), ischemic stroke (<xref rid=""B41"" ref-type=""bibr"">41</xref>), myocardial infarction (<xref rid=""B42"" ref-type=""bibr"">42</xref>), systemic lupus erythematosus (<xref rid=""B43""",9_41,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"systemic lupus erythematosus (<xref rid=""B43"" ref-type=""bibr"">43</xref>), cancer (<xref rid=""B44"" ref-type=""bibr"">44</xref>), and sepsis (<xref rid=""B45"" ref-type=""bibr"">45</xref>).",9_42,A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema,17 9 2024,,Hereditary_Angioedema
"Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report Hereditary angioedema (HAE) is a rare disorder that causes episodes of angioedema due to a mutation in the C1 esterase inhibitor gene (C1-INH). Complications of HAE include intestinal obstruction, asphyxiation, and venous thromboembolism (VTE). In this case, we report a 34-year-old G4P2011 female with HAE at 24 weeks gestation presenting with acute right upper extremity pain and swelling following a",10_0,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"upper extremity pain and swelling following a peripherally inserted central catheter (PICC) line for HAE treatment infusion, revealing a right upper extremity VTE. Early treatment with Lovenox, PICC line removal, and continuation of HAE therapy via peripheral IV infusion resolved and prevented further angioedema and subsequent VTEs during this patient’s pregnancy. This case serves as an example of effective management of HAE complications during pregnancy and supports peripheral IV line usage over PICC",10_1,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"and supports peripheral IV line usage over PICC lines for medication infusions in pregnant patients with HAE. The overall purpose of this case report is to improve safety outcomes for pregnant patients with HAE by mitigating the risks of PICC line usage and to highlight the significance of VTE inclusion within the differential diagnosis in this population. Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by a mutation in the C1 esterase inhibitor gene (C1-INH), predisposing affected",10_2,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"inhibitor gene (C1-INH), predisposing affected individuals towards episodes of angioedema during times of acute stress [<xref rid=""REF1"" ref-type=""bibr"">1</xref>]. Symptoms of HAE include cutaneous, gastrointestinal, and airway angioedema leading to complications such as small intestinal obstruction and asphyxiation [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Additionally, research suggests that individuals with HAE are at a significantly elevated risk for venous thromboembolism (VTE) compared to the",10_3,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"for venous thromboembolism (VTE) compared to the general population [<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. Episodes of HAE are often unpredictable and severe, and without effective treatment, mortality rates exceed 30% [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. HAE is thought to affect 1 per 50,000 people in the general population without significant differences in sex or ethnicity [<xref rid=""REF4"" ref-type=""bibr"">4</xref>]. Although males and females are thought to be equally affected by HAE,",10_4,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"are thought to be equally affected by HAE, females may be at an increased risk for more severe cases of angioedema due to the coagulative effects of estrogen [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Furthermore, the complex and changing nature of hormones during pregnancy puts patients with HAE at a variable and unpredictable risk of acute attacks which must be carefully monitored and managed by their medical provider [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. This case report illustrates a",10_5,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"This case report illustrates a 34-year-old G4P2011 female patient at 24 weeks gestation with HAE who presented with an acute peripherally inserted central catheter (PICC) line malfunction and upper extremity VTE treated with Lovenox protocol and PICC line removal. Replacement of the PICC line with a peripheral IV for HAE medication administration resolved and prevented further angioedema and VTEs during this patient’s pregnancy and delivery, supporting the use of peripheral IV lines for primary medical",10_6,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"use of peripheral IV lines for primary medical management. Given the inherent hypercoagulable state of both HAE and pregnancy, physicians should have a higher index of suspicion for VTE upon patient presentation and include thrombotic complications in the differential diagnosis. A 34-year-old G4P2011 female patient at 24 weeks gestation with HAE presented to the emergency department (ED) complaining of PICC line leakage. After flushing the line and ensuring proper functioning, the patient was discharged",10_7,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"proper functioning, the patient was discharged home to follow up with home health for medication infusions. No labs were obtained at that time.  The next day, the patient returned to the ED with two to three days of worsening right upper extremity erythema with pain radiating to the right axilla, and serous leakage from a PICC line on the right arm. She had a past medical history significant for fibromyalgia, arthritis, opioid use disorder on Suboxone, and prior VTE six years ago involving bilateral",10_8,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"and prior VTE six years ago involving bilateral subclavian veins and proximal right superior vena cava, currently on heparin subcutaneously (SQ). Additionally, the patient was originally taking Haegarda SQ and Firazyr SQ for HAE management. During this pregnancy, she was switched from Firazyr SQ to Ruconest as Firazyr is not preferred for pregnancy. As Ruconest is given intravenously (IV), a PICC line was inserted for infusions ten days prior to this ED evaluation. The patient stated that her last Ruconest",10_9,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"The patient stated that her last Ruconest infusion was two days before this ED visit. After the infusion, she developed erythema and pain in the right upper arm and described the return of serous leakage from the PICC line, thereby prompting ED evaluation. She admitted to similar symptoms with a previous left upper extremity VTE six years prior. She denied chest pain, shortness of breath, vaginal bleeding, vaginal discharge, and abdominal pain. The patient denied any pertinent family history. Her social",10_10,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"denied any pertinent family history. Her social history was significant for a five-pack-year smoking history and daily vaping. Physical examination revealed an afebrile, gravid, obese (BMI 34.5) female who appeared uncomfortable and was exhibiting no obvious signs of distress. There was mild edema and induration near the PICC line insertion site on the patient’s right upper arm and tenderness in the medial right upper arm that extend to the right axilla. Complete blood count (CBC) included a leukocytosis",10_11,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"blood count (CBC) included a leukocytosis of 13.4, neutrophilia of 10.2, and monocytosis of 0.9. Others including comprehensive metabolic panel (CMP), prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), urine drug screen, and the remainder of CBC were within normal limits. Venous Doppler duplex ultrasound of the right upper extremity showed an occlusive thrombus of the right subclavian, brachial, and axillary veins (Figure <xref rid=""FIG1""",10_12,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"and axillary veins (Figure <xref rid=""FIG1"" ref-type=""fig"">1</xref>). There was no thrombus present in the internal jugular vein or cephalic vein. The patient was subsequently admitted for acute VTE in the setting of PICC line malfunction and chronic HAE. The patient’s PICC line was removed. Home heparin treatment was held. A Lovenox protocol, 1 mg/kg SQ every 12 hours, was initiated. Home HAE medications were continued through a peripheral IV line. The patient was discharged home on day six of",10_13,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"The patient was discharged home on day six of hospitalization with the resolution of her right arm symptoms. Upon discharge, her home heparin treatment was reinitiated, and per cardiology recommendations, the patient was scheduled for placement of an additional PICC line in the left arm within two weeks. Due to patient nonadherence, PICC line placement was delayed to two months post-discharge and ultimately failed due to incompetent veins. Therefore, the patient continued to receive her Ruconest infusions",10_14,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"continued to receive her Ruconest infusions via peripheral IV. The remainder of the patient's pregnancy proceeded without any known complications. Three months after this admission, the patient delivered at 39 1/7 weeks gestation via C-section due to umbilical cord prolapse and fetal decelerations. Delivery was uncomplicated. Patients with HAE are at greater risk of experiencing acute attacks of angioedema spanning various organ systems [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Cutaneous angioedema is",10_15,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"Cutaneous angioedema is the most common symptom of HAE, affecting the face, extremities, and urogenital region [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Gastrointestinal angioedema can cause severe abdominal pain and swelling, leading to nausea, vomiting, and diarrhea [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Airway angioedema is the least common symptom of HAE but affects at least 50% of patients and results in asphyxiation if not treated [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Additional",10_16,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"rid=""REF2"" ref-type=""bibr"">2</xref>]. Additional complications of HAE include small intestinal obstruction and VTE [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Untreated episodes of angioedema typically last for three to five days [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. The frequency of attacks varies from weekly to less than once a year [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. This case highlights the management of acute HAE complications in a pregnant patient, encourages a high index of",10_17,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"in a pregnant patient, encourages a high index of suspicion for VTE in pregnant patients with HAE, and supports the use of peripheral IV lines instead of PICC lines in patients with an elevated risk for thrombosis. While males and females are equally affected by HAE, females are predisposed to more severe attacks of angioedema due to the thrombotic effects of estrogen [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. These attacks become more unpredictable in pregnancy due to the ever-changing hormonal",10_18,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"in pregnancy due to the ever-changing hormonal landscape of a gravid individual, making it crucial to carefully mitigate and manage potential HAE complications [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Current literature suggests that the frequency of acute HAE attacks increases by 83% in pregnancy [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Typical management of HAE includes acute and chronic treatments with C1-INH, kallikrein inhibitors, and receptor antagonists which may be administered via oral",10_19,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"antagonists which may be administered via oral route, SQ, or IV infusions [<xref rid=""REF1"" ref-type=""bibr"">1</xref>]. In a pregnant patient, management of HAE must change due to certain medication side effects. Icatibant, known by the brand name Firazyr, is a treatment for acute attacks of HAE and is not preferred for use in pregnancy due to documented preterm birth and miscarriages in animal studies [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Drugs currently indicated for the treatment of acute attacks",10_20,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"indicated for the treatment of acute attacks of HAE in pregnancy include plasma-derived C1-INH (Berinert) and Recombinant Human C1-INH (Ruconest) [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Medications indicated for long-term prophylaxis of HAE in pregnancy include plasma-derived C1-INH (Cinryze, Haegarda), lanadelumab (Takhzyro), berotralstat (Orladeyo), androgens (danazol), and antifibrinolytics (tranexamic acid) [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Most HAE medications are given orally and SQ.",10_21,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"Most HAE medications are given orally and SQ. However, some medications such as Ruconest, can only be administered IV. IV infusions may be given through a PICC line instead of a peripheral IV due to patient preference, increased comfort, and line durability [<xref rid=""REF5"" ref-type=""bibr"">5</xref>]. However, PICC lines have shown an increased association with upper extremity VTEs [<xref rid=""REF5"" ref-type=""bibr"">5</xref>]. As the use of central venous catheters and PICC lines increases, so does the",10_22,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"catheters and PICC lines increases, so does the incidence of upper extremity deep venous thrombosis (DVT) [<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. Upper extremity DVTs constitute 5-10% of all DVTs with an incidence of 14-23% in patients with central venous catheters [<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. Clinical presentation may include standard limb swelling and asymmetry but may be asymptomatic [<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. The most serious complication of an upper extremity DVT",10_23,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"serious complication of an upper extremity DVT is a pulmonary embolism [<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. Therefore, a high clinical index of suspicion for an upper extremity DVT should be present on the differential diagnosis in patients with a central venous catheter or PICC line malfunction, especially in high-risk populations. Due to the increased risk of thrombotic events in pregnancy and PICC line use, compounded by the inherent risk of VTE in HAE, it is imperative to consider using",10_24,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"of VTE in HAE, it is imperative to consider using peripheral IV lines for HAE medication administration instead of PICC lines [<xref rid=""REF2"" ref-type=""bibr"">2</xref>,<xref rid=""REF3"" ref-type=""bibr"">3</xref>,<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. Peripheral IV lines have been associated with a higher safety profile, easier placement, and decreased pain compared to PICC lines [<xref rid=""REF7"" ref-type=""bibr"">7</xref>]. While peripheral IV lines may cause discomfort and complicate the ability to",10_25,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"cause discomfort and complicate the ability to receive home medication infusions, they should be considered when the risks of using a PICC line do not outweigh the benefits, such as in the patient presented in this case. This case presentation illustrates successful medical management utilizing peripheral IV lines instead of a PICC line without additional adverse events or complications. It supports peripheral IV line usage over PICC lines for medication infusions in pregnant patients with HAE. As a",10_26,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"infusions in pregnant patients with HAE. As a result, one goal is to improve safety outcomes for pregnant patients with HAE by mitigating the risks of PICC line usage within this population. HAE is an inheritable disorder that causes acute episodes of angioedema that can lead to serious complications such as VTE. Few cases have been reported on the management of HAE complications in pregnant patients. This case supports the importance of including VTE in the differential diagnosis for patients with HAE,",10_27,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"the differential diagnosis for patients with HAE, showcases the effective management of an acute VTE in a gravid patient with HAE, and examines the benefits of using peripheral IV lines for HAE medication infusions instead of PICC lines in patients with a high risk for thrombosis.",10_28,Hereditary Angioedema in Pregnancy Complicated by Upper Extremity Deep Venous Thrombosis: A Case Report,4 9 2024,,Hereditary_Angioedema
"Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada Hereditary angioedema (HAE) is a chronic and rare disease characterized by recurrent and unpredictable episodes of swelling, predominantly in the subcutaneous and/or submucosal tissues of the extremities, larynx, face, abdomen, and genitals [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. HAE can be categorized",11_0,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"rid=""CR2"">2</xref>]. HAE can be categorized into two main types: HAE due to C1 inhibitor deficiency (HAE-C1-INH) and HAE with normal C1 inhibitor (HAE nC1-INH). HAE-C1-INH is due to an absolute or functional deficit of C1 inhibitor (Type I and Type II, respectively). In contrast, HAE nC1-INH presents with normal serum concentrations and function of C1 inhibitor, but similarly causes recurrent angioedema that is refractory to antihistamines and glucocorticoids [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Six",11_1,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"[<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Six monogenic forms of HAE nC1-INH have been described, but in most patients a genetic etiology is not identified [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Additionally, there are patients with recurrent non-histaminergic angioedema and normal C1 inhibitor who do not have a family history of similar disease, which can be termed idiopathic angioedema of unknown etiology (AE-UNK) [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr""",11_2,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>]. HAE nC1-INH and AE-UNK appear to be far less prevalent than HAE C1-INH [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>, <xref ref-type=""bibr"" rid=""CR8"">8</xref>], but there are few epidemiologic studies assessing their frequency [<xref ref-type=""bibr"" rid=""CR8"">8</xref>] In Germany, case numbers of HAE nC1-INH were estimated to be 1:100,000 in 2015 and 1:200,000 in Manitoba, Canada in 2019 [<xref",11_3,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"and 1:200,000 in Manitoba, Canada in 2019 [<xref ref-type=""bibr"" rid=""CR9"">9</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>], based on cases identified and the population of Germany and Manitoba respectively, and for AE-UNK they were estimated to be 1:200,000 in Manitoba, Canada in 2022 [<xref ref-type=""bibr"" rid=""CR5"">5</xref>]. Clinical care and research in HAE nC1-INH and AE-UNK are severely hindered by the lack of confirmatory diagnostic tests and limited genetic testing which are collected.",11_4,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"and limited genetic testing which are collected. Presently the diagnosis of HAE nC1-INH (in the majority without an identifiable genetic cause) and AE-UNK relies on the careful exclusion of alternate causes by a specialist physician typically by therapeutic trials of antihistamines, glucocorticoids, and anti-IgE biologic therapy. This process leads to long delays in diagnosis and difficulties in accessing treatment for patients, and impedes the development of novel therapeutic agents [<xref ref-type=""bibr""",11_5,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"novel therapeutic agents [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR8"">8</xref>]. There are no approved treatments for HAE nC1-INH or AE-UNK. Based on observational studies and case reports, however, on demand (e.g., icatibant and plasma-derived C1 inhibitor [pdC1-INH] and long-term prophylaxis treatments (e.g., lanadelumab, pdC1-INH, and berotralstat) for HAE-C1-INH may be effective in some patients with HAE nC1-INH or AE-UNK [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref",11_6,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"[<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>, <xref ref-type=""bibr"" rid=""CR12"">12</xref>]. Development of such treatments for HAE nC1-INH and AE-UNK requires improved characterization of these patient populations to understand the burden of disease and clinical outcomes. In Canada, patients with HAE are primarily treated by allergists or immunologists. During routine clinical care, these clinics collect considerable real-world evidence (RWE) in the form of",11_7,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"real-world evidence (RWE) in the form of structured data (e.g., hospital pharmacy orders) and unstructured data (e.g., clinical notes), which is collected and stored in Electronic Health Records (EHR). RWE from EHR can be utilized to better understand disease prevalence, treatment patterns and clinical outcomes over time, and is particularly important for rare diseases for which patient numbers are small and clinical trials are lacking. The aim of this study was to extract RWE from the EHR of patients with",11_8,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"was to extract RWE from the EHR of patients with HAE nC1-INH and AE-UNK from selected practices of Canadian HAE-treating specialist physicians, to better understand the case numbers, treatment use, clinical outcomes, and healthcare resource utilization among patients with HAE nC1-INH or AE-UNK, in Canada.   This is the first study to evaluate the demographics, treatment response, and healthcare resource utilization among patients with HAE nC1-INH and AE-UNK, across Canada. The main findings of the study",11_9,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"across Canada. The main findings of the study are (1) there is an average delay in diagnosis of more than 10 years for these conditions; (2) the frequency of angioedema attacks before starting LTP is high; and (3) despite a significant response to treatment, many patients continue to have frequent episodes. The average age at diagnosis was 39.4 years for HAE nC1-INH and 37.0 years for AE-UNK, representing a > 10-year diagnostic delay from the first onset of symptoms. This delay underscores the current",11_10,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"of symptoms. This delay underscores the current difficulties in making these diagnoses given the absence of confirmatory tests for most patients, rarity of the diseases, and requirement for highly specialized physician assessment. This could potentially be addressed by establishing consensus guidelines specifically for these conditions that describe diagnostic and therapeutic approaches based on the best available evidence and collective experience. Prior to the initiation of HAE treatment, patients with",11_11,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"to the initiation of HAE treatment, patients with both conditions were highly symptomatic. In the three months before treatment, the mean angioedema attack frequency was 24.1 and 7.9 for HAE nC1-INH and AE-UNK, respectively. The duration of attacks was 1.5 days for HAE nC1-INH and 2.3 days for AE-UNK. These data taken together with the diagnostic delay indicates a highly significant burden of disease in untreated patients. Clinical outcomes after treatment initiation demonstrated that starting treatment",11_12,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"initiation demonstrated that starting treatment decreased the duration and number of angioedema attacks, thus potentially supporting the use of preventative treatments such as pd-C1-INH and tranexamic acid for angioedema attacks in patients with HAE nC1-INH and AE-UNK. However, the mean number of attacks after treatment initiation was still high with an average of 9.7 attacks over three months, lasting an average of 0.86 days, in HAE nC1-INH. Additionally, 22% of patients with HAE nC1-INH and 13% of",11_13,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"22% of patients with HAE nC1-INH and 13% of patients with AE-UNK were receiving more than one LTP treatment concurrently, suggesting poor efficacy of monotherapy in many patients, with clinicians combining LTP in an effort to improve control. This suggests a significant unmet need for effective preventative treatments for these patients. Baseline demographics and clinical characteristics were in keeping with previously published studies investigating patients with HAE nC1-INH [<xref ref-type=""bibr""",11_14,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"patients with HAE nC1-INH [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR13"">13</xref>, <xref ref-type=""bibr"" rid=""CR14"">14</xref>]. For both HAE nC1-INH and AE-UNK, patients were predominantly women and the age at first symptom/attack was 21.5 (5.0–57.0) and 23.0 (10.0–50.0) years, respectively. AE-UNK is generally thought to present similarly to HAE nC1-INH [<xref ref-type=""bibr"" rid=""CR5"">5</xref>], and this may be because they represent",11_15,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"and this may be because they represent the same disease in certain patients. At least some cases of AE-UNK are likely the result of de novo mutations, which is seen in ~ 25% of patients with HAE C1-INH, and thus these patients would be reclassified as HAE nC1-INH when the next generation is found to be symptomatic. We thus investigated the differences between patients with HAE nC1-INH and AE-UNK. Anacdotally, it is thought that patients with HAE nC1-INH and AE-UNK both equally experience stress as the",11_16,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"and AE-UNK both equally experience stress as the predominant attack trigger. However, interestingly, in this study it was found that among patients with HAE nC1-INH, 65% experienced stress as the predominant trigger for angioedema—similar to a recent study of 295 patients with HAE nC1-INH in which stress was identified as the second most common trigger for angioedema attacks, affecting 59.6% of patients [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]—however this was significantly different (p = 0.007) to",11_17,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"this was significantly different (p = 0.007) to patients with AE-UNK, for whom 26% experienced stress as the attack trigger. Furthermore, in the three months before HAE treatment initiation, there were significantly fewer patients with AE-UNK experiencing angioedema attacks affecting their extremities and GI system compared to patients with HAE nC1-INH. Following treatment initiation, significantly fewer patients with AE-UNK experienced angioedema attacks affecting their GI system and fewer patients",11_18,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"affecting their GI system and fewer patients experienced abdominal pain. Interestingly, this is the first time that significant differences for the symptomatic presentation of angioedema attacks between patients with HAE nC1-INH and AE-UNK have been observed. Caution is needed, however, as a trial of high-dose antihistamine therapy is generally recommended prior to diagnosing these conditions, particularly AE-UNK in which genetic testing and family history is negative, but a substantial minority of",11_19,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"is negative, but a substantial minority of patients did not receive antihistamines, so these differences could be accounted for by inclusion of patients with mast cell mediated angioedema in the AE-UNK group [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Further studies using rigorously defined patient populations, and appropriate genetic testing are needed to confirm these observations. The study has important limitations—the diagnosis of HAE nC1-INH or AE-UNK was established by individual clinicians, not",11_20,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"was established by individual clinicians, not using a specific set of standardized inclusion criteria. In particular, some were not treated with antihistamines and most were not treated with omalizumab prior to establishing the diagnosis, so patients with mast cell mediated angioedema may have been included. However, the presented data reflect current clinical practice in Canada. Data were collected from specialized centers, which may have introduced bias by including more severely affected patients. Given",11_21,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"including more severely affected patients. Given the retrospective design using data extracted there are inherent limitations due to the availability and accuracy of data. Certain variables are not consistently documented in medical notes, such as the details of each angioedema attack and dates of each healthcare resource utilization. As many angioedema attacks and visits with external healthcare providers related to HAE occur outside of the HAE specialist’s clinic settings, these data are only collected",11_22,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"clinic settings, these data are only collected if a patient reports them to their treating HAE specialist. The number of included patients was small, consistent with the rarity of the conditions. Despite these limitations, this is the only real-world study examining outcomes in HAE nC1-INH and AE-UNK, across Canada. There is an average diagnostic delay of more than a decade in patients with HAE nC1-INH and AE-UNK, and these patients often have frequent angioedema episodes without treatment. Presently",11_23,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"angioedema episodes without treatment. Presently available treatment options in Canada for these patients appear to improve angioedema frequency and duration, but patients remain significantly affected. Future prospective studies would be helpful to better understand the clinical manifestations, disease burden, and treatment responses in these diseases.",11_24,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"<supplementary-material content-type=""local-data"" id=""MOESM1""><media http://www.w3.org/1999/xlink href=""13223_2024_910_MOESM1_ESM.docx""><caption><p>Additional file 1.</p></caption></media></supplementary-material>",11_25,Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada,27 9 2024,,Hereditary_Angioedema
"Advent of oral medications for the treatment of hereditary angioedema Hereditary angioedema (HAE) is a rare genetic disorder most commonly caused by either deficiency or dysfunction of C1 inhibitor (C1INH; HAE‐C1INH‐Type1 and HAE‐C1INH‐Type2, respectively). Less commonly, HAE with normal C1INH levels (HAE‐nC1INH) may occur. All types of HAE are characterized by unpredictable and recurrent debilitating attacks of subcutaneous (SC) and mucosal tissue swelling, which may be life‐threatening depending on the",12_0,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"which may be life‐threatening depending on the affected location.<xref rid=""clt212391-bib-0001"" ref-type=""bibr"">",12_1,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"<sup>1</sup>
</xref>, <xref rid=""clt212391-bib-0002"" ref-type=""bibr"">
<sup>2</sup>
</xref>, <xref rid=""clt212391-bib-0003"" ref-type=""bibr"">
<sup>3</sup>
</xref> This article will focus on patients with HAE‐C1INH. The goals of HAE treatment are to achieve total control of the disease and to normalize patients' lives.<xref rid=""clt212391-bib-0004"" ref-type=""bibr"">
<sup>4</sup>",12_2,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"</xref> The World Allergy Organization (WAO)/European Academy of Allergy and Clinical Immunology (EAACI) guidelines for HAE management include the following recommendations: (1) all angioedema attacks should be considered for on‐demand treatment and should be treated as early as possible; (2) short‐term prophylaxis (STP) should be considered before medical, surgical, or dental procedures, as well as exposure to other events that could induce angioedema attacks; and (3) patients should be routinely",12_3,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"attacks; and (3) patients should be routinely evaluated for long‐term prophylaxis (LTP), considering disease activity, burden, control, and patient preference. Currently, nearly all approved HAE treatments require SC or intravenous (IV) administration (Figure <xref rid=""clt212391-fig-0001"" ref-type=""fig"">1A</xref>); however, the use of parenteral treatments for HAE has been associated with administration‐related anxiety (e.g., trypanophobia [fear of needles]), challenges related to administration (e.g.,",12_4,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"challenges related to administration (e.g., long preparation time, inconvenient storage/preparation),<xref rid=""clt212391-bib-0005"" ref-type=""bibr"">",12_5,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"<sup>5</sup>
</xref>, <xref rid=""clt212391-bib-0006"" ref-type=""bibr"">
<sup>6</sup>
</xref>, <xref rid=""clt212391-bib-0007"" ref-type=""bibr"">
<sup>7</sup>
</xref> and adverse events that often accompany parenteral treatments, including injection‐site reactions.<xref rid=""clt212391-bib-0007"" ref-type=""bibr"">
<sup>7</sup>
</xref>, <xref rid=""clt212391-bib-0008"" ref-type=""bibr"">
<sup>8</sup>",12_6,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"<sup>8</sup>
</xref> Limitations of parenteral treatments contribute to poor compliance, including administration delays, and result in a high treatment burden and impaired quality of life (QoL) for many patients with HAE.<xref rid=""clt212391-bib-0005"" ref-type=""bibr"">
<sup>5</sup>
</xref>, <xref rid=""clt212391-bib-0006"" ref-type=""bibr"">
<sup>6</sup>
</xref>, <xref rid=""clt212391-bib-0007"" ref-type=""bibr"">
<sup>7</sup>
</xref>",12_7,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"<sup>7</sup>
</xref>
 No oral medication has been approved by regulatory agencies (United States [US] Food and Drug Administration [FDA] or European Medicines Agency [EMA]) for on‐demand treatment<xref rid=""clt212391-bib-0009"" ref-type=""bibr"">
<sup>9</sup>",12_8,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"<sup>9</sup>
</xref>; however, phase 2 and 3 clinical trials have been completed for oral agents (Table <xref rid=""clt212391-tbl-0001"" ref-type=""table"">1</xref>; Figure <xref rid=""clt212391-fig-0001"" ref-type=""fig"">1B</xref>).<xref rid=""clt212391-bib-0010"" ref-type=""bibr"">
<sup>10</sup>
</xref>, <xref rid=""clt212391-bib-0011"" ref-type=""bibr"">
<sup>11</sup>",12_9,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"</xref> As for STP, attenuated androgens (e.g., danazol and stanozolol) have been used in adults but are not FDA‐ or EMA‐approved and are considered second‐line alternatives to IV treatment with plasma‐derived C1 inhibitor (pdC1INH). Oral tranexamic acid, also not FDA‐ or EMA‐approved, has been used in the past for STP as well as LTP but is not recommended by guidelines given safety concerns and limited data suggesting benefit for LTP and proven minimal effectiveness for use as an on‐demand therapy.<xref",12_10,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"for use as an on‐demand therapy.<xref rid=""clt212391-bib-0004"" ref-type=""bibr"">",12_11,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"<sup>4</sup>
</xref>, <xref rid=""clt212391-bib-0009"" ref-type=""bibr"">
<sup>9</sup>
</xref>, <xref rid=""clt212391-bib-0012"" ref-type=""bibr"">
<sup>12</sup>
</xref>, <xref rid=""clt212391-bib-0013"" ref-type=""bibr"">
<sup>13</sup>
</xref>, <xref rid=""clt212391-bib-0014"" ref-type=""bibr"">
<sup>14</sup>
</xref> For LTP, the only oral agents approved by the FDA or EMA are berotralstat<xref rid=""clt212391-bib-0015"" ref-type=""bibr"">
<sup>15</sup>
</xref>, <xref rid=""clt212391-bib-0016"" ref-type=""bibr"">
<sup>16</sup>",12_12,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"<sup>16</sup>
</xref> and attenuated androgens (considered a second‐line treatment in the WAO/EAACI guidelines).<xref rid=""clt212391-bib-0004"" ref-type=""bibr"">
<sup>4</sup>
</xref>, <xref rid=""clt212391-bib-0012"" ref-type=""bibr"">
<sup>12</sup>
</xref>
 Oral treatments for HAE could potentially optimize patient outcomes by reducing treatment barriers, improving patient adherence, and decreasing out‐of‐pocket costs for patients and their caregivers.<xref rid=""clt212391-bib-0017"" ref-type=""bibr"">",12_13,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"<sup>17</sup>
</xref> Furthermore, some studies have revealed that patients with HAE would prefer oral medications over parenteral medications and that ease of access and fit with lifestyle are important factors to consider when selecting treatment.<xref rid=""clt212391-bib-0018"" ref-type=""bibr"">
<sup>18</sup>
</xref>, <xref rid=""clt212391-bib-0019"" ref-type=""bibr"">
<sup>19</sup>
</xref>, <xref rid=""clt212391-bib-0020"" ref-type=""bibr"">
<sup>20</sup>",12_14,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"<sup>20</sup>
</xref> Oral on‐demand medications therefore represent an unmet need.<xref rid=""clt212391-bib-0018"" ref-type=""bibr"">
<sup>18</sup>",12_15,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"</xref> To provide the most comprehensive understanding of the potential benefits of oral treatments, we have summarized data from all publicly available resources through a targeted literature review using PubMed and supplemented by information noted on company websites (search cutoff of May 31, 2024) to provide the most up‐to‐date information for each compound.  Substantial advances have been made in the development of oral treatments for HAE, with international regulatory approvals of berotralstat for",12_16,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"regulatory approvals of berotralstat for LTP and the first oral therapy, sebetralstat, completing phase 3 clinical development for on‐demand treatment. Additional agents are under investigation in preclinical, phase 1, and phase 2 programs. Oral treatments have the potential to improve and optimize clinical outcomes, satisfaction, and QoL among patients with HAE.",12_17,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
<bold>Anna Valerieva</bold>: Conceptualization; investigation; writing—review & editing. <bold>Teresa Caballero</bold>: Conceptualization; validation; writing—review & editing. <bold>Markus Magerl</bold>: Conceptualization; methodology; writing—review & editing. <bold>Joao P. Frade</bold>: Investigation; validation; writing—review & editing. <bold>Paul K. Audhya</bold>: Conceptualization; methodology; validation; writing—review & editing; supervision. <bold>Timothy Craig</bold>: Conceptualization;,12_18,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"<bold>Timothy Craig</bold>: Conceptualization; methodology; validation; writing—review & editing; supervision. T.J.C. served as a speaker and researcher for Biomarin, CSL Behring, Regeneron, Kalvista and Takeda; researcher for Astria, Ionis, KalVista, Intellia, GSK and Pharvaris; speaker for Grifols; consultant for Astria, BioCryst, Biomarin, CSL Behring, Intellia, and KalVista; Director for ACARE International Hereditary Angioedema Center and Alpha‐1 Resource Center; member of the Medical Advisory Board",12_19,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"Center; member of the Medical Advisory Board for the HAE‐A. A.V. has received consultancy/speaker honoraria/meeting sponsorship from, or collaborated in research with, Pharming Group NV, Takeda/Shire, Sobi, CSL Behring, Pharvaris, and Ionis. T.C. has participated on advisory boards from Austria, BioCryst, CSL Behring, KalVista, Novartis, Pharming NV, Pharvaris, and Takeda and is a member of speakers’ bureaus for CSL Behring, Novartis, Pharming and Takeda. She has received grants or honoraria from BioCryst,",12_20,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"has received grants or honoraria from BioCryst, CSL Behring, Kalvista, Novartis, Pharming NV, and Takeda and funding to attend conferences and educational events from BioCryst, CSL Behring, Novartis, Pharming, and Takeda. She is a clinical trial/registry/study investigator for BioCryst, Biomarin, CSL Behring, Ionis, KalVista, Novartis, Pharming NV, and Takeda and a researcher on the Instituto de Investigación Hospital Universitario La Paz (IdiPAZ) program for promoting research activities. M.M. received",12_21,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
"for promoting research activities. M.M. received research grant support and/or speaker/consultancy fees from and/or is/was investigator in clinical studies for BioCryst, CSL Behring, Intellia, KalVista, Novartis, Octapharma, Pharming, Pharvaris, Takeda/Shire and Ionis. J.F. and P.A. are employees of KalVista Pharmaceuticals.",12_22,Advent of oral medications for the treatment of hereditary angioedema,27 9 2024,,Hereditary_Angioedema
Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,13_0,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"Hereditary angioedema is a rare, genetic disorder characterized by painful, debilitating and potentially life-threatening angioedema attacks in subcutaneous and submucosal tissue. While usually unpredictable, attacks can be provoked by a variety of triggers including physical injury and certain medication and are often preceded by prodromal symptoms. Hereditary angioedema has a profound influence on the patients' lives. The fundamental cause of hereditary angioedema in almost all patients is a mutation in",13_1,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
in almost all patients is a mutation in the,13_2,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<italic toggle=""yes"">SERPING1</italic>",13_3,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"gene leading to a deficiency in C1-inhibitor. Subsequently, the contact activation cascade and kallikrein-kinin pathway are insufficiently inhibited, resulting in excessive bradykinin production triggering vascular leakage. While C1-inhibitor is an important regulator of the intrinsic coagulation pathway, fibrinolytic system and complement cascade, patients do not have an increased risk of coagulopathy, autoimmune conditions or immunodeficiency disorders. Hereditary angioedema is diagnosed based on",13_4,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"Hereditary angioedema is diagnosed based on C1-inhibitor level and function. Genetic analysis is only required in rare cases where hereditary angioedema with normal C1-inhibitor is found. In recent years, new, highly specific therapies have greatly improved disease control and angioedema-related quality of life. This article reviews the clinical picture of hereditary angioedema, the underlying pathophysiology, diagnostic process and currently available as well as investigational therapeutic options.",13_5,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"A 21-year-old female was referred to the emergency department with an acute swelling of the throat. She had a history of recurrent episodes of non-pruritic swelling of extremities that usually resolved spontaneously within three days. These episodes started in puberty, occurred about once a month and were never accompanied by hives. The patient had presented to the emergency department twice before, both times with extreme abdominal pain accompanied by vomiting and diarrhea without an identified cause.",13_6,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"and diarrhea without an identified cause. Her mother had similar episodes of edema, although less frequently. Her grandfather passed away at the age of 30 as a result of asphyxiation. The patient used combined estrogen-progestin oral contraceptives and in the past had tried high-dose anti-histamines without effect on the episodes of swelling. At presentation, epinephrine, clemastine, and dexamethasone, were administered immediately, with no effect on what was diagnosed as laryngeal edema. Laryngeal",13_7,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"what was diagnosed as laryngeal edema. Laryngeal intubation was necessary to secure the airway and the patient was admitted to the intensive care unit. An empirical dose of plasma-derived C1-inhibitor was administered, after which the edema swiftly resolved. The patient was discharged with a subcutaneous bradykinin B2 receptor inhibitor to be administered in case of another attack. Several weeks later, laboratory tests confirmed the diagnosis of hereditary angioedema (HAE) type 1, due to deficiency of",13_8,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"angioedema (HAE) type 1, due to deficiency of C1-inhibitor. The patient started with prophylactic subcutaneous plasma-derived C1-inhibitor concentrates twice weekly and switched to a type of contraception without estrogen. In the following months, she continued to experience occasional break-through attacks that responded well to self-administered subcutaneous bradykinin B2 receptor inhibitor.",13_9,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"HAE is a rare, genetic disease that is estimated to affect about 1 in 50,000 to 100,000 individuals.
<xref rid=""JR03076-1"" ref-type=""bibr"">1</xref>
Patients with HAE have recurring episodes of non-pitting, non-pruritic angioedema. Angioedema occurs in subcutaneous and submucosal areas and causes different symptoms depending on the location. If untreated, attacks typically worsen in the first 24 hours before resolving in two to five days.
<xref rid=""JR03076-2"" ref-type=""bibr"">2</xref>",13_10,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-2"" ref-type=""bibr"">2</xref>
Contrary to mast cell-mediated angioedema, attacks are not accompanied by urticaria or anaphylaxis.
<xref rid=""JR03076-2"" ref-type=""bibr"">2</xref>
Onset of symptoms is usually during childhood or adolescence, with a mean age at first symptoms of 11 years.
<xref rid=""JR03076-3"" ref-type=""bibr"">3</xref>
Frequency and locations of attacks vary significantly between patients and can even vary during a single patient's lifetime.",13_11,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-2"" ref-type=""bibr"">2</xref>
Up to 30% of patients experience edema at multiple anatomically unrelated regions simultaneously.
<xref rid=""JR03076-4"" ref-type=""bibr"">4</xref>",13_12,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-4"" ref-type=""bibr"">4</xref>
Hindering and debilitating dermal swelling predominantly occurs in the extremities, in the orofacial or genital region. When submucosa of the gastrointestinal tract is involved, patients present with extreme abdominal pain and vomiting, mimicking an acute abdomen, in some cases leading to unnecessary surgical interventions. HAE patients are estimated to be two-and-a-half times more likely to undergo abdominal surgery compared to the general population.",13_13,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-5"" ref-type=""bibr"">5</xref>
In the case of upper airway edema, impending airway obstruction can lead to asphyxiation if the airway is not secured or the edema treated in time. A review of literature published in 1962, before adequate treatment was developed, reported that 77% of HAE patients died due to acute laryngeal edema.
<xref rid=""JR03076-6"" ref-type=""bibr"">6</xref>",13_14,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-6"" ref-type=""bibr"">6</xref>
More recently, worldwide mortality amongst HAE patients due to laryngeal edema was still estimated to be as high as 5%.
<xref rid=""JR03076-7"" ref-type=""bibr"">7</xref>
 
Various events and circumstances can trigger attacks of angioedema. Trauma caused by invasive procedures is well known to induce attacks and therefore pre-procedural prophylactic medication is recommended.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>",13_15,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
Patients should refrain from inhibitors of angiotensin-converting enzyme or dipeptidyl peptidase IV for inhibition of these enzymes is known to increase attack frequency as illustrated in
<xref rid=""FI03076-1"" ref-type=""fig"">Fig. 1</xref>
.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>",13_16,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
".
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
Increased exogenous or endogenous estrogen levels typically enhance attacks in female patients. This can occur in physiological circumstances like pregnancy and during the menstrual cycle, and also with the use of oral contraceptives or hormonal replacement therapy.
<xref rid=""JR03076-9"" ref-type=""bibr"">9</xref>
Other reported triggers include infection, fever, mental stress, and physical activity.
<xref rid=""JR03076-10"" ref-type=""bibr"">10</xref>",13_17,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-10"" ref-type=""bibr"">10</xref>
<xref rid=""JR03076-11"" ref-type=""bibr"">11</xref>
 
The occurrence of angioedema attacks is often unpredictable; however, 90% of patients experience prodromal symptoms hours to days before an attack.
<xref rid=""JR03076-12"" ref-type=""bibr"">12</xref>
<xref rid=""JR03076-13"" ref-type=""bibr"">13</xref>
<xref rid=""JR03076-14"" ref-type=""bibr"">14</xref>",13_18,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-14"" ref-type=""bibr"">14</xref>
These symptoms span a wide range including dermal manifestations, tiredness, emotional disturbances and gastro-intestinal symptoms. The most common dermal manifestation described to precede HAE attacks is erythema marginatum. This non-pruritic skin rash is sometimes misinterpreted as urticaria and is associated with a longer diagnostic delay.
<xref rid=""JR03076-12"" ref-type=""bibr"">12</xref>",13_19,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-12"" ref-type=""bibr"">12</xref>
The majority of patients report to be able to predict the onset of an attack and a recent study described the sensitivity and specificity of prodromes as a predictor of attacks as 89.5 and 63.1%, respectively.
<xref rid=""JR03076-14"" ref-type=""bibr"">14</xref>",13_20,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"Frequent unpredictable and debilitating angioedema attacks can have a significant impact on the daily life of HAE patients. Depression and anxiety are reported in a substantial percentage of HAE patients, corresponding with a lower than average quality of life with regard to mental health and social relationships.
<xref rid=""JR03076-15"" ref-type=""bibr"">15</xref>
<xref rid=""JR03076-16"" ref-type=""bibr"">16</xref>
<xref rid=""JR03076-17"" ref-type=""bibr"">17</xref>",13_21,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-17"" ref-type=""bibr"">17</xref>
<xref rid=""JR03076-18"" ref-type=""bibr"">18</xref>
Patients report a loss of productivity and absence from work due to attacks. Especially facial, abdominal, and laryngeal attacks correlate with higher absenteeism and activity impairment.
<xref rid=""JR03076-17"" ref-type=""bibr"">17</xref>
Even in attack-free periods, patients report anxiety due to the unpredictability of attacks, as well as worries about passing HAE on to their offspring.",13_22,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-18"" ref-type=""bibr"">18</xref>
HAE is shown to influence reproductive choices in approximately 20% of HAE patients.
<xref rid=""JR03076-19"" ref-type=""bibr"">19</xref>",13_23,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"In HAE patients, angioedema is caused by insufficient inhibition of the contact activation pathway and kallikrein-kinin system. In the majority of patients, this is caused by an absolute C1-inhibitor deficiency (type 1, 85% of HAE with C1-inhibitor deficiency) or C1-inhibitor dysfunction (type 2, 15% of HAE with C1-inhibitor deficiency). C1-inhibitor is a heavily glycosylated single chain polypeptide of 478 amino acid residues with a molecular weight of 105 kDa. The physiological plasma concentration is",13_24,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
The physiological plasma concentration is about 240 mg/L with a long estimated half-life of about 70 hours.,13_25,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-20"" ref-type=""bibr"">20</xref>
C1-inhibitor regulates various pathways, including the kallikrein-kinin system, intrinsic coagulation system, fibrinolytic pathway, and the complement cascade (
<xref rid=""FI03076-2"" ref-type=""fig"">Fig. 2</xref>",13_26,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"). The contact activation route and subsequent kallikrein-kinin system are initiated when factor XII (FXII) is autoactivated upon contact with negatively charged surfaces and subsequently induces cleavage of the zymogen prekallikrein into plasma kallikrein (PKa). PKa activates more FXII in a positive feedback loop and induces cleavage of high-molecular-weight kininogen, thereby producing bradykinin,
<xref rid=""JR03076-21"" ref-type=""bibr"">21</xref>",13_27,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"a nonapeptide of the kinin family. Bradykinin is considered to be principally responsible for the vasodilation and subsequent transfer of fluid to extravasal tissue in the case of angioedema formation in HAE patients. Bradykinin binds to the bradykinin B2 receptor (BKB2R) expressed on endothelial cells, initiating a signaling cascade leading to increased vascular permeability through several mechanisms including the release of nitric oxide, contraction of endothelial cells, and the uncoupling of tight",13_28,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"of endothelial cells, and the uncoupling of tight junctions between endothelial cells. Carboxypeptidases N and M cleave the terminal arginine from bradykinin, forming des-Arg9-bradykinin, an agonist for the bradykinin B1 receptor (BKB1R).",13_29,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-21"" ref-type=""bibr"">21</xref>
This receptor is not constitutively present on endothelial cells, but is expressed following tissue injury or inflammatory stimuli. It is unclear what the function of the BKB1R is in the formation of angioedema in the context of HAE. The receptor is slowly and partially desensitized after binding, in contrast to the BKB2R which is rapidly desensitized.
<xref rid=""JR03076-22"" ref-type=""bibr"">22</xref>",13_30,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-22"" ref-type=""bibr"">22</xref>
Therefore, it has been hypothesized that stimulation of the BKB1R could explain the long duration of angioedema attacks.
<xref rid=""JR03076-23"" ref-type=""bibr"">23</xref>
Bradykinin and des-Arg9bradykinin are rapidly broken down into inactive metabolites by aminopeptidase P, neutral endopeptidase, dipeptidyl peptidase IV, and angiotensin-converting enzyme.
<xref rid=""JR03076-24"" ref-type=""bibr"">24</xref>",13_31,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"C1-inhibitor is an important regulator of other pathways as well. C1-inhibitor regulates the intrinsic coagulation pathway by partially inhibiting the activation of factor XI and the functions of activated factor XI.
<xref rid=""JR03076-25"" ref-type=""bibr"">25</xref>
Likewise, C1-inhibitor regulates the fibrinolytic system directly by inhibiting plasmin activity, though less efficient than α2-antiplasmin,
<xref rid=""JR03076-26"" ref-type=""bibr"">26</xref>",13_32,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-26"" ref-type=""bibr"">26</xref>
and indirectly by inhibiting the conversion of plasminogen to plasmin by PKa.
<xref rid=""JR03076-20"" ref-type=""bibr"">20</xref>
Signs of activation of the thrombotic and fibrinolytic systems in HAE patients include elevated levels of activated factor XII (FXIIa), D-dimer, plasmin-α2-antiplasmin complexes and thrombin generation during attacks.
<xref rid=""JR03076-27"" ref-type=""bibr"">27</xref>
<xref rid=""JR03076-28"" ref-type=""bibr"">28</xref>",13_33,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-28"" ref-type=""bibr"">28</xref>
<xref rid=""JR03076-29"" ref-type=""bibr"">29</xref>
<xref rid=""JR03076-30"" ref-type=""bibr"">30</xref>
Despite the impact of C1-inhibitor on both coagulation and fibrinolysis, C1-inhibitor deficiency does not translate into an increased risk of thrombosis or bleeding.
<xref rid=""JR03076-31"" ref-type=""bibr"">31</xref>",13_34,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-31"" ref-type=""bibr"">31</xref>
Furthermore, C1-inhibitor is a key player in the complement system, for it is the only known inhibitor of C1r and C1s proteases in the classical complement pathway. It also regulates the lectin pathway by inactivating mannose-associated serine proteases 1 and 2.
<xref rid=""JR03076-32"" ref-type=""bibr"">32</xref>
<xref rid=""JR03076-33"" ref-type=""bibr"">33</xref>
There is no proven association between immunodeficiency disorders or autoimmune conditions and HAE.",13_35,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-34"" ref-type=""bibr"">34</xref>
 
In HAE type 1 and 2, lack of (functional) C1-inhibitor is caused by a mutation in the
<italic toggle=""yes"">SERPING1</italic>
gene. About 750 different pathogenic mutations are reported to be associated with HAE type I, including missense, nonsense, deletions, insertions, duplications and splice site mutations.
<xref rid=""JR03076-35"" ref-type=""bibr"">35</xref>
<xref rid=""JR03076-36"" ref-type=""bibr"">36</xref>",13_36,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-36"" ref-type=""bibr"">36</xref>
Most cases of HAE type 2 are caused by a missense mutation in exon 8, resulting in the reduced ability to inhibit target proteases.
<xref rid=""JR03076-22"" ref-type=""bibr"">22</xref>",13_37,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-22"" ref-type=""bibr"">22</xref>
HAE is inherited as an autosomal dominant trait in almost all cases. While HAE type I patients possess one functional allele, levels of C1-inhibitor normally vary between 5 and 30% of normal levels. Recent studies suggest that in a limited subset of mutations, this could be due to the formation of polymers between functional and dysfunctional C1-inhibitor leading to intracellular retention.
<xref rid=""JR03076-37"" ref-type=""bibr"">37</xref>",13_38,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-37"" ref-type=""bibr"">37</xref>
<xref rid=""JR03076-38"" ref-type=""bibr"">38</xref>",13_39,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
Homozygous forms of HAE have long been considered embryonically lethal and only in recent years case reports of consanguineous families with homozygous HAE have sporadically been published. The inheritance pattern in these families is most likely recessive since heterogeneous members of these families are almost always asymptomatic. An unusual biochemical feature found in some patients with homozygous C1-INH deficiency is a significant reduction in C1q levels.,13_40,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-39"" ref-type=""bibr"">39</xref>
<xref rid=""JR03076-40"" ref-type=""bibr"">40</xref>
<xref rid=""JR03076-41"" ref-type=""bibr"">41</xref>
<xref rid=""JR03076-42"" ref-type=""bibr"">42</xref>
 
In rare cases, HAE with normal functional and absolute levels of C1-inhibitor (HAE-nC1-INH) occurs. This type of HAE has a very heterogeneous phenotype. Known mutations causing this third type of HAE are summarized in
<xref rid=""TB03076-1"" ref-type=""table"">Table 1</xref>",13_41,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
". In up to 25% of HAE-nC1-INH patients a mutation in the gene coding for FXII (HAE-FXII) is found, leading to an increase in autoactivation of FXII. While this mutation is inherited as an autosomal dominant trait, the majority of symptomatic carriers is female,
<xref rid=""JR03076-43"" ref-type=""bibr"">43</xref>
implying an association with estrogen. In patients with HAE type 1 and 2, the influence of estrogen on attack frequency and severity has been described extensively.",13_42,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-44"" ref-type=""bibr"">44</xref>
Previously suggested mechanisms for this observation are the increase of FXII levels, decrease of C1-inhibitor levels, induction of the release of nitric oxide and impairment of the functionality of angiotensin converting enzyme.
<xref rid=""JR03076-44"" ref-type=""bibr"">44</xref>
<xref rid=""JR03076-45"" ref-type=""bibr"">45</xref>",13_43,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-45"" ref-type=""bibr"">45</xref>
The specific characteristics of HAE-FXII suggest the influence of estrogen on FXII might be an important factor in the development of angioedema. Another noteworthy difference in the clinical presentation of patients with HAE-FXII is the absence of erythema marginatum as a prodromal symptom.
<xref rid=""JR03076-46"" ref-type=""bibr"">46</xref>",13_44,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"When HAE is suspected, serum levels of C1-inhibitor protein, C1-inhibitor function, and complement component 4 are measured (
<xref rid=""TB03076-2"" ref-type=""table"">Table 2</xref>",13_45,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"). While HAE type 1 and 2 are clinically indistinguishable, laboratory tests will make it possible to differentiate between these types: serum of patients with type 1 HAE will show a C1-inhibitor protein level of <50% of normal combined with a decreased functionality of C1-inhibitor, whereas patients with type 2 will have a decrease in C1-inhibitor functionality in the presence of normal or increased levels of C1-inhibitor protein. Even though C4 levels are usually decreased in HAE patients, it is not",13_46,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"are usually decreased in HAE patients, it is not recommended to use this as a single screening tool due to its limited sensitivity and specificity, estimated at 81 and 85%, respectively.",13_47,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-47"" ref-type=""bibr"">47</xref>
The most recent guideline recommends to repeat C1-inhibitor function, C1-inhibitor protein, and C4 testing in patients to confirm the diagnosis.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
Genetic sequencing is not recommended as a diagnostic tool for patients with HAE type 1 or 2. However, in case of a high suspicion of HAE with normal C1-inhibitor, assessment for known mutations underlying HAE-nC1-INH is recommended.",13_48,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
While C1-inhibitor level and function remain the golden standard for diagnosis of HAE type 1 and 2, analysis can take weeks, making them impractical to distinguish HAE from other forms of angioedema in the acute setting. In patients that are already diagnosed with HAE, there is a need for biomarkers to correctly identify and predict attacks. While recent studies have yielded promising results, none are recommended to be used in daily practice yet.",13_49,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-48"" ref-type=""bibr"">48</xref>
<xref rid=""JR03076-49"" ref-type=""bibr"">49</xref>",13_50,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"A reduced level of C1-inhibitor protein has a short differential diagnosis. However, if a patient with laboratory findings corresponding with HAE type 1 has a negative family history and onset of symptoms later in life (>30 years), it is important to exclude acquired angioedema with C1-inhibitor deficiency (AAE-C1-INH). This condition has an even lower prevalence than HAE and is estimated to affect 1 in 500,000 individuals. It is associated with plasma cell dyscrasias, lymphoproliferative disorders, and",13_51,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"dyscrasias, lymphoproliferative disorders, and autoimmune diseases that cause a deficiency of C1-inhibitor either through neutralizing antibodies or through increased consumption by massive activation of the complement system.",13_52,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-50"" ref-type=""bibr"">50</xref>
<xref rid=""JR03076-51"" ref-type=""bibr"">51</xref>
Contrary to HAE, laboratory tests of about 75% of AAE-C1-INH patients show low levels of C1q and in part of the population C1-inhibitor autoantibodies can be identified.
<xref rid=""JR03076-52"" ref-type=""bibr"">52</xref>
<xref rid=""JR03076-53"" ref-type=""bibr"">53</xref>",13_53,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-53"" ref-type=""bibr"">53</xref>
AAE-C1-INH requires additional diagnostics to exclude or confirm associated disorders and has different treatment options than HAE, therefore it is important to distinguish between these disorders.
<xref rid=""JR03076-54"" ref-type=""bibr"">54</xref>
 
HAE patients have a 50% chance to pass the affected gene on to their offspring. However, severity and frequency of symptoms are highly variable even within one family. Notably, in about 25% of patients a",13_54,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<italic toggle=""yes"">de novo</italic>
mutation occurs.
<xref rid=""JR03076-55"" ref-type=""bibr"">55</xref>
Recent guidelines recommend to test children from HAE patients as early as possible.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
<xref rid=""JR03076-56"" ref-type=""bibr"">56</xref>
However, the testing of neonates and infants proves difficult, since antigenic and functional C1-inhibitor levels in peripheral and cord blood of healthy children are lower than in adults.",13_55,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-57"" ref-type=""bibr"">57</xref>
Therefore, tests performed in infants should be repeated after the child is one year old. Genetic testing (preferably of umbilical cord blood) can be considered if the mutation of the parent is known, which is not the case in up to 10% of patients.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
<xref rid=""JR03076-56"" ref-type=""bibr"">56</xref>
Prenatal diagnosis and pre-implantation genetic testing are available depending on national laws and practice.",13_56,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-9"" ref-type=""bibr"">9</xref>
<xref rid=""JR03076-19"" ref-type=""bibr"">19</xref>
 
In contrast to mast cell-mediated forms of angioedema, HAE attacks do not respond to epinephrine, antihistamines, or corticosteroids.
<xref rid=""JR03076-58"" ref-type=""bibr"">58</xref>",13_57,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-58"" ref-type=""bibr"">58</xref>
In recent years, new improved therapies have drastically changed the landscape of HAE and have even led to a change in treatment goals. In 2021, a global Delphi initiative among HAE specialists concluded that the ultimate goals of treatment should be complete control of the disease and normalization of the patient's life.
<xref rid=""JR03076-59"" ref-type=""bibr"">59</xref>",13_58,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-59"" ref-type=""bibr"">59</xref>
More highly effective drugs are expected to become available in the near future, making the ambitious treatment goals more realistic for a growing number of patients. Currently available treatment options and therapies in development are summarized in
<xref rid=""TB03076-3"" ref-type=""table"">Table 3</xref>
.",13_59,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
".
 
HAE treatment consists of a twin-track approach, comprising of symptom relief in the case of an attack on one hand, and the overall decrease in attacks on the other hand. The most recent guideline advises to treat an HAE attack with on demand treatment (ODT) as early as possible, for this is associated with the best treatment response.
<xref rid=""JR03076-60"" ref-type=""bibr"">60</xref>
<xref rid=""JR03076-61"" ref-type=""bibr"">61</xref>
<xref rid=""JR03076-62"" ref-type=""bibr"">62</xref>",13_60,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-62"" ref-type=""bibr"">62</xref>
First line ODT options are plasma-derived or recombinant C1-inhibitor, icatibant or ecallantide.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
Plasma-derived C1-inhibitor was first administered to an HAE patient in 1979
<xref rid=""JR03076-63"" ref-type=""bibr"">63</xref>
and was approved by the Food and Drug Administration in 2008. Self-administration of intravenous plasma-derived C1-inhibitor concentrate is shown to be safe and effective,",13_61,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-64"" ref-type=""bibr"">64</xref>
though complications may arise if frequent venous access is required.
<xref rid=""JR03076-65"" ref-type=""bibr"">65</xref>
Even though C1-inhibitor has a direct effect on both the intrinsic coagulation and the fibrinolytic pathway, there is no evidence of an elevated risk of thromboembolic events with the use of C1-inhibitor concentrate at recommended doses.
<xref rid=""JR03076-66"" ref-type=""bibr"">66</xref>",13_62,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-66"" ref-type=""bibr"">66</xref>
A recombinant intravenous C1-inhibitor concentrate called conestat alfa was developed as an alternative for plasma-derived C1-inhibitor.
<xref rid=""JR03076-67"" ref-type=""bibr"">67</xref>
Another frequently used ODT option is icatibant, a competitive selective antagonist of the BKB2R.
<xref rid=""JR03076-68"" ref-type=""bibr"">68</xref>",13_63,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-68"" ref-type=""bibr"">68</xref>
Icatibant can be self-administered subcutaneously and has been proven to efficiently shorten the time to onset of symptom relief, especially when administered quickly after the first symptoms have emerged.
<xref rid=""JR03076-60"" ref-type=""bibr"">60</xref>
<xref rid=""JR03076-68"" ref-type=""bibr"">68</xref>
In the United States of America, the subcutaneous direct PKa inhibitor ecallantide is available for ODT. Efficacy has been proven,",13_64,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-69"" ref-type=""bibr"">69</xref>
however, utilization is limited for it can only be administrated by a health care professional with adequate medical support due to the occurrence of anaphylaxis in 3.5% of patients.
<xref rid=""JR03076-70"" ref-type=""bibr"">70</xref>
Before the development of specific therapies, fresh-frozen plasma has been used to replenish deficient C1-inhibitor in case of severe, life-threatening attacks, although not without risks.",13_65,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-71"" ref-type=""bibr"">71</xref>
<xref rid=""JR03076-72"" ref-type=""bibr"">72</xref>
Nowadays, the use of fresh-frozen plasma is only recommended if no targeted therapies are available,
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
which is still the case in some countries where targeted therapies are unaffordable or not yet registered.
<xref rid=""JR03076-73"" ref-type=""bibr"">73</xref>",13_66,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"Short-term prophylaxis (STP) is indicated for invasive procedures known to trigger attacks. The only recommended first-line STP in the most recent guideline is intravenous plasma-derived C1-inhibitor.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
The need for long-term prophylaxis (LTP) is patient-specific and depends on disease activity and burden, as well as patient preferences.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>",13_67,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
The recently updated guideline advises the following first line options for LTP: plasma-derived C1-inhibitor, lanadelumab, and berotralstat.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
A new subcutaneous form of plasma-derived C1-inhibitor demonstrated a positive effect on HAE-related quality of life.
<xref rid=""JR03076-74"" ref-type=""bibr"">74</xref>
<xref rid=""JR03076-75"" ref-type=""bibr"">75</xref>",13_68,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-75"" ref-type=""bibr"">75</xref>
In recent years, two new prophylactic therapies targeting PKa have been licensed by the Food and Drug Administration and the European Medicines Agency. Lanadelumab is an IgG1 type monoclonal antibody directed at PKa with a high efficacy: a subcutaneous dose once every 2 weeks reduced angioedema attacks with more than 90% in a placebo-controlled trail.
<xref rid=""JR03076-76"" ref-type=""bibr"">76</xref>",13_69,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-76"" ref-type=""bibr"">76</xref>
Berotralstat is an oral PKa inhibitor that reduced angioedema attacks by 44% compared to placebo in a phase 3 study.
<xref rid=""JR03076-77"" ref-type=""bibr"">77</xref>
Attenuated androgens (danazol, oxandrolone, and stanozol) have been used as first-line STP and LTP for more than four decades.
<xref rid=""JR03076-78"" ref-type=""bibr"">78</xref>",13_70,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-78"" ref-type=""bibr"">78</xref>
They are thought to reduce attack frequency through various mechanisms: induction of C1-inhibitor synthesis in hepatocytes, increased expression of C1-inhibitor mRNA in peripheral blood mononuclear cells,
<xref rid=""JR03076-79"" ref-type=""bibr"">79</xref>
and increased bradykinin degradation by induction of aminopeptidase P activity.
<xref rid=""JR03076-80"" ref-type=""bibr"">80</xref>",13_71,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-80"" ref-type=""bibr"">80</xref>
While effective in some, long-term use of attenuated androgens comes with considerable side effects in a majority of patients.
<xref rid=""JR03076-81"" ref-type=""bibr"">81</xref>
With the development of effective alternatives, attenuated androgens are now only recommended as second-line LTP.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>",13_72,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>
Likewise, antifibrinolytics such as tranexamic acid have long been used as LPT as they prevent plasmin-mediated amplification of FXII activation by inhibiting the activation of plasminogen into plasmin. However, due to insufficient efficacy, they are no longer recommended in the latest international guideline.
<xref rid=""JR03076-8"" ref-type=""bibr"">8</xref>",13_73,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
New targeted therapies now in development are highly specific to individual components of the contact activation pathway or kallikrein-kinin system. Therapies targeting FXIIa prevent angioedema by hampering contact activation at the very beginning of the cascade. Garadacimab is a IgG4 type recombinant monoclonal antibody directed against FXIIa that is administered subcutaneously. It showed an almost 99% reduction in breakthrough attacks compared to placebo in a phase 2 trial.,13_74,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-82"" ref-type=""bibr"">82</xref>
KalVista has announced to anticipate the start of clinical studies with KV998086, a prophylactic oral FXIIa inhibitor in 2023.
<xref rid=""OR03076-83"" ref-type=""bibr"">83</xref>
<xref rid=""OR03076-84"" ref-type=""bibr"">84</xref>",13_75,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"Other investigational drugs target PKa or its zymogen prekallikrein (PK), thereby directly preventing the cleavage of high-molecular-weight kininogen and liberation of bradykinin as well as haltering the acceleration of the kallikrein-kinin cascade by preventing the activation of more FXII by kallikrein. Donidalorsen is an antisense oligonucleotide targeted at PK that showed a significant reduction in attack rate of 90% and improvement in angioedema-related quality of life compared to placebo.",13_76,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""JR03076-85"" ref-type=""bibr"">85</xref>
<xref rid=""OR03076-86"" ref-type=""bibr"">86</xref>
Notably, the reduction in PKa level does not lead to changes in thrombin formation or fibrinolytic activity.
<xref rid=""JR03076-87"" ref-type=""bibr"">87</xref>
Investigational drugs that target PKa include sebetralstat,
<xref rid=""JR03076-88"" ref-type=""bibr"">88</xref>
<xref rid=""OR03076-89"" ref-type=""bibr"">89</xref>
ATN-249
<xref rid=""JR03076-91"" ref-type=""bibr"">91</xref>
and STAR-0215.",13_77,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"and STAR-0215.
<xref rid=""OR03076-92"" ref-type=""bibr"">92</xref>
Therapies targeting the BKB2R prevent angioedema by inhibiting the effects of the end-product of the contact activation cascade and kallikrein-kinin system, bradykinin. Oral BKB2R antagonist PHA-022121 is currently in development for both LTP and ODT.
<xref rid=""JR03076-93"" ref-type=""bibr"">93</xref>",13_78,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"The field of HAE might well be revolutionary changed again in upcoming years, for several gene therapies are currently in development with the goal of curation. One of these is BMN 331, an adeno-associated virus-based gene therapy vector targeting hepatocytes to express more wild-type C1-inhibitor.
<xref rid=""OR03076-94"" ref-type=""bibr"">94</xref>
With NTLA-2002, the Nobel-prize winning CRISPR-Cas9 technique is used to inactivate the
<italic toggle=""yes"">KLKB1</italic>",13_79,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<italic toggle=""yes"">KLKB1</italic>
gene in hepatocytes, aiming to continuously suppress HAE activity by reducing the level of PK.
<xref rid=""OR03076-95"" ref-type=""bibr"">95</xref>
These gene therapies are currently studied in phase 1/2 trials in patients. Following a different approach, OTL-105 makes use of
<italic toggle=""yes"">ex vivo</italic>
autologous gene therapy to express the
<italic toggle=""yes"">SERPING1</italic>
gene in hematopoietic stem cells and is currently studied in pre-clinical trials.",13_80,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"<xref rid=""OR03076-96"" ref-type=""bibr"">96</xref>
Furthermore, RegenxBio and Spark Therapeutics have announced to be in the early stages of development of a gene therapy for HAE.",13_81,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"While C1-inhibitor is an important regulator in several intravascular pathways, symptoms in HAE patients are caused by insufficient inhibition of the contact activation pathway and kallikrein-kinin system. The subsequent unpredictable and potentially life-threatening angioedema attacks have a pronounced effect on quality of life. However, the future is bright for patients like the 21-year old female in our clinical case. New, highly specific therapies have the potential to drastically reduce their attack",13_82,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"the potential to drastically reduce their attack rate, improve their safety, and enable them to lead a normal life.",13_83,Hereditary Angioedema: The Clinical Picture of Excessive Contact Activation,23 11 2022,,Hereditary_Angioedema
"Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen Hereditary angioedema (HAE) is a rare autosomal dominant condition characterized by C1-INH gene mutations, leading to recurrent angioedema episodes affecting various body parts, including the gastrointestinal tract. This case report describes a 24-year-old female presenting with symptoms mimicking an acute abdomen, characterized by severe abdominal cramps, anorexia, and diarrhea, with a significant",14_0,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"anorexia, and diarrhea, with a significant past medical history of angioedema flares and emergency intubation for asphyxiation at age 11. Despite initial treatment with antihistamines showing no improvement, her symptoms spontaneously resolved. Further investigation revealed low complement C4 levels and reduced C1-INH function, confirming HAE with an unusual isolated involvement of the ascending and transverse colon. This case underscores the importance of considering HAE in patients presenting with acute",14_1,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"considering HAE in patients presenting with acute abdominal symptoms, especially with a history suggestive of angioedema. It highlights the need for emergency physicians and gastroenterologists to be aware of HAE’s clinical manifestations to avoid misdiagnosis and unnecessary interventions. Moreover, the case emphasizes the significance of patient education on recognizing symptoms and seeking timely medical attention to prevent severe complications. This report adds to the existing literature by detailing",14_2,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"adds to the existing literature by detailing an uncommon presentation of HAE, aiming to enhance early diagnosis and management of this potentially life-threatening condition. Angioedema refers to localized, non-pitting swelling of the subcutaneous and/or submucosal tissues, impacting areas such as the lips, face, neck, limbs, oral cavity, larynx, and gastrointestinal tract, and can be classified as an acquired or hereditary form.<sup>",14_3,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"<xref rid=""bibr1-2050313X241272574"" ref-type=""bibr"">1</xref>
</sup> Hereditary angioedema (HAE) is a rare autosomal dominant disorder that results from mutations in the C1-INH gene on chromosome 11.<sup><xref rid=""bibr2-2050313X241272574"" ref-type=""bibr"">2</xref>,<xref rid=""bibr3-2050313X241272574"" ref-type=""bibr"">3</xref></sup> The incidence of HAE falls between 1:10,000 and 1:150,000.<sup>
<xref rid=""bibr2-2050313X241272574"" ref-type=""bibr"">2</xref>",14_4,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> There is not yet any information on differences in HAE prevalence by gender or ethnicity.<sup>
<xref rid=""bibr4-2050313X241272574"" ref-type=""bibr"">4</xref>
</sup> HAE is characterized by repeated episodes of angioedema, impacting the skin, gastrointestinal tract, or upper respiratory tract.<sup>
<xref rid=""bibr2-2050313X241272574"" ref-type=""bibr"">2</xref>",14_5,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> When HAE affects the upper respiratory tract, it can be fatal due to the risk of asphyxiation, while its non-specific gastrointestinal symptoms could lead to misdiagnosis and unnecessary procedures, highlighting the importance of accurate diagnosis.<sup>
<xref rid=""bibr5-2050313X241272574"" ref-type=""bibr"">5</xref>",14_6,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> This case report provides valuable insights into a rare presentation of HAE, where colon swelling mimicked acute abdomen symptoms in a 24-year-old female. It underscores the diverse clinical spectrum of HAE and highlights the complexities in diagnosis, emphasizing the need for comprehensive evaluation and interdisciplinary collaboration. By sharing this experience, we aim to enhance awareness and promote early recognition of rare conditions like HAE, ultimately improving patient outcomes. A",14_7,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"HAE, ultimately improving patient outcomes. A 24-year-old woman presented to the Emergency department complained of severe abdominal cramps and diarrhea for 2 days, the patient denied any combined symptoms of skin rash, swelling over the face, generalized urticaria, difficulty breathing, nausea, or vomiting. She denied any drug use recently, travel history, or sick contacts. She had one episode of fever 3 days before the presentation. The maximum degree was 39°C, and she had a loss of appetite for 1 week.",14_8,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"39°C, and she had a loss of appetite for 1 week. Her medical history was significant for angioedema flares when she was young, her face, larynx, and tongue were affected and treated with danazol, an androgen derivative discontinued 5 years ago due to adverse effects of breathlessness, weakness, and amenorrhea. At 11, she underwent emergency intubation for asphyxiation. Her medical family history was not significant for similar presentation or a hereditary medical condition. Upon examination, her vitals",14_9,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"medical condition. Upon examination, her vitals were stable and afebrile, but her abdomen was distended, and tender, with hyperactive bowel sounds, with no skin rash, urticarial, or swelling of face and tongue noted. Laboratory results showed a WBC count of 6.2 × 10<sup>9</sup>/L, C-reactive protein of 4 g/L, serum ferritin 102 ng/mL, stool culture was negative for both Salmonella and Shigella, and urinalysis was negative. She was admitted with a suspected acute abdomen, she was kept nil per oral, given",14_10,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"acute abdomen, she was kept nil per oral, given intravenous fluids for hydration, Perfalgan (paracetamol) for pain control, Pantover (Pantoprazole), and intravenous antibiotic ceftriaxone was initiated empirically. Abdominal computed tomography (CT) findings were conducted. A significant wall thickening with submucosal edema affecting the ascending colon was found (<xref rid=""fig1-2050313X241272574"" ref-type=""fig"">Figure 1</xref>), in addition to the affected proximal transverse colon with an abrupt",14_11,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"affected proximal transverse colon with an abrupt transformation into a normal colon (<xref rid=""fig2-2050313X241272574"" ref-type=""fig"">Figure 2</xref>). Endoscopy showed no significant findings. A gastroenterologist was consulted, who started Cetirizine, an antihistamine, with her as he suspected histamine-mediated angioedema, but no response was noted. The patient was discharged as her symptoms were relieved spontaneously. The family denied doing complement screening before despite the history of danazol",14_12,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"screening before despite the history of danazol taking. So we advise them to do complement screening, as the previous history of angioedema and the long time response to danazol, unresponsiveness to antihistamines, and CT findings, raise the suspicion of HAE being the cause. As these tests do not exist in our institution, they are done in an external laboratory, and we recommend following up until the result comes. After 1 month, results revealed low complement C4 levels of 4 mg/dL (normal range 10–40) an",14_13,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"C4 levels of 4 mg/dL (normal range 10–40) an abnormally low function of C1-INH 40% (normal range equals or more than 68%) with normal C1q levels of 187 mg/dL (normal range 50–250). Depending on the result, the patient was diagnosed with HAE. We educated the patient about her condition and advised her to follow up with an allergy and immunology specialist to describe the treatment. HAE, a rare autosomal dominant disorder, stems from C1-INH gene mutations, with 85% of cases showing C1-INH deficiency (Type 1)",14_14,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
85% of cases showing C1-INH deficiency (Type 1) and 15% having C1-INH dysfunction (Type 2).<sup>,14_15,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"<xref rid=""bibr2-2050313X241272574"" ref-type=""bibr"">2</xref>
</sup> This causes excessive bradykinin, leading to angioedema flares.<sup>
<xref rid=""bibr6-2050313X241272574"" ref-type=""bibr"">6</xref>
</sup> HAE, lacking histamine or mast cell pathways, differs from histamine-mediated angioedema, explaining its antihistamine resistance.<sup>
<xref rid=""bibr7-2050313X241272574"" ref-type=""bibr"">7</xref>",14_16,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> First attacks often occur in childhood, peak at puberty, and are diagnosed by or after adolescence.<sup>
<xref rid=""bibr4-2050313X241272574"" ref-type=""bibr"">4</xref>
</sup> Attacks may be triggered by emotional stress, infection, medical or dental operations, etc.; however, some may be idiopathic.<sup>
<xref rid=""bibr8-2050313X241272574"" ref-type=""bibr"">8</xref>",14_17,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> Gastrointestinal manifestations of angioedema can include non-specific symptoms, including nausea, vomiting, abdominal pain, and rarely hypovolemic shock. These symptoms mimic an acute abdomen, leading to wrong treatment and unnecessary laparotomies.<sup>
<xref rid=""bibr5-2050313X241272574"" ref-type=""bibr"">5</xref>
</sup> Abdominal attacks were found to occur in more than 90% of patients.<sup>
<xref rid=""bibr9-2050313X241272574"" ref-type=""bibr"">9</xref>",14_18,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> Despite that, it is rarely the main manifestation of HAE. More rarely present is isolated intestinal angioedema, characterized by an edematous swelling of a segment of the bowel with no other manifestation, but it can cause important morbidity.<sup>
<xref rid=""bibr3-2050313X241272574"" ref-type=""bibr"">3</xref>
</sup> Isolated colon involvement in HAE is quite unusual.<sup>
<xref rid=""bibr10-2050313X241272574"" ref-type=""bibr"">10</xref>",14_19,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> which was found in our case. Classically, the symptoms are worse during the first 24 h and then gradually get better throughout the next 48–72 h.<sup>
<xref rid=""bibr3-2050313X241272574"" ref-type=""bibr"">3</xref>
</sup> This explains the spontaneous relief of our patient’s symptoms. CT imaging facilitates the diagnosis of the patient suspected of having an abdominal attack due to C1INH-HAE.<sup>
<xref rid=""bibr9-2050313X241272574"" ref-type=""bibr"">9</xref>",14_20,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> However, the literature recommends complement screening as an initial laboratory test, with serum C4 being the fastest screening test in emergencies with an accuracy of >95% to exclude C1-INH-HAE.<sup>
<xref rid=""bibr11-2050313X241272574"" ref-type=""bibr"">11</xref>
</sup> Confirmation of HAE requires a decreased C1-INH function.<sup>
<xref rid=""bibr4-2050313X241272574"" ref-type=""bibr"">4</xref>",14_21,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> Although our patient previously responded well to danazol, raising suspicion for HAE, a definite diagnosis was not established due to the patient’s incomplete follow-up with her doctor, and the trial treatment was based on her clinical presentation without genetic or immunological labs. Our patient had low levels of C4, decreased function of C1-INH, and normal levels of C1q, which confirm the diagnosis of HAE. A genetic study is used for sporadic cases and to understand pathophysiology more than",14_22,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"cases and to understand pathophysiology more than diagnosis, which is unnecessary.<sup><xref rid=""bibr4-2050313X241272574"" ref-type=""bibr"">4</xref>,<xref rid=""bibr11-2050313X241272574"" ref-type=""bibr"">11</xref></sup> Screening of C1-INH serum level is used to distinguish between the types of HAE; Low serum C1-INH levels are diagnostic of type I HAE, and normal levels of C1-INH are diagnostic of type II HAE and both have low C1-INH function.<sup>",14_23,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"<xref rid=""bibr8-2050313X241272574"" ref-type=""bibr"">8</xref>
</sup> The potential differential diagnoses encompass systemic lupus erythematosus (SLE), inflammatory bowel diseases (IBD), familial Mediterranean fever (FMF), infections, and mesenteric ischemia (<xref rid=""table1-2050313X241272574"" ref-type=""table"">Table 1</xref>). Lupus enteritis, linked to SLE, shares characteristics like submucosal edema and hypocomplementemia with HAE’s abdominal attacks.<sup>",14_24,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"<xref rid=""bibr4-2050313X241272574"" ref-type=""bibr"">4</xref>",14_25,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> The distinction between SLE and HAE lies in their autoantibody and complement profiles. While SLE often involves high antinuclear antibodies (ANA)and low C3 levels, HAE typically exhibits negative ANA and normal C3 levels even during attacks. In IBD or certain infections like Salmonella and Shigella, CT scans often reveal bowel-wall thickening and occasional inflammatory markers, contrasting with HAE’s rare hypocomplementemia and negative inflammatory markers.<sup>",14_26,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"<xref rid=""bibr4-2050313X241272574"" ref-type=""bibr"">4</xref>
</sup> FMF typically presents with recurrent abdominal pain and fever, while HAE patients are typically without fever.<sup>
<xref rid=""bibr4-2050313X241272574"" ref-type=""bibr"">4</xref>",14_27,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> Mesenteric ischemia, caused by various factors, results in sudden abdominal pain and bowel edema with elevated inflammatory markers, unlike HAE. Notably, C1-inhibitor levels are consistently normal in these conditions, highlighting the importance of examining C1-inhibitor levels in cases of abdominal pain with normal C3 levels but low C4 and CH50 levels, as this can help distinguish HAE from other diseases.<sup>
<xref rid=""bibr4-2050313X241272574"" ref-type=""bibr"">4</xref>",14_28,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> First-line treatment of bradykinin-mediated HAE attacks includes plasma-derived C1-INH concentrate, recombinant C1-INH, Icatibant, or Ecallantide; however, these drugs are expensive and are not always readily available. Although it is regarded as a second line of therapy, fresh frozen plasma has been utilized to treat acute attacks. Despite all of that the most crucial intervention is patient education, which includes recognizing symptoms and avoiding triggers to prevent acute episodes. Patients",14_29,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"triggers to prevent acute episodes. Patients should be urged to see the ED immediately if they experience an attack. Use of C1-INH concentrate, lanadelumab (monoclonal antibody to plasma kallikrein), berotralstat (plasma kallikrein inhibitor), danazol, or tranexamic acid is an example of long-term prophylactic therapy.<sup><xref rid=""bibr3-2050313X241272574"" ref-type=""bibr"">3</xref>,<xref rid=""bibr12-2050313X241272574"" ref-type=""bibr"">12</xref></sup> This case spotlight on another uncommon presentation of",14_30,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
spotlight on another uncommon presentation of HAE emphasizes that a diagnosis of HAE is challenging as HAE has an overlapping presentation and CT findings.<sup>,14_31,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"<xref rid=""bibr11-2050313X241272574"" ref-type=""bibr"">11</xref>",14_32,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> Makes it more challenging in our case that it mimics an acute abdomen on presentation without a family history of the same condition and just isolated ascending and transverse colon on CT, resulting in inappropriate treatment and suffering of the patient. Emergency physicians (EP) or gastroenterologists, being unable to recognize this condition results in a delay in the diagnosis of HAE to older age, which increases the risk of mortality not just for the patient but for her blood relevant, as they",14_33,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"the patient but for her blood relevant, as they cannot recognize the attack which may be fatal.<sup>",14_34,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"<xref rid=""bibr4-2050313X241272574"" ref-type=""bibr"">4</xref>
</sup> To avoid this, the literature recommends screening all family members from all generations for unrecognized angioedema and abdominal pain.<sup>
<xref rid=""bibr13-2050313X241272574"" ref-type=""bibr"">13</xref>",14_35,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> Diagnosing and treating hereditary angioedema (HAE) is particularly challenging in underserved and rural areas. A 2015 survey found that about 24% of HAE patients live in rural areas with populations under 20,000, where finding an experienced specialist is difficult. The Centers for Disease Control and Prevention report that rural U.S. counties have fewer specialists, emergency facilities, and transportation options than urban areas. In addition, rural residents are more likely to have",14_36,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"addition, rural residents are more likely to have government-issued health insurance, which many specialists do not accept. Riedl et al. identified several challenges in managing HAE in rural areas, including (1) diagnostic barriers misdiagnosis and incorrect interpretation of laboratory results; (2) access to specialist care, travel difficulties, and high costs; (3) local healthcare issues, physician shortages, and delays in therapy initiation; (4) patient education, limited resources for educating",14_37,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"education, limited resources for educating patients; (5) medication supply, maintaining adequate on-demand and prophylactic medication; (6) telemedicine barriers, lack of internet access or smartphones; and (7) economic disparities, insufficient insurance, and provider payments. These findings highlight the need for improved strategies to manage HAE effectively in rural settings.<sup>",14_38,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"<xref rid=""bibr14-2050313X241272574"" ref-type=""bibr"">14</xref>",14_39,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"</sup> We see that by improving healthcare infrastructure and accessibility to essential diagnostics and treatments. In addition, education and awareness among healthcare professionals about HAE are vital to ensure timely and accurate diagnosis, thereby preventing unnecessary treatments and reducing patient morbidity and mortality. Given that our patient was from a different area, the C1-INH serum level test was difficult to perform in addition to financial issues. So we cannot determine the exact type of",14_40,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"issues. So we cannot determine the exact type of HAE, the follow-up process of her treatment and outcomes was restricted. This case highlights the importance of EP and gastroenterologists’ awareness of such a rare disease with overlapping symptoms and findings on CT, and the importance of evaluating the personal and family history of recurrent severe acute medically unexplained abdominal pain. Educating patients about their condition is more important so they can recognize it and hurry up to the ED. This",14_41,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"can recognize it and hurry up to the ED. This may help avoid additional misdiagnoses of HAE, delays in receiving appropriate medical attention, unnecessary procedures, and associated complications.",14_42,Hereditary angioedema presented as isolated ascending and transverse colon swelling mimicking acute abdomen,31 8 2024,,Hereditary_Angioedema
"A human centred innovative approach based on persona in hereditary angioedema Hereditary Angioedema (HAE) is a rare inherited and potentially life-threatening condition [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>] characterized by intermittent, localized, and self-limiting episodes of swelling in the subcutaneous tissues, resulting from a temporary increase in vascular permeability [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. In a recent consensus [<xref",15_0,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"rid=""CR3"">3</xref>]. In a recent consensus [<xref ref-type=""bibr"" rid=""CR4"">4</xref>], the authors categorized Angioedema (AE) into five primary types and endotypes. HAE is subdivided into HAE-C1INH-type 1 (deficiency of C1INH proteins), HAE-C1INH-type 2 (disfunction of C1INH proteins) and HAE with normal levels of C1INH [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>]. The latter is associated with various genetic mutations such as those in factor XII, plasminogen and",15_1,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"such as those in factor XII, plasminogen and other related genes [<xref ref-type=""bibr"" rid=""CR7"">7</xref>].The most common form of HAE are C1INH-type 1 and C1INH-type 2. Most patients with HAE report a familial history of the illness in parents or other first-degree relatives [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. The prevalence of HAE worldwide ranges from 1:10,000 to 1:150,000 and on average is considered to be 1:50,000 [<xref ref-type=""bibr"" rid=""CR8"">8</xref>–<xref ref-type=""bibr""",15_2,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"rid=""CR8"">8</xref>–<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. In Italy, its prevalence rate is slightly lower with 1 in 64,000 people being diagnosed with HAE. However, statistics show that this number is slowly increasing towards the world average [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Symptomatic episodes of HAE are characterized by severe swellings (angioedema) of the mucous membrane in the patients’ arms, legs or face, as well as gastrointestinal attacks [<xref ref-type=""bibr""",15_3,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"gastrointestinal attacks [<xref ref-type=""bibr"" rid=""CR12"">12</xref>, <xref ref-type=""bibr"" rid=""CR13"">13</xref>]. The attack develops gradually over several hours, increases slowly for 12–36 h, and lasts for around two to five days [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. Most patients do not require admission to the hospital [<xref ref-type=""bibr"" rid=""CR15"">15</xref>]; however, in severe cases, the abdominal lining and/or lining of the upper respiratory tract may also be affected leading to more",15_4,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"tract may also be affected leading to more serious manifestations that in extreme cases could prove fatal [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. Throughout their lives, HAE patients and their caregivers face numerous disease-specific challenges, influencing the patients’ physical and mental health and limiting them in their everyday routine [<xref ref-type=""bibr"" rid=""CR17"">17</xref>, <xref ref-type=""bibr"" rid=""CR18"">18</xref>]. The diagnostic process is also complex and prolonged. Since symptoms",15_5,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"is also complex and prolonged. Since symptoms present in HAE patients are similar to other conditions, such as allergic reactions, gastroenteritis etc., a high number of patients are misdiagnosed and experience delays in getting the right treatment. Studies have reported that the mean delay in diagnosis of HAE-C1INH patients is on average 8.3–10.3 years in Europe [<xref ref-type=""bibr"" rid=""CR19"">19</xref>, <xref ref-type=""bibr"" rid=""CR20"">20</xref>]. In the process of visiting various physicians, 65% of",15_6,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"process of visiting various physicians, 65% of participants received a misdiagnosis of their condition, with the most common misdiagnoses being allergy/allergic reaction (38%) and appendicitis (17%). In addition, 24% of participants in Europe underwent an unnecessary surgical procedure [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. The unpredictability of attacks limits the ability of patients to perform daily tasks. In a study involving 92 Hungarian HAE patients over 7 years, the most common attack",15_7,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"HAE patients over 7 years, the most common attack triggers were physical exertion (71%), mental stress (59%), and mechanical trauma (59%) [<xref ref-type=""bibr"" rid=""CR21"">21</xref>]. Recently, an increased vagal modulation to the sinus node, reflecting localized vasodilation mediated by the release of bradykinin has been identified as an early marker of an impending angioedema attack [<xref ref-type=""bibr"" rid=""CR22"">22</xref>], helping to identify patients at higher risk of attack recurrence. Depression",15_8,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"at higher risk of attack recurrence. Depression and anxiety are also common in patients with HAE [<xref ref-type=""bibr"" rid=""CR23"">23</xref>]. In a study conducted in the US with 457 HAE patients, 42.5% experienced depression and anxiety symptoms, which may be related to the severity of the chronic disease, to the associated pathophysiologic characteristics, or both [<xref ref-type=""bibr"" rid=""CR24"">24</xref>]. In general, patients who suffer more frequent and severe attacks experience more hindrances to",15_9,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"and severe attacks experience more hindrances to their education and ability to work, with a consequent significant economic burden [<xref ref-type=""bibr"" rid=""CR25"">25</xref>].These data suggest the need for a Human-Centred Design (HCD) approach that focuses on the discovery of users’ unexpressed and unarticulated needs to enable the development of tailored solutions [<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. Such kind of approach includes not only clinical treatment, but also addresses psychosocial",15_10,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"treatment, but also addresses psychosocial issue to lead to prevention of the attacks and improved quality of life [<xref ref-type=""bibr"" rid=""CR27"">27</xref>, <xref ref-type=""bibr"" rid=""CR28"">28</xref>]. A common human–computer interaction technique utilised by the HCD approach to describe the needs of different user types is called <italic toggle=""yes"">persona</italic>. Persona is a data-driven narrative tool based on qualitative and quantitative data collected through ethnographic interviews. Personas",15_11,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"through ethnographic interviews. Personas are composite archetypes derived from this tool that are used during the design process to capture attitudes, goals, and behaviours of real people, to build empathy towards users, and to communicate their needs [<xref ref-type=""bibr"" rid=""CR29"">29</xref>–<xref ref-type=""bibr"" rid=""CR31"">31</xref>]. In health domains, personas are used in the design and human interaction for health technology research; however, personas could be extended to studies of the",15_12,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"personas could be extended to studies of the psychosocial and care experience [<xref ref-type=""bibr"" rid=""CR32"">32</xref>]. Based on this framework the main aim of the present study was to create personas starting from anthropological conversations on HAE C1INH-type 1 and C1INH-type 2 patients and their caregivers. This approach will represent the first attempt to better understand the unmet and unarticulated needs relating to psychosocial aspects and care experiences of this rare disease [<xref",15_13,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"and care experiences of this rare disease [<xref ref-type=""bibr"" rid=""CR33"">33</xref>].   In the realm of rare diseases, the emphasis on treating symptoms rather than achieving a complete cure of the affected individual stems from the unique challenges presented by these conditions. Rare diseases, often characterized by their limited prevalence and insufficient understanding, frequently lack early diagnosis and definitive cures due to the complexities of their underlying mechanisms. As a result, the",15_14,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"of their underlying mechanisms. As a result, the medical approach tends to prioritize managing and alleviating specific symptoms that impact patients' daily lives, aiming to provide relief and improve functionality. The administration of ad hoc questionnaires for the evaluation of the QoL, such as AE-QoL [<xref ref-type=""bibr"" rid=""CR36"">36</xref>] and HAE QoL [<xref ref-type=""bibr"" rid=""CR40"">40</xref>], is routinely used and recommended by guidelines [<xref ref-type=""bibr"" rid=""CR41"">41</xref>]. They are",15_15,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"ref-type=""bibr"" rid=""CR41"">41</xref>]. They are extensively applied as a patient related outcome measure in the evaluation of the efficacy of therapy, whether the on-demand treatment or prophylaxis [<xref ref-type=""bibr"" rid=""CR42"">42</xref>]. However, even with highly effective treatments out of the four domains evaluated by the AE-QoL, the more impactful improvement can be observed inside the “functionality” domain (ref HELP study). In many instances, this approach enhances the overall QoL of affected",15_16,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"approach enhances the overall QoL of affected individuals, but a complete cure may remain elusive. Furthermore, the individualized nature of rare diseases necessitates a personalized treatment strategy. Tailoring interventions to manage symptoms acknowledges the diversity of manifestations within a particular rare disease and recognizes that each patient may experience a unique set of challenges. This personalized approach extends beyond the physical symptoms to encompass the psychological and social",15_17,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"to encompass the psychological and social aspects of the individual's well-being. Creating detailed, fictional representations of typical patients and caregivers, the persona-based approach allowed us to identify a total of 6 personas—4 patients, 1 patient-caregiver, and 1 non-affected caregiver personas—expressing the diverse needs, preferences, and characteristics of individuals who live with a rare and disabling disease, such as HAE. This approach also brought to the identification of the most expressed",15_18,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"to the identification of the most expressed patients’ needs including psychological support, better awareness amongst healthcare professionals, disability benefits, more information about the impact of the condition on fertility and pregnancy, a dedicated phone line for emergencies, new drugs (ex. that can be taken orally), and bureaucratic challenges between different regions of Italy. From the side of patient-caregivers and caregivers, better information about the condition, such as informative",15_19,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"about the condition, such as informative newsletters about novel treatments, and information for schools and other facilities for children affected by HAE emerged as the primary needs. Of interest, in our interviews, severity of attacks and the psycho-social impact of the condition were not reported as correlated. This is partially in contrast with previous work [<xref ref-type=""bibr"" rid=""CR43"">43</xref>] in which the high attack frequency is a major determinant in the management of home therapy since in",15_20,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"in the management of home therapy since in the semi-structured interviews there was not a specific question addressing this item. Obtaining different archetypal individual characters and knowing their often unexpressed, unknown and unmet needs is essential for improving healthcare. It allows healthcare providers and systems to tailor their services to better meet the expectations and requirements of those they serve, enhancing empathy, communication, and the overall quality of care. The creation of",15_21,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"and the overall quality of care. The creation of archetypal characters is supported by a shared methodology. This is at the same time a scientific and experience-based approach that overcomes the limitation of the single case-report and website reports. From a more general perspective, the approach used in this study is in line with the well-known Value-Based Healthcare, a model of designing healthcare systems with the rationale that achieving high value for patients must become the overarching goal of",15_22,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"for patients must become the overarching goal of healthcare delivery. The value is defined as the health outcomes that matter to patients relative to the cost of achieving these outcomes and should always be defined around the user’s needs, to develop personalised solutions [<xref ref-type=""bibr"" rid=""CR44"">44</xref>]. This concept applies to the entire care pathway, in particular for chronic conditions, including rare diseases, that often require long-time and resource-intensive care management [<xref",15_23,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"and resource-intensive care management [<xref ref-type=""bibr"" rid=""CR45"">45</xref>]. In the modern approach to care, the long-time care management should include preventive strategies and rehabilitation programs, that refer to a multidisciplinary approach aimed at restoring, maintaining, preventing relapses, and improving the individual's physical, cognitive, and/or psychosocial functions and overall well-being. In the case of HAE patients, who often present significant limitations in their level of",15_24,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"present significant limitations in their level of autonomy, as well as in private and working-related relationships, rehabilitation, intended as the achievement of the highest possible level of independence and participation in daily life and working activities, becomes a fundamental part of the care process. To be effective in terms of health results and costs, rehabilitation also benefits from the proposed approach focused on personalized interventions centred on the individuals’ needs and values [<xref",15_25,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"on the individuals’ needs and values [<xref ref-type=""bibr"" rid=""CR46"">46</xref>, <xref ref-type=""bibr"" rid=""CR47"">47</xref>]. The study has some limitations. Firstly, pediatric/adolescent subjects were not included in the creation of the personas, despite the fact that HAE often starts at this age and can significantly impact quality of life. Another limitation is the small sample size, as the study involved only 17 participants. This relatively small sample size may affect how generalizable the findings",15_26,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"size may affect how generalizable the findings are, as the experiences and needs identified may not fully represent the broader population of individuals with HAE. Additionally, conducting the study at a single center may limit the external validity of the results which may also depend on cultural differences. In conclusion, we argue that a better understanding of unmet and unarticulated needs, relating to psychosocial aspects and care experiences of patients and their caregivers may improve patient",15_27,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"patients and their caregivers may improve patient experience, and increase organisational efficiency and cost-effectiveness of HAE care. By using persona as a narrative tool and following an innovative value-based healthcare research, care providers and other stakeholders may be able to make better-informed decisions for the management of people affected by rare diseases and enhance resource utilisation. While the ultimate goal in healthcare remains the discovery of curative interventions, the current",15_28,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"discovery of curative interventions, the current reality of rare diseases underscores the importance of a holistic and needs-focused approach.",15_29,A human centred innovative approach based on persona in hereditary angioedema,10 8 2024,,Hereditary_Angioedema
"Vascular endothelial growth factor (VEGF) emerging as a mediator of hereditary angioedema (HAE) DAB2IP; Disabled homolog 2 interacting protein, GAP; GTPase-activating protein, HAE; Hereditary Angioedema, VEGF; Vascular Endothelial Growth Factor, VEGFr2; VEGF receptor 2. Not applicable. It does not apply. All authors participated in the design and the development of the present letter. As this work is a correspondence, it is exempt from approval by the ethics committee. All authors wrote, read, approved, and",16_0,Vascular endothelial growth factor (VEGF) emerging as a mediator of hereditary angioedema (HAE),30 7 2024,,Hereditary_Angioedema
"committee. All authors wrote, read, approved, and consented to the publication of this manuscript. The authors have no financial or conflicts of interest to disclosure.",16_1,Vascular endothelial growth factor (VEGF) emerging as a mediator of hereditary angioedema (HAE),30 7 2024,,Hereditary_Angioedema
"Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series The role of psychotherapy in the management of chronic conditions has been widely explored and supported. The current approach to the utilization of family-oriented psychotherapy in treatment plans is individualized to the patient and focused on the development of personal coping skills alongside identifying and changing negative thoughts, emotions, and behaviors. Alleviation of symptom burden, improvement in",17_0,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"Alleviation of symptom burden, improvement in psychiatric co-morbidities like anxiety and depression, and enhancement of quality of life have all been found to be associated with incorporating family-oriented psychotherapy in the management of chronic conditions. In contrast, heritable conditions, such as hereditary angioedema (HAE), have not been the center of extensive research. Heritable conditions introduce a new category of stressors that require management like the anxiety of a parent, a sibling, a",17_1,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"like the anxiety of a parent, a sibling, a child, or another family member decompensating at the same time as oneself. Family-centered psychotherapy focuses on discussing the stressors of the family unit and the development of coping strategies to prevent the time course of one family member’s condition from exacerbating another family member’s condition. This model has been utilized for families with separate chronic conditions, but its role and effectiveness in managing inherited conditions have room for",17_2,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"in managing inherited conditions have room for investigation. This paper presents a case series on a family engaging in family-centered psychotherapy for HAE. Hereditary angioedema (HAE) is a rare autosomal dominant disorder that affects 1/50,000 individuals worldwide [<xref rid=""REF1"" ref-type=""bibr"">1</xref>]. The pathophysiology of this disorder is a deficiency or dysfunction of the C1 esterase inhibitor (C1-INH), which is a key component of the complement, coagulation, fibrinolysis, and",17_3,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"of the complement, coagulation, fibrinolysis, and kallikrein-kinin systems [<xref rid=""REF1"" ref-type=""bibr"">1</xref>]. If C1-INH is deficient or dysfunctional, there is continuous production of kallikrein, which is responsible for cleaving high molecular weight kininogen into bradykinin [<xref rid=""REF1"" ref-type=""bibr"">1</xref>]. Continuous production of kallikrein will ultimately lead to overproduction and accumulation of bradykinin. Bradykinin increases vascular permeability, leading to angioedema",17_4,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"vascular permeability, leading to angioedema [<xref rid=""REF1"" ref-type=""bibr"">1</xref>]. There are three subtypes of HAE, which are all bradykinin-mediated. Type I is a quantitative deficiency of C1-INH that accounts for about 85% of cases while type II is a qualitative dysfunction of C1-INH that accounts for the rest of the cases [<xref rid=""REF1"" ref-type=""bibr"">1</xref>]. Type III is estrogen-dependent with normal C1-INH activity, but several specific gene mutations have been found to be",17_5,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"specific gene mutations have been found to be associated. Due to the estrogen dependence of type III, affected individuals are predominantly females, and the presentation of symptoms appears later in life [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. Type I and type II show presentations more commonly in the second decade of life, and young children are typically asymptomatic [<xref rid=""REF2"" ref-type=""bibr"">2</xref>]. The symptomatic presentation varies from individual to individual, but the most",17_6,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"from individual to individual, but the most classical is non-pitting angioedema and abdominal pain [<xref rid=""REF3"" ref-type=""bibr"">3</xref>]. The angioedema most frequently involves the face, and laryngeal edema is a major complication of an acute attack [<xref rid=""REF3"" ref-type=""bibr"">3</xref>,<xref rid=""REF4"" ref-type=""bibr"">4</xref>]. Laryngeal edema can lead to air compromise and asphyxiation [<xref rid=""REF4"" ref-type=""bibr"">4</xref>]. The gastrointestinal tract can also be affected, which can",17_7,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"tract can also be affected, which can result in debilitating visceral abdominal pain [<xref rid=""REF4"" ref-type=""bibr"">4</xref>]. Acute episodes may have a preceding trigger for some individuals such as trauma, medical procedures, stress, infections, and starting angiotensin-converting enzyme inhibitor therapy; however many individuals have no consistent identifiable triggers [<xref rid=""REF4"" ref-type=""bibr"">4</xref>].  The multitude of triggers and burdens of this illness causes patients with HAE to have",17_8,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"of this illness causes patients with HAE to have an increased risk of mental health disorders [<xref rid=""REF5"" ref-type=""bibr"">5</xref>]. Tunçel et al. found that HAE significantly impairs quality of life, which correlates with depression, anxiety, perceived social support, and perceived limitations. They also found that higher levels of C1-inhibitor function and C1q, the first subcomponent of the C1 complex of the classical pathway of complement activation, correlate with better quality of life. They",17_9,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"correlate with better quality of life. They also propose that patients with HAE who suffer from depressive and anxious symptoms be referred to psychiatrists as this can further decrease quality of life and augment perceived discrimination [<xref rid=""REF6"" ref-type=""bibr"">6</xref>]. In children with HAE, the incidence of alexithymia or impaired regulation and processing of emotions has been found to be higher. This in itself compounds the baseline stress, anxiety, and low mood the patient may be",17_10,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"stress, anxiety, and low mood the patient may be experiencing, ultimately becoming a trigger of edema attacks [<xref rid=""REF7"" ref-type=""bibr"">7</xref>]. In this case series, we report a family who has been suffering from HAE and will discuss the intergenerational mental health implications this condition has within one nuclear family as well as the role family-centered psychotherapy has had in the management of their disease. This family of four integrated by a married couple with a son and daughter was",17_11,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"by a married couple with a son and daughter was initially referred to the child psychiatrist due to the son’s suicidal ideation, at which point his sister and mother were encouraged to participate in the family-centered psychotherapy as well. The father of the children, while not afflicted with HAE, also actively participates in psychotherapy and is a key supportive figure for the family. Specific focus was placed on positive psychotherapy to develop coping skills for the family unit. Case one: mother A",17_12,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"skills for the family unit. Case one: mother A 57-year-old female began experiencing HAE flares in childhood. Her records from that time could not be located for the exact age of her initial flare. Her most recent flare was in 2022 due to uncontrolled pain from lumbar radiculopathy. She has been seen in the psychiatric outpatient setting since 2015 for post-traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD), which were diagnosed shortly after her first HAE flare. Her two children have",17_13,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"after her first HAE flare. Her two children have also inherited HAE and have also been diagnosed with GAD and major depressive disorder (MDD) with psychotic features secondary to their known, unpredictable medical condition, all of which have exacerbated her personal anxiety.  Her psychiatric history is additionally significant for separation anxiety and alexithymia as the patient's daughter reports the patient suppresses many of her thoughts and emotions to avoid worrying the family. In times when her",17_14,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"to avoid worrying the family. In times when her kids have been suffering from HAE flares and ridiculed by others, causing them strife, she endorses feelings of helplessness.  Her current psychiatric management comprises consistent family-oriented psychotherapy and medication management including olanzapine, oxcarbazepine, lorazepam, haloperidol, and sertraline all at adequate dosages. She attends psychotherapy sessions with her two children, which focus on improving her ability to communicate her emotions",17_15,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"improving her ability to communicate her emotions and thoughts with her children. Family-oriented psychotherapy was first initiated on a weekly basis and then transitioned to monthly sessions once symptoms were effectively managed. Case two: daughter A 29-year-old female began receiving treatment for HAE in 2010 after experiencing an upper respiratory infection-induced flare. Her medical treatment consists of prophylactic intravenous infusions of C1-INH concentrate at therapeutic doses. The following year,",17_16,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"at therapeutic doses. The following year, she experienced flares every few months, which led to increased absenteeism from school and ultimately decreased academic performance.  Her psychiatric history is significant for ADHD, which was diagnosed in childhood, GAD, and PTSD, which was diagnosed after her first HAE flare in 2010. Her last documented HAE flare was in 2011. She was started on escitalopram at that time and titrated to a therapeutic dose. Her anxiety would lead to stress-induced binge eating",17_17,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"anxiety would lead to stress-induced binge eating that resulted in substantial weight gain. The increased stress from her poor academic performance compounded with her anxiety of experiencing another HAE flare led to increased fatigue, sleepiness, appetite, and weight gain. She was subsequently diagnosed with MDD, and her medication regimen was changed to sertraline 100 mg. As she began her college career, she endorsed her PTSD, ADHD, anxiety, and depression all significantly interfered with day-to-day",17_18,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"all significantly interfered with day-to-day functioning and school performance.  Her current psychiatric management comprises psychotherapy, which was started when her brother had a suicide attempt in 2016. She has been engaging in family-oriented psychotherapy with her brother and mother since 2016 along with pharmacologic interventions. The frequency of family-oriented psychotherapy, just as with the mother, was first initiated on a weekly basis and then transitioned to monthly sessions once symptoms",17_19,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"transitioned to monthly sessions once symptoms were effectively managed. During her initial evaluations and therapy sessions, she was noted to maintain a positive image and not communicate the post-traumatic effects of her and her family’s struggle with HAE. Long-term consistent psychotherapy has focused on building stress reduction strategies to aid in managing her psychiatric well-being and also prevent stress-induced HAE flares.  Case three: son A 27-year-old male began receiving treatment for HAE in",17_20,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"male began receiving treatment for HAE in 2009. His medical treatment consists of prophylactic intravenous infusions of C1-INH concentrate at therapeutic doses. He experienced two hospitalizations by February 2011 for abdominal pain secondary to a HAE flare. He has had significant school absenteeism, multiple emergency room visits for HAE flares, and inadequate pain management with opioids. He has a medical history significant for obesity that was exacerbated by systemic corticosteroids that were required",17_21,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"by systemic corticosteroids that were required pre-infusions for asthma.  His psychiatric history is significant for GAD, MDD, PTSD, attention deficit hyperactivity disorder, self-harm behaviors, and suicidal ideation and multiple attempts, for which he has received outpatient psychiatric treatment since 2015. His psychiatric conditions are related to and frequently exacerbated by his frustrations and stress in regard to caring for his mother and sister as well as dealing with his HAE flares and long-term",17_22,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"well as dealing with his HAE flares and long-term treatment requirements.  His current psychiatric management is consistent psychotherapy to enhance his functionality, mood stabilization, and development of coping strategies to navigate his and his family’s labile, chronic conditions coupled with pharmacological therapy including dextroamphetamine-amphetamine, sertraline, gabapentin, and lorazepam at adequate dosages. His last angioedema flare that required emergency medicine evaluation was in November",17_23,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"emergency medicine evaluation was in November 2014. The documentation from that visit states he presented with severe abdominal pain, and edema was anxious, and endorsed significant school-related stress. Outcomes All three family members are stable and have been able to continue keeping their HAE exacerbation under control with the help of their medication management and regular family-oriented psychotherapy sessions. They have continued to lead productive lives even when negative life circumstances",17_24,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"lives even when negative life circumstances continue to present themselves. They have developed coping strategies with the help of their psychiatrist and have been able to ensure that the stresses they do not have control over are able to be managed. They report that the open communication developed from family-oriented psychotherapy has significantly alleviated anxiety and stress related to each other and equipped them with coping strategies to focus on their personal mental health. For example, the",17_25,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"on their personal mental health. For example, the husband of the mother (father of the children) developed a terminal illness that has been a significant point of stress for this family. Through this challenging circumstance, they have continued to effectively communicate their emotions during the psychotherapy sessions led by their psychiatrist to prevent stress-induced HAE flares. Both children have additionally been able to finish their education and maintain employment with the coping strategies that",17_26,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"employment with the coping strategies that were developed through the psychotherapy sessions. Internal and external psychological stressors can be triggers to HAE. Stress is actually the most frequently cited trigger [<xref rid=""REF8"" ref-type=""bibr"">8</xref>]. The unpredictability of HAE also leads to increased levels of stress, leaving patients in a particularly curious circumstance. During the COVID-19 pandemic, one of the most recent global stressors, it was found that disease morbidity and",17_27,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"it was found that disease morbidity and psychological stress outcomes related to HAE worsened and common co-morbid diagnoses of anxiety, depression, and PTSD were associated with worse outcomes [<xref rid=""REF9"" ref-type=""bibr"">9</xref>]. As patients suffer from HAE attacks, they accumulate anxiety and stress, which then leave them more prone to another attack; they live in a self-fulfilling prophecy. Management of stress utilizing psychotherapy can be integrated to better manage these symptoms in hopes of",17_28,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"to better manage these symptoms in hopes of curbing upcoming attacks. The benefits of psychotherapy for chronic conditions such as asthma, diabetes, cancer, and chronic pain have been widely studied and supported. Cognitive behavior therapy (CBT), including newer forms such as acceptance and commitment therapy, has shown significant effectiveness in managing chronic pain by improving the patient’s ability to cope with pain, engage in activities of daily living, and overall quality of life [<xref",17_29,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"daily living, and overall quality of life [<xref rid=""REF10"" ref-type=""bibr"">10</xref>]. More broadly, CBT has been shown to aid in psychological adjustment to a diagnosis of a chronic medical condition and reduce the symptom burden of common psychological co-morbidities to chronic conditions like anxiety and depression [<xref rid=""REF11"" ref-type=""bibr"">11</xref>]. The framework for the effectiveness of psychotherapy focuses on the connections between thoughts, emotions, behaviors, and physical symptoms",17_30,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"emotions, behaviors, and physical symptoms [<xref rid=""REF12"" ref-type=""bibr"">12</xref>]. Negative thoughts or ruminations about a chronic condition can lead to emotions of anxiety and depression. These emotions can then encourage hypervigilance and/or avoidance behaviors [<xref rid=""REF12"" ref-type=""bibr"">12</xref>]. The behaviors can then manifest in physical symptoms such as increased heart rate or shortness of breath, which will ultimately validate the precipitating thoughts [<xref rid=""REF12""",17_31,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"the precipitating thoughts [<xref rid=""REF12"" ref-type=""bibr"">12</xref>]. CBT emphasizes focusing on the present and being goal-oriented, which facilitates dissociation of the thoughts, emotions, behaviors, and physical symptoms cycle at the thoughts and behaviors stage [<xref rid=""REF12"" ref-type=""bibr"">12</xref>]. A vast majority of the literature on the role of psychotherapy in the management of chronic conditions focuses on an individualized approach and does not adequately represent heritable, chronic",17_32,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"does not adequately represent heritable, chronic conditions. The implementation of family-centered psychotherapy between all three of the members of this family who all suffer from HAE was not only critical to the management of their own chronic illness, but it stood to make them resilient enough to withstand the stresses of each other’s chronic illness. In contrast to other chronic conditions where family is often viewed as a protective factor and a valuable element of strong social support, family serves",17_33,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"element of strong social support, family serves as both a protective and precipitating factor for heritable conditions. Positive strategic family and individual psychotherapy enables the identification of interpersonal relationships that comprise a family unit and possible stressors existent in those relationships to then implement coping strategies to mitigate the stress, while still preserving the relationship [<xref rid=""REF13"" ref-type=""bibr"">13</xref>,<xref rid=""REF14"" ref-type=""bibr"">14</xref>]. If",17_34,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"rid=""REF14"" ref-type=""bibr"">14</xref>]. If one member of this family experiences an HAE flare, the event would subsequently be a new stressor for the whole family unit. Family-centered psychotherapy can encourage familial resilience while simultaneously decreasing stress-induced angioedema flares. Since engaging in family-centered psychotherapy, both children in this case series have not required hospitalization for a stress-induced flare in 10 years. The family unit continues to navigate difficult",17_35,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"The family unit continues to navigate difficult educational, vocational, physical, mental, and emotional situations. With the coping skills and open communication facilitated by family-centered psychotherapy, they are able to focus and work on improving those aspects of their life without exacerbating their HAE. Heritable conditions would benefit from family-oriented early, psychotherapy for the management of individual stress as well as group stress. This case series illustrates how HAE not only affects",17_36,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"case series illustrates how HAE not only affects individuals physically but also places a significant emotional and psychological burden on entire families. Integrating family-centered psychotherapy into the treatment plans for families dealing with HAE has shown promise in enhancing coping skills, improving overall mental health, and stabilizing the emotional dynamics within the family unit. By improving the emotional dynamics within the family unit, there can be a reduction in stress-induced angioedema",17_37,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
"can be a reduction in stress-induced angioedema flares, hospitalizations, and symptom burden of psychiatric co-morbidities. Moving forward, the adoption of family-centered psychotherapy for managing other hereditary conditions may be more effective and rewarding compared to individualized psychotherapy as the implications of family dynamics play a larger role in inherited conditions.",17_38,Implications of Family-Oriented Psychotherapy for Hereditary Angioedema Management: A Case Series,27 7 2024,,Hereditary_Angioedema
Perioperative management of a patient with hereditary angioedema undergoing oral surgery Full text not available in PMC,18_0,Perioperative management of a patient with hereditary angioedema undergoing oral surgery,8 2024,,Hereditary_Angioedema
"The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks Hereditary angioedema (HAE) is a genetic disease resulting in deficiency (type I) or dysfunction (type II) in the complement-1 esterase inhibitor (C1-INH) protein and subsequent uncontrolled activation of the kallikrein kinin system [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. The symptoms of a HAE attack are well recognized and include swelling in the extremities or face, abdominal pain caused by",19_0,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"the extremities or face, abdominal pain caused by intestinal swelling, and respiratory difficulties as a result of laryngeal and airway angioedema [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. The frequency and severity of HAE attacks are highly variable between patients and even can vary within a patient, over their lifetime, making each patient’s HAE attack journey highly individualized [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. A recent prevalence analysis reported 8,904 HAE patients in the United States",19_1,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"reported 8,904 HAE patients in the United States (US), which aligns with previous prevalence estimates of 1 in 50,000 within the global population (range 1 in 10,000 to 1 in 150,000) [<xref ref-type=""bibr"" rid=""CR4"">4</xref>–<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. The rarity of HAE may contribute to diagnostic delays for many patients, with time to conclusive diagnosis ranging from 2 to 13.5 years [<xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR8"">8</xref>]. The recent",19_2,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"ref-type=""bibr"" rid=""CR8"">8</xref>]. The recent international World Allergy Organization (WAO)/European Academy of Allergy and Clinical Immunology (EAACI) guideline for HAE acknowledges that early diagnosis and effective therapy are critical for the management of this disabling disease [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. The goal of HAE treatment is to achieve complete disease control and normalize patients’ lives [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Current management of HAE includes the",19_3,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"Current management of HAE includes the use of medications targeting the kallikrein-kinin pathway for on-demand treatment of acute angioedema events (HAE attacks) with the objective of relieving acute symptoms as quickly and completely as possible [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. As attacks are unpredictable and potentially life-threatening, it is essential that all HAE patients have effective on-demand therapy readily available [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Long-term prophylaxis",19_4,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"rid=""CR9"">9</xref>]. Long-term prophylaxis is recommended for some HAE patients to reduce the frequency of attacks. The need for long-term prophylaxis is highly individualized based on attack frequency and severity, and patient preference [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Guidelines state that HAE attacks should be treated early with intravenous (IV) plasma-derived C1-INH and recombinant human C1-INH, plasma kallikrein inhibitor ecallantide administered subcutaneously by a health professional,",19_5,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"subcutaneously by a health professional, or self-injected subcutaneous (SC) bradykinin B2 receptor antagonist icatibant, and that early treatment provides far better clinical outcomes than late treatment [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. For long-term prophylactic treatment, guidelines recommend the use of IV or SC plasma-derived C1-INH, the SC plasma kallikrein monoclonal antibody lanadelumab, or orally administered plasma kallikrein inhibitor berotralstat. Guidelines also recommend an",19_6,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"berotralstat. Guidelines also recommend an individualized approach to prophylaxis, including careful and regular monitoring of HAE patients who use long-term prophylactic treatment in order to inform dose optimization, with the goal of improving tolerability, adherence to therapy, and quality of life [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. It is recognized that current HAE treatments are effective and have greatly improved the lives of patients with HAE.",19_7,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"greatly improved the lives of patients with HAE. Despite these benefits, treatment administration may impose additional burden to some patients and caregivers, as most prophylactic and all on-demand therapies are administered by SC or IV injection [<xref ref-type=""bibr"" rid=""CR12"">12</xref>–<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. Patients have indicated that the route of administration is the factor they consider the most important in their choice of HAE treatment, citing the need for less ”traumatic”",19_8,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"treatment, citing the need for less ”traumatic” administration with oral therapies preferred over SC and IV [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. Availability of self-administered on-demand parenteral treatments has improved health-related quality of life and HAE attack management. However, deciding when to initiate on-demand therapy may be challenging for patients as attack symptoms may escalate over hours and attacks can be unpredictable and vary in intensity. Patient education is crucial for",19_9,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"in intensity. Patient education is crucial for appropriate and early initiation of on-demand therapy and to minimize attack severity and duration. However, decision-making associated with on-demand treatment administration as reported by patients and the impact of this process on the patient’s HAE attack journey have not been fully described in the literature. Characterizing patient behavior and understanding the patient perspective are essential for addressing the factors restricting the optimal use of",19_10,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"the factors restricting the optimal use of on-demand treatment for HAE attacks. Patients’ experiences, including the self-reported reasons for delaying treatment or not treating attacks, would offer valuable insights into the decision-making process surrounding on-demand treatment administration. Here, we describe the findings of a patient survey that aimed to encompass the overall behaviors and decision-making process regarding the on-demand treatment of HAE attacks. We present an evaluation of the",19_11,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"of HAE attacks. We present an evaluation of the factors that drive the on-demand treatment decision-making process, including reasons to delay or not treat an attack, as reported by those living with HAE.   While major advances have been made with the availability of effective parenteral on-demand treatment options and the development of prophylactic treatments for HAE, patients including those on prophylaxis can still experience HAE attacks requiring on-demand therapy. Thus, the WAO/EAACI guideline states",19_12,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"therapy. Thus, the WAO/EAACI guideline states that all patients should have and carry on-demand medication for the treatment of at least two HAE attacks [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. The findings of this patient survey characterize a personal decision-making process for why, when, and where to administer currently available on-demand treatment despite early recognition of attacks by patients and clear understanding of the benefits of early treatment. While self-administration of current",19_13,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"treatment. While self-administration of current parenteral on-demand therapies has improved opportunities for HAE attack management, the decisions faced by patients about if and when to administer treatment may be complex. The survey found that despite recognizing the initial onset of an attack, many patients delay administration of on-demand treatment while also acknowledging that delayed treatment leads to a longer recovery time. Respondents provided various reasons for doing so, with most respondents",19_14,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"reasons for doing so, with most respondents answering that the attack is not severe enough. This response is also linked directly to patients feeling the need to justify giving themselves permission to treat as a result of evaluating many other burden of treatment parameters such as, ‘treatment is too painful,’ ‘lack of a suitable/private area to administer treatment,’ and, ‘fear of needles,’ as key factors that influence their treatment decisions. The results showing the reasons for delaying or forgoing",19_15,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"showing the reasons for delaying or forgoing on-demand treatment highlight the need for patient and physician education regarding the importance of shared decision-making on the prompt recognition and appropriate treatment of HAE attacks. In addition, access to on-demand treatment weighs on the minds of patients and causes anxiety when they consider the cost of treatment and ability to get refills quickly. Survey results indicated patients using prophylaxis also use on-demand therapy more often than",19_16,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"also use on-demand therapy more often than on-demand only patients. One explanation might be that patients in the former group may have a higher level of comfort and experience with medications and injections than those in the latter group. Regardless of prophylaxis status, the financial burden associated with HAE medications is well documented and may play a significant role in the decision to treat for all patients, with high treatment costs serving as a barrier to access [<xref ref-type=""bibr""",19_17,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"as a barrier to access [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. The WAO/EAACI guideline states that all attacks should be treated as early as possible [<xref ref-type=""bibr"" rid=""CR9"">9</xref>] yet this survey demonstrated that patients felt the need to justify that an attack was worth treating due to many different reasons, some of which are not captured explicitly in this survey, and that are independent of the severity or intensity of attack symptoms. The survey results highlight that there are",19_18,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"The survey results highlight that there are complexities associated with the decision to treat. Most patients (89%) stated that their decision to treat or not influenced their plans for the day, with possible consequences for work or school activities as well as economic and social implications. Despite recognizing the consequences, patients report delaying or forgoing on-demand treatment even with the availability of effective parenteral treatment. These findings emphasize the need to address the reasons",19_19,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"emphasize the need to address the reasons why patients choose to delay or forgo on-demand treatment even with the knowledge of the potential for serious outcomes. Therefore, it is critical for clinicians to be aware of patients’ perspectives, which allows for a greater understanding of their motivations, behaviors, and barriers to on-demand treatment adherence. Given the inherent nature of survey-related research, it is important to acknowledge that the results presented here be interpreted considering the",19_20,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"presented here be interpreted considering the following limitations. Due to the anonymity of survey responses, verification of self-reported data is not possible. Additionally, reported baseline anxiety and increased anxiety are based on patient reports and an accurate determination of the degree to which each attack contributed to overall anxiety is not feasible. We also acknowledge that factors such as disease duration, frequency of attacks, time since last attack and experience with individual therapies",19_21,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"attack and experience with individual therapies may have influenced the reported outcomes. Future studies are needed to determine the extent of these influences on patient responses. Although this would be considered a large sample for a rare disease, all findings may not represent a broader or more global population. The majority of survey respondents were female (80.4%), indicating a higher proportion of females compared with previous research which cited 60% female predominance [<xref ref-type=""bibr""",19_22,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"60% female predominance [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. This finding is consistent with previous research showing higher online survey response rates among females compared with males [<xref ref-type=""bibr"" rid=""CR18"">18</xref>] and may also reflect the greater severity of HAE observed in females [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. The current survey is also subject to potential sampling bias due to it being available online only and administered in English, limiting the potential",19_23,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"administered in English, limiting the potential to reach certain populations including non-English speakers and those with limited access to the internet. Participants were recruited by the HAEA, which has a deep and established relationship with the US HAE population, and these patients may likely be more educated on HAE than the general HAE patient population. These findings were observational only and not reported in comparison with any control group. Although the survey questions used were original in",19_24,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"the survey questions used were original in nature and customized to the study objectives, the survey itself was not derived from existing validated instruments. We acknowledge that patient-driven surveys are subjective in nature; however, they do present the patients’ experience, which may help to identify gaps in care. Analyzing patient behavior by exploring patients’ perceptions regarding HAE treatment is vital for facilitating informed decision-making and optimizing HAE management. This is the first",19_25,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
and optimizing HAE management. This is the first characterization of the on-demand treatment decision-making process that people living with HAE undergo as part of the HAE attack journey. This survey also highlights the how characteristics of current parenteral on-demand treatments contribute to suboptimal attack management by patients. Incorporating the patient perspective into care strategies can lead to more patient-centered approaches that enhance treatment adherence and improve overall outcomes. These,19_26,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"adherence and improve overall outcomes. These findings may help to inform future treatment discussions and may enhance aspects of the physician/patient dialogue, aiding in building patient behaviors that are aligned with current guidelines and goals of treatment [<xref ref-type=""bibr"" rid=""CR19"">19</xref>].",19_27,The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks,25 7 2024,,Hereditary_Angioedema
"Centralized care model for hereditary angioedema overcomes geographical barriers Hereditary angioedema due to C1 inhibitor deficiency (HAE) is a rare inborn error of immunity that presents with episodic swelling. Management is multifaceted and includes on-demand treatment of swelling episodes, short-term prophylaxis to prevent swelling episodes from procedures, and long-term prophylaxis (LTP) to prevent angioedema on an ongoing basis. All approved on-demand therapies are parenteral, necessitating patient",20_0,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"therapies are parenteral, necessitating patient training for home administration, particularly intravenous C1 inhibitor. These complexities can result in care gaps for rural HAE patients. We conducted a cross-sectional study at our Angioedema Center of Reference and Excellence to assess the care provided to urban and rural patients. The proportion of patients receiving LTP, proportion of patients diagnosed as children, and disease control measured using the Angioedema Control Test (AECT) were collected.",20_1,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"Angioedema Control Test (AECT) were collected. Logistic and Poisson regression models adjusted for age and sex were used to compare the two groups. The proportion using LTP was similar at 62% and 61% in urban and rural patients, respectively (odds ratio [OR] 1.01 (CI 95% 0.34-2.99)). Among urban patients, 52% were diagnosed as children compared to 60% among rural residents (1.43 (0.37-5.56)). The mean (IQR) AECT score was 14.0 (8.5-15.5) in urban patients and 13.0 (10.0-14.0) in rural patients (Poisson β",20_2,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"and 13.0 (10.0-14.0) in rural patients (Poisson β -0.001 (-0.23-0.23). These data indicate that rural patients received similar high-quality care. We attribute these findings to the centralized care model employed in which HAE patients in the region are seen at a single comprehensive care clinic. Hereditary angioedema due to C1 inhibitor deficiency (HAE) is a genetic disease characterized by recurrent swelling of the cutaneous and submucosal tissues (<xref rid=""B1"" ref-type=""bibr"">1</xref>). It is caused",20_3,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"rid=""B1"" ref-type=""bibr"">1</xref>). It is caused by mutations in <italic toggle=""yes"">SPERING1</italic>, which lead to reduced or dysfunctional C1 inhibitor (C1-inh) (<xref rid=""B2"" ref-type=""bibr"">2</xref>). C1-inh is the primary regulator of the kinin-kallikrein pathway and acts through the inhibition of plasma kallikrein and Factor XIIa. The absence of effective C1-inh, which normally inhibits plasma kallikrein from overproducing bradykinin through the proteolysis of high-molecular-weight kininogen,",20_4,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"proteolysis of high-molecular-weight kininogen, results in angioedema as bradykinin increases vascular permeability (<xref rid=""B3"" ref-type=""bibr"">3</xref>). HAE care is multifaceted and complex, leading to significant challenges for rural patients (<xref rid=""B4"" ref-type=""bibr"">4</xref>–<xref rid=""B6"" ref-type=""bibr"">6</xref>). Local physicians must recognize the condition despite the low disease prevalence of around 1 in 50,000 persons and arrange testing or specialist consultation (<xref rid=""B1""",20_5,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"or specialist consultation (<xref rid=""B1"" ref-type=""bibr"">1</xref>). Definitive diagnosis requires testing of C1-inh function, which is often only performed at tertiary care centers (<xref rid=""B7"" ref-type=""bibr"">7</xref>). Once diagnosed, patients need education on the appropriate self-administration of on-demand therapy, including self-injection training since all approved on-demand therapies are parenteral. This is of particular importance for those who use intravenous C1-inh for on-demand treatment",20_6,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"use intravenous C1-inh for on-demand treatment as patients must be competent to obtain intravenous access. For those who reside in small communities, arrangements must be made to ensure they have access to on-demand treatments in the local emergency department (ED) as well. Ongoing care additionally involves organizing short-term prophylaxis with intravenous C1-inh to prevent angioedema episodes triggered by invasive procedures (<italic toggle=""yes"">e.g.</italic>, dental surgery). In many cases, long-term",20_7,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"dental surgery). In many cases, long-term prophylaxis (LTP) to prevent attacks with regular treatment is needed to reduce the disease burden and achieve an acceptable quality of life (<xref rid=""B1"" ref-type=""bibr"">1</xref>). Given the autosomal dominant inheritance of the disease, genetic counseling and screening of first-degree relatives is also indicated (<xref rid=""B8"" ref-type=""bibr"">8</xref>). A recent physician survey regarding the difficulties faced by rural HAE patients found that ~12% of HAE",20_8,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"by rural HAE patients found that ~12% of HAE patients resided in a remote community and highlighted delays in diagnosis and cost of therapy as key issues (<xref rid=""B6"" ref-type=""bibr"">6</xref>). Riedl et al. conducted a systematic literature review on HAE care in rural patients and identified several important challenges, including barriers to diagnosis, access to specialist care, and availability of on-demand treatments for home and ED use (<xref rid=""B5"" ref-type=""bibr"">5</xref>). There is, however, a",20_9,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"ref-type=""bibr"">5</xref>). There is, however, a paucity of data to inform policies and clinical programs designed to overcome these geographical barriers. We conducted a cross-sectional study to evaluate the quality of care provided to urban and rural patients with HAE seen at the Edmonton Angioedema Center of Reference and Excellence (<xref rid=""B9"" ref-type=""bibr"">9</xref>). This clinic provides centralized HAE care for patients residing in Edmonton, Alberta, Canada (population of 1.1 million) and rural",20_10,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"Canada (population of 1.1 million) and rural patients living in northern parts of Alberta and British Columbia, and western parts of Nunavut. The approximate geographic size of the catchment area is 1.9 million km<sup>2</sup>. The study was approved by the University of Alberta Biomedical Research Ethics Board. Individual consent was waived given that the study was designed as an audit of clinical records. Included patients had HAE type 1 or 2, were ≥18 years of age, and were assessed at least once at the",20_11,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"of age, and were assessed at least once at the Edmonton ACARE between January 1 and March 31, 2023. Demographic data, postal code, use of LTP, age at diagnosis, and angioedema control (based on the angioedema control test score [AECT] (<xref rid=""B10"" ref-type=""bibr"">10</xref>)) were extracted from the most recent clinical records. Patients were classified as rural using the Statistics Canada preferred definition of those residing in census subdivisions with <10,000 inhabitants who are outside city",20_12,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"with <10,000 inhabitants who are outside city commuting zones (<xref rid=""B11"" ref-type=""bibr"">11</xref>, <xref rid=""B12"" ref-type=""bibr"">12</xref>). Logistic regression was used to calculate the odds ratios for LTP use and diagnosis before age 18 in rural <italic toggle=""yes"">versus</italic> urban patients. Poisson regression was used to compare the mean AECT score between the two groups. All models were adjusted for age and sex.",20_13,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"<xref rid=""T1"" ref-type=""table"">
<bold>Table 1</bold>",20_14,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"</xref> shows the demographic data of the included patients. Approximately 38% of patients were classified as living in a rural area. The average straight-line distance to the clinic for rural patients was 504.6 km whereas the average straight-line distance for urban patients was nearly 6-fold less at 86.7 km. Four patients resided in highly remote areas that were accessible only by aircraft. Most patients were receiving LTP, similar to other centers in developed countries (<xref rid=""B13""",20_15,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"centers in developed countries (<xref rid=""B13"" ref-type=""bibr"">13</xref>). All patients on LTP were receiving subcutaneous/intravenous pd-C1, lanadelumab, berotralstat, or an investigational product; no patients were treated with attenuated androgens or tranexamic acid, consistent with international guideline recommendations (<xref rid=""B1"" ref-type=""bibr"">1</xref>). There was no difference between the quality of rural and urban HAE care based all metrics assessed (<xref rid=""T2"" ref-type=""table"">",20_16,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
<bold>Table 2</bold>,20_17,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"</xref>). LTP usage was comparable at 62% and 61% in urban and rural patients, respectively (odds ratio [OR] 1.01 (CI 95% 0.34-2.99)). Of urban residents, 52% were diagnosed as children compared to 60% as adults (1.43 (0.37-5.56)). The mean (IQR) AECT score comparable at 14.0 (8.5-15.5) in urban patients and 13.0 (10.0-14.0) in rural patients (Poisson β -0.001 (-0.23-0.23), and indicated adequate control (>10) in both groups. This is the largest primary study comparing the care provided to HAE patients who",20_18,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"comparing the care provided to HAE patients who reside in rural and urban areas. More than 1/3 of patients resided in a rural community, many of whom lived several hours away by vehicle. Nonetheless, use of LTP, angioedema control, and frequency of diagnosis in childhood were comparable between urban and rural patients. We ascribe the absence of inequity in these measures to the centralized care model employed for HAE. Rather than distributing care amongst smaller local clinics, concentrating patients",20_19,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"smaller local clinics, concentrating patients within a tertiary care center has many advantages. It allows the provision of comprehensive care with specialist physicians and allied health team members, implementation of best practices in telehealth care delivery, creation a single point of contact for rural providers who require advice, and creation of processes to navigate insurance procedures for medication coverage. The implications of these findings are broad. A recently published US physician survey",20_20,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"broad. A recently published US physician survey found that most rural patients were cared for in local clinics. Some of the geographical challenges faced by patients could thus potentially be addressed by leveraging tertiary care centers and telehealth (<xref rid=""B6"" ref-type=""bibr"">6</xref>). Studies have reported broad benefits telemedicine in clinical immunology and allergy clinics since its adoption increased during the COVID-19 pandemic (<xref rid=""B14"" ref-type=""bibr"">14</xref>, <xref rid=""B15""",20_21,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"ref-type=""bibr"">14</xref>, <xref rid=""B15"" ref-type=""bibr"">15</xref>). Additionally, globally many patients with HAE live in developing nations in the Asia Pacific region, a large proportion of whom reside in rural areas, and up to 99% of affected patients are thought to be undiagnosed in some countries (<xref rid=""B16"" ref-type=""bibr"">16</xref>, <xref rid=""B17"" ref-type=""bibr"">17</xref>). The use of digital health technologies coordinated through specialized HAE centers to provide expert advice to rural",20_22,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"HAE centers to provide expert advice to rural healthcare providers and directly to patients using smartphones could help address these care gaps as has been described for other diseases (<xref rid=""B18"" ref-type=""bibr"">18</xref>). These findings must be considered with the context of the Alberta health care system. Canadian Blood Services provides access to subcutaneous pd-C1 LTP (Haegarda/Berinert 2000) to all patients irrespective of private insurance coverage. Lanadelumab and berotralstat were also",20_23,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"coverage. Lanadelumab and berotralstat were also available for most patients and there is significant local experience in using these drugs as first line LTP therapies (<xref rid=""B19"" ref-type=""bibr"">19</xref>, <xref rid=""B20"" ref-type=""bibr"">20</xref>). Those residing in extremely remote regions can be provided with transportation services funded by territorial health systems to attend appointments. Physician reimbursement of telehealth is also comparable to in-person visits in most cases. This study has",20_24,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"to in-person visits in most cases. This study has limitations. Data were collected from a single center located in a highly developed country with universal health coverage and thus may not be generalizable to other settings. Whether a patient resided in a rural area was determined using their current postal code. We could thus not account for whether they previously resided in a different area. The use of census subdivisions with <10,000 residents as a metric for rural residency may not fully capture the",20_25,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"for rural residency may not fully capture the challenges experienced by HAE patients in all cases. In conclusion, the creation of centralized HAE clinics employing a comprehensive care model can help rural patients overcome barriers to quality HAE care and achieve disease outcomes comparable to those in urban patients. Implementing such a care model using networks of centralized clinics in underserved countries may help address global inequities in HAE outcomes. The raw data supporting the conclusions of",20_26,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. The studies involving humans were approved by University of Alberta Research Ethics Board. The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants’ legal guardians/next of kin because",20_27,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"participants’ legal guardians/next of kin because This study was conducted as a clinical audit. AH: Writing – review & editing, Writing – original draft. CS: Writing – review & editing. JB: Writing – review & editing. HB: Writing – review & editing. BR: Writing – review & editing, Writing – original draft. AA: Writing – review & editing, Writing – original draft.",20_28,Centralized care model for hereditary angioedema overcomes geographical barriers,15 7 2024,,Hereditary_Angioedema
"Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series Hereditary angioedema (HAE) is a rare genetic disorder characterized by episodes of localized, spontaneous soft tissue swelling without urticaria [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. The swelling can affect multiple locations including the face, upper respiratory tract, extremities and the gastrointestinal (GI) tract [<xref",21_0,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"and the gastrointestinal (GI) tract [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. The frequency and length of episodes varies, but episodes may last for days and just over half of those affected experience twelve or more episodes a year [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Complications include pain, disability and laryngeal edema potentially leading to life-threatening airway compromise [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. HAE negatively impacts",21_1,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"rid=""CR1"">1</xref>]. HAE negatively impacts patients’ work attendance, quality of life, and mental wellbeing; its burden is also felt by patients’ caregivers [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>]. HAE is classified by whether the C1-inhibitor (C1-INH) protein is abnormal in quantity or function – Type I and Type II HAE-C1-INH respectively [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. The etiology of HAE-C1-INH is linked to mutations in the <italic",21_2,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"HAE-C1-INH is linked to mutations in the <italic toggle=""yes"">SERPING1</italic> gene [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. C1-INH is a key regulator of the kallikrein-kinin pathway (the contact system) [<xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR8"">8</xref>]. Defects in C1-INH lead to uncontrolled kallikrein activity and therefore excess levels of bradykinin which increases vascular permeability, causing soft tissue swelling [<xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref",21_3,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"[<xref ref-type=""bibr"" rid=""CR4"">4</xref>, <xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Management of HAE includes treating acute attacks, and preventing attacks in both the short and long term [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Acute attacks may be treated with on-demand plasma-derived C1-INH (pdC1-INH) or icatibant [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Long-term prophylaxis (LTP) has been shown to reduce the frequency and duration of episodes and",21_4,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"reduce the frequency and duration of episodes and therefore prevent life-threatening complications and improve patients’ quality of life [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Today, for adults, first-line LTP agents include pdC1-INH, lanadelumab and berotralstat; others include attenuated androgens (AAs) and tranexamic acid [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Lanadelumab, administered subcutaneously, and pdC1-INH, available in subcutaneous or intravenous formulations, are effective",21_5,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"or intravenous formulations, are effective methods of LTP [<xref ref-type=""bibr"" rid=""CR11"">11</xref>, <xref ref-type=""bibr"" rid=""CR12"">12</xref>]. However, some patients and caregivers find injectable prophylactic treatments burdensome [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR13"">13</xref>]. Berotralstat is an oral, once-daily plasma kallikrein inhibitor that has been shown to significantly reduce the frequency and duration of angioedema episodes compared with placebo [<xref",21_6,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"angioedema episodes compared with placebo [<xref ref-type=""bibr"" rid=""CR14"">14</xref>, <xref ref-type=""bibr"" rid=""CR15"">15</xref>]. Some patients with HAE, especially those diagnosed before the availability of newer agents, continue to receive AAs, progestins and tranexamic acid as LTP in light of ease of access, price and patient habituation [<xref ref-type=""bibr"" rid=""CR16"">16</xref>–<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. However, AAs have several limitations related to efficacy, adverse effects",21_7,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"limitations related to efficacy, adverse effects (AEs) and contraindications [<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. Adverse effects of AAs include mood disturbances, an increased risk of cardiovascular events, an increased risk of hepatocellular carcinoma, virilization and menstrual irregularities [<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. AAs are contraindicated in pregnancy and in children [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. In light of these limitations, AAs are no longer recommended",21_8,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"these limitations, AAs are no longer recommended as first-line treatment in the 2021 World Allergy Association/ European Academy of Allergy and Clinical Immunology (WAO/EAACI) Guidelines [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Transitioning between prophylactic therapies can be a source of concern for patients and healthcare professionals. One such concern is the potential impact on disease control [<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. In patients transitioning from lanadelumab to",21_9,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"In patients transitioning from lanadelumab to berotralstat, berotralstat can be initiated concurrently with the final dose of lanadelumab because the latter has a half-life of approximately 2 weeks while berotralstat reaches steady state in 6–12 days [<xref ref-type=""bibr"" rid=""CR19"">19</xref>]. Moreover, there is a lower risk for withdrawal effects associated with stopping lanadelumab than there is with AAs [<xref ref-type=""bibr"" rid=""CR18"">18</xref>, <xref ref-type=""bibr"" rid=""CR20"">20</xref>]. It has",21_10,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"ref-type=""bibr"" rid=""CR20"">20</xref>]. It has been particularly difficult for patients to transition from AAs owing to rebound attacks, AEs associated with withdrawal, and psychological dependence [<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. While there are no consensus guidelines on how best to stop AAs, several real-world strategies have been described for the transition from AAs to lanadelumab, pdC1-INH and on-demand only therapy [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. These strategies are based",21_11,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"rid=""CR16"">16</xref>]. These strategies are based on tapering or overlapping of treatments, or an immediate switch [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR18"">18</xref>]. The latter approach has raised concerns regarding an increase in HAE attacks and other adverse events [<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. It is recommended to avoid abrupt withdrawal of AAs when transitioning to berotralstat [<xref ref-type=""bibr"" rid=""CR21"">21</xref>, <xref ref-type=""bibr""",21_12,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"rid=""CR21"">21</xref>, <xref ref-type=""bibr"" rid=""CR22"">22</xref>]. As the main aim of these recommendations is to minimize side effects from AA withdrawal, their validity is also expected when transitioning to other LTP. Given the variety of therapies and methods to transition between LTP, it is important to consider individual patient preferences in treatment. Treatment choices should therefore be based on principles of shared decision-making (SDM), an adaptive, collaborative model of working between",21_13,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"adaptive, collaborative model of working between healthcare professionals and patients to find the most appropriate solution for the patient [<xref ref-type=""bibr"" rid=""CR23"">23</xref>]. The importance of SDM in patients with HAE is reflected in the latest WAO/EAACI guidelines for HAE management which state that SDM should be used to determine which of the three first-line LTP to use [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Previous case series that have examined the transition between LTP have",21_14,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"have examined the transition between LTP have included pdC1-INH and lanadelumab [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR24"">24</xref>]. Some LTP transitions have been looked at in the context of a clinical trial. APEX-S was an open-label study that aimed to evaluate the long-term safety and effectiveness of berotralstat, concluding that berotralstat was generally well-tolerated and showed durable effectiveness [<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. Within APEX-S",21_15,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"rid=""CR25"">25</xref>]. Within APEX-S separate subgroups of patients who switched from lanadelumab to berotralstat (<italic toggle=""yes"">n</italic> = 21) or who had prior AA use within 60 days of starting berotralstat (<italic toggle=""yes"">n</italic> = 39) were analyzed [<xref ref-type=""bibr"" rid=""CR22"">22</xref>, <xref ref-type=""bibr"" rid=""CR26"">26</xref>]. However there remains a gap in real-world evidence and in our understanding of the transition to berotralstat from other agents. Here we present a",21_16,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"berotralstat from other agents. Here we present a family case series where the similar genetic and environmental factors allow for a comparison of treatment choices and transition protocols. The objective of this case series is to outline the approaches in transitioning between different LTP in HAE and to consider how and why changes to the transition plan were necessary, with the aim of informing future transition guidelines. This retrospective case series describes four patients in the same family",21_17,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"series describes four patients in the same family identified at Regional University Hospital Centre (CHRU), Tours, France — a partner in the national reference center for angioedema (CREAK) network. Chronological case narratives were described by the center from medical records and experience with the patients. Only descriptive data are provided. Consent was obtained, data were anonymized, and ethics requirements were met.  This case series describes four patients from two generations in a family with HAE",21_18,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"from two generations in a family with HAE type I, caused by a single <italic toggle=""yes"">SERPING1</italic> gene mutation, who all underwent LTP transition to newer therapies. Despite having the same genotype there was variability in patient management, both in relation to the type of treatment given and the transition to new therapy. As such they each received an individualized treatment plan and ultimately three patients were prescribed berotralstat and one lanadelumab. All patients received regular",21_19,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"one lanadelumab. All patients received regular follow-up during the transition in person or by telephone. Those transitioning from AAs to a newer, targeted LTP attended more follow-up visits than the patient transitioning from lanadelumab to berotralstat. Patient 4 who transitioned from no prophylaxis to lanadelumab was stabilized easily on LTP but suffered withdrawal effects after an attempt to space out the lanadelumab doses. In the transition from AAs, a gradual, rather than abrupt, approach was",21_20,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"AAs, a gradual, rather than abrupt, approach was employed in both patients 1 and 2. Between the two approaches though, patient 2 reduced her AA dose more gradually. In both cases the real reduction was performed more gradually than first intended. A similar need to modify the transition plan has been previously demonstrated in a similar case series where it was necessary to reintroduce AAs and taper more slowly [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. Both the original plan and the final reduction",21_21,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"Both the original plan and the final reduction regimen were slower than the method previously suggested in the literature of reducing to 200 mg danazol every other day for a few weeks then every third day for a few weeks before stopping [<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. Transition approaches to berotralstat with an immediate stop of AAs in type 1 HAE have been described in the past with varying degrees of withdrawal effects and breakthrough attacks [<xref ref-type=""bibr"" rid=""CR16"">16</xref>].",21_22,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"[<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. However, current expert opinion suggests avoiding this approach owing to the potential for AEs caused by an abrupt withdrawal of AAs [<xref ref-type=""bibr"" rid=""CR18"">18</xref>, <xref ref-type=""bibr"" rid=""CR21"">21</xref>]. That said, there is no current consensus or evidence-based guidance on how best to stop AAs under these circumstances, although it is hoped that ongoing research from the Stopping Androgen Treatment in Patients with HAE – Characterization of",21_23,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"in Patients with HAE – Characterization of Reasons and Protocols and Development of Advice for Patients and Physicians (SHAERPA) project will help standardize this process [<xref ref-type=""bibr"" rid=""CR28"">28</xref>]. The individual patient’s wishes should still be taken into account together with any forthcoming guidance. When transitioning from lanadelumab to berotralstat, it is accepted practice that an immediate switch can be made owing to the overlap in the half-life of lanadelumab and the time taken",21_24,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"the half-life of lanadelumab and the time taken for berotralstat to achieve steady-state concentration [<xref ref-type=""bibr"" rid=""CR19"">19</xref>]. The case described here reinforces an immediate transition strategy. This case series demonstrates the utility of the SDM model in three main areas of HAE management: guiding LTP discontinuation; choosing alternative therapy; and managing side effects. Regarding LTP discontinuation, several patient concerns were apparent in these cases including the occurrence",21_25,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"apparent in these cases including the occurrence of attacks, concordance with the treatment plan and anxiety around dose reduction. Patients who have had effective disease control with AAs may be reluctant to change treatment and abruptly stopping AAs is sometimes anxiety-provoking [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. One concern is that if attacks occur during the transition, the patient’s confidence in the new treatment may be compromised. A patient-centered approach was taken in these cases and",21_26,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"approach was taken in these cases and their involvement in decision making was reflected by the differences in the time taken to transition between LTP therapies. For example, one patient discontinued AAs after an 11-month transition period, whereas another discontinued after 17 months and later restarted AA treatment. A previous case series by Maurer et al<italic toggle=""yes"">.</italic> has also found heterogeneity in discontinuation strategies for patients prescribed AAs [<xref ref-type=""bibr""",21_27,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"patients prescribed AAs [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. It was necessary to adapt the initial discontinuation plan in both patients prescribed AAs, one of whom felt anxious, and the reduction of AAs had to be slowed and at times even reversed. The decision to temporarily increase the dose was made by the treating physician in conjunction with the patient at a clinic appointment where this patient had reported further attacks. As such, psychological and physiological aspects surrounding",21_28,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"and physiological aspects surrounding androgen withdrawal should be accounted for in this dynamic process. Reducing AAs at an acceptable pace to the individual patient and taking an adaptive approach may help with concordance, enable the patient to overcome psychological dependence and increase the chances of them completing transition. Patient non-adherence to prescribed medication is a well-described phenomenon in those with chronic disease, and medication adherence in these patients has been estimated",21_29,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"adherence in these patients has been estimated at only 50% [<xref ref-type=""bibr"" rid=""CR29"">29</xref>]. This should be accounted for in the transition process. In this case series patients 1 and 2 were not able to adhere to the initial androgen reduction plan because of attacks. Their adherence to AA treatment prior to this was inferred to be good given that a reduction in AA dose precipitated attacks. Imperfect adherence with berotralstat may have been another explanation for these attacks. Patient 3",21_30,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"another explanation for these attacks. Patient 3 received lanadelumab as an injectable therapy administered by the nurse, hence, adherence could be monitored more easily. For this patient, no adherence issues were reported. In relation to the different LTP options available, there were two notable aspects: preferences for route of administration and the patient’s own experience. Concerns around injections were a major factor impacting treatment decisions – three of the four patients stated that they did",21_31,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"– three of the four patients stated that they did not want an injectable treatment. However, patient 4 overcame her childhood fear of self-administered injections when she was older, emphasizing that patient preferences may also change over time. One patient cited their independence and autonomy as a reason why they wished to avoid injectable therapy. The views expressed by the patients in this case series are in line with previous research showing that the majority of patients taking non-oral prophylactic",21_32,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"majority of patients taking non-oral prophylactic treatment for HAE would prefer an oral alternative and were interested in treatments that were easier to administer [<xref ref-type=""bibr"" rid=""CR30"">30</xref>, <xref ref-type=""bibr"" rid=""CR31"">31</xref>]. Over 50% of patients surveyed in previous work reported feeling tired of their injections or infusions [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. It may therefore be beneficial to discuss routes of administration with patients using the principles of",21_33,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"with patients using the principles of SDM as recommended in the WAO/EAACI guidelines [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. In the patient who changed her mind regarding injectable therapy, a SDM approach, considering decision-making as an iterative process in patients with HAE and accounting for their changing needs and attitudes towards treatment over time, was helpful [<xref ref-type=""bibr"" rid=""CR23"">23</xref>]. The patient’s previous experience is also important in decision-making. For example,",21_34,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"also important in decision-making. For example, patient 3 had seen her father taking berotralstat and wished to take this medication herself. This underscores the importance of eliciting patients’ ideas around treatment in this hereditary disorder where they may have witnessed first-hand the impact of treatment on family members. The experience of patient 2 in noticing an increase in the frequency of attacks when she temporarily stopped berotralstat led to her feeling more confident in its effectiveness.",21_35,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"her feeling more confident in its effectiveness. The experience of patients also relates to how long they have lived with HAE. For example, those who have experienced previous attacks including life-threatening attacks may be more anxious regarding a change in therapy, as was seen here. In patients who have had less experience of attacks, it may be more important to discuss the significance of these attacks with them prior to planning LTP transition. The patient demographics including the sex and age of",21_36,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"patient demographics including the sex and age of the patients should be considered in the SDM process as the AE profile of some LTPs and their potential impact on patients’ quality of life may be influenced by this. For example, AAs are linked with virilization and menstrual irregularities in women [<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. This is an important consideration in young women such as patients 3 and 4 (aged 21 and 19 years old, respectively). Adverse effects should also be considered",21_37,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"Adverse effects should also be considered preemptively in patients already taking AAs. Patients 1 and 2 had not yet experienced any long-term side effects from taking AAs. However, side effects from AAs may develop in the future and therefore a proactive approach was taken to transitioning their LTP to avoid safety issues in the future. In France, the cost of any HAE treatments is reimbursed [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. Consequently, the SDM process in this French case series hence focused",21_38,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"process in this French case series hence focused on clinical and patient factors rather than economic considerations. However, cost may be a factor to be considered as part of SDM when both treatment options are considered equal in other aspects and in other healthcare systems [<xref ref-type=""bibr"" rid=""CR17"">17</xref>, <xref ref-type=""bibr"" rid=""CR23"">23</xref>]. From the perspective of the costs to the wider healthcare system, the higher costs of newer LTP treatments are reported to be offset by",21_39,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"newer LTP treatments are reported to be offset by reducing disease burden and therefore direct and indirect costs to the healthcare system [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. Adverse effects reported by patients in this case series were consistent with data from clinical trials [<xref ref-type=""bibr"" rid=""CR15"">15</xref>, <xref ref-type=""bibr"" rid=""CR32"">32</xref>, <xref ref-type=""bibr"" rid=""CR33"">33</xref>]. One patient reported GI upset in the form of diarrhea and abdominal pain, which resolved",21_40,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"of diarrhea and abdominal pain, which resolved quickly while berotralstat treatment continued. This is similar to what was seen in the Phase II/III clinical trials, where a constellation of AEs relating to GI disturbance (abdominal pain, vomiting and diarrhea) were among the most commonly reported AEs [<xref ref-type=""bibr"" rid=""CR15"">15</xref>, <xref ref-type=""bibr"" rid=""CR32"">32</xref>, <xref ref-type=""bibr"" rid=""CR33"">33</xref>]. Therefore, it may be useful to discuss this with patients initiating",21_41,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"useful to discuss this with patients initiating berotralstat as part of the SDM process to promote concordance. Patients may have concerns related to other potential AEs from any new LTP and these too should be elicited and addressed. Novel approaches have been employed in these cases to address some of the challenges in LTP transition. Patients may require multiple follow-up appointments, and this has been aided by remote consultations, in particular telephone consultations. The benefits of consulting in",21_42,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"consultations. The benefits of consulting in this way include better use of resources and closer collaboration between patients and doctors [<xref ref-type=""bibr"" rid=""CR34"">34</xref>]. Where resources are constrained, remote consultation may allow for more regular follow-up of patients with HAE undergoing a change in LTP. It may also help to identify where there are issues with concordance. This is of particular importance in patients who have been prescribed AAs for a long time and who require close",21_43,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"AAs for a long time and who require close monitoring during the discontinuation period. Involving an advanced practice nurse (APN) is another innovative approach to managing LTP transition in HAE. The APN is an advanced nurse practitioner role in France and there was a new APN in the unit where this family were treated. The role of the APN is to bridge the gap between the traditional doctor and nurse roles [<xref ref-type=""bibr"" rid=""CR35"">35</xref>]. They have a Master’s level degree in Nursing Science",21_44,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"have a Master’s level degree in Nursing Science and can adjust or continue prescriptions, which may be useful where dose titration is needed for AAs. They can also monitor concordance with treatment and any AEs in line with WAO/EAACI guideline recommendations [<xref ref-type=""bibr"" rid=""CR10"">10</xref>]. This case series has limitations. By nature of its design, it describes a select group of patients from a single center. Therefore, generalization of the findings to the wider HAE population should be",21_45,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"findings to the wider HAE population should be taken with care. Moreover, the retrospective design of this case series needs to be considered. In summary, transitioning between LTP in HAE may be required to gain better control of HAE attacks, avoid unwanted AEs or better suit patient preferences. In particular, transitioning away from first generation LTP with AAs is an important step for each HAE patient to minimize side effects from long-term androgen exposure. There are now newer targeted LTP options",21_46,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"There are now newer targeted LTP options available, and these should be actively discussed with HAE patients to enable them to make an informed treatment decision together with their treating physician. SDM discussions should take into account patient anxieties around stopping previous treatment and AEs, preferred routes of administration, and speed of transition. Patients should be followed closely during the transition process; there may be a role for an APN to adapt the plan to avoid break-through",21_47,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"an APN to adapt the plan to avoid break-through attacks, optimize observance, reassure the patient, and monitor safety signals.",21_48,Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series,9 7 2024,,Hereditary_Angioedema
"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review Hereditary angioedema (HAE) is a rare, debilitating, life-threatening genetic disorder characterized by recurrent attacks of subcutaneous and/or submucosal angioedema [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Several forms of HAE have been defined based on gene mutations: (1) type 1 HAE identified as C1 inhibitor (C1-INH) deficiency with low levels of C1-INH; (2) type 2 HAE identified as C1-INH dysfunction with",22_0,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"type 2 HAE identified as C1-INH dysfunction with normal or slightly increased levels of C1-INH but low functional levels, both type 1 and type 2 are due to mutations of the serine protease inhibitor gene 1 (<italic toggle=""yes"">SERPING1</italic>); and (3) HAE with normal C1-INH levels (HAE-nC1-INH) including (a) mutations of FXII gene (HAE-FXII), (b) HAE with a mutation in the angiopoietin-1 gene (HAE-ANGPT1), (c) HAE with a mutation in the plasminogen gene (HAE-PLG), (d) HAE with a mutation in the",22_1,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"gene (HAE-PLG), (d) HAE with a mutation in the kininogen 1 gene (HAE-KNG1), (e) HAE with a mutation in the myoferlin gene (HAE-MYOF), and (f) HAE with a mutation in the heparan sulfate 3-O-sulfotransferase 6 gene (HAE-HS3ST6); some patients have HAE due to unknown mutations identified as HAE-UNK [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. C1-INH is an inhibitor of plasma kallikrein and factor XII that are responsible for the generation of bradykinin. An increase in the levels of bradykinin causes",22_2,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"An increase in the levels of bradykinin causes extravasation of plasma, which leads to painful swelling. In cases of larynx angioedema, it could be life-threatening to the patients [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Hereditary angioedema accounts for approximately 2% of clinical angioedema cases [<xref ref-type=""bibr"" rid=""CR3"">3</xref>]. Although the global prevalence of HAE is estimated at 1:50,000, the true prevalence of HAE remains unclear because the disease is rare [<xref ref-type=""bibr""",22_3,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"the disease is rare [<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. Furthermore, according to the epidemiologic reports, the prevalence of type 1 HAE is observed in the majority of patients (80%-85%), whereas type 2 HAE is present in 15% to 20% of patients [<xref ref-type=""bibr"" rid=""CR5"">5</xref>–<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. HAE-nC1-INH is only accounted for by a minor proportion of patients [<xref ref-type=""bibr"" rid=""CR9"">9</xref>]. An earlier study has observed no major gender or ethnic",22_4,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"study has observed no major gender or ethnic differences in the HAE type 1/2 [<xref ref-type=""bibr"" rid=""CR4"">4</xref>–<xref ref-type=""bibr"" rid=""CR7"">7</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>]. However, an analysis reported that HAE-nC1-INH is exclusive to women and postulated it to be related to X-linked dominant mode of inheritance [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Likewise, HAE-FXII and HAE-unknown were more pronounced in females with a male to female ration of 1:68 and 1:6.3,",22_5,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"with a male to female ration of 1:68 and 1:6.3, respectively [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]. The onset of HAE symptoms varies by age and can occur in children aged < 1 year, with the development of laryngeal attacks occurring usually after the age of 3 years with an increased frequency observed after puberty [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]. Patients with HAE had angioedema attacks including pain and swelling at the extremities, abdomen, genitourinary tract, face, or oropharynx",22_6,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"abdomen, genitourinary tract, face, or oropharynx and any other possible site. More often, because of the overlap of clinical symptoms between various forms of angioedema or with other systemic diseases, and the relatively rare of it, HAE remains underreported or misdiagnosed. Consequently, there is a considerable delay in the accurate diagnosis of HAE from the onset of symptoms [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. This may lead to unnecessary treatments and surgeries further delaying the timely",22_7,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"and surgeries further delaying the timely treatment of HAE, which may contribute to a substantial burden in patients with HAE. HAE attacks are usually variable as well as unpredictable and might be induced by various stimuli. The empirical triggering factors include stress, physical exertion, trauma, infection, hormonal changes, medical interventions, seasonal changes, and the use of certain medicinal products [<xref ref-type=""bibr"" rid=""CR14"">14</xref>]. On average, the frequency of attacks ranges from 1",22_8,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"average, the frequency of attacks ranges from 1 to 26 per year [<xref ref-type=""bibr"" rid=""CR10"">10</xref>, <xref ref-type=""bibr"" rid=""CR15"">15</xref>]. But in rare cases, patients have reported 100 attacks per year, which may last up to 5 days [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. The unpredictability of angioedema attacks, high risk of asphyxia, and the need for emergency intervention often result in a significant burden for patients with C1-INH-HAE[<xref ref-type=""bibr"" rid=""CR17"">17</xref>].",22_9,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"ref-type=""bibr"" rid=""CR17"">17</xref>]. Moreover, the above factors adversely affect the patients’ health-related quality of life (HRQoL) and increase the economic burden. Many efforts have been taken to quantify the epidemiologic, economic, and humanistic burden of this disease, but the poor comparability between the studies has limited the detection of common issues and real differences. To address this gap, we sought to systematically synthesize the evidence on the epidemiologic, economic, and humanistic",22_10,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"on the epidemiologic, economic, and humanistic burden associated with HAE. This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42022352377).  To the best of our knowledge, this systematic review is the first to provide a comprehensive understanding of the epidemiologic, economic, and humanistic burden of HAE. This",22_11,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"economic, and humanistic burden of HAE. This review indicates that HAE is associated with a substantial burden and will undoubtedly become more pronounced with rising awareness of the disease globally. At present, because of rarity and limited symptom specificity, HAE is indeed often misdiagnosed, leading to a significant delay (> 10 years) in correct diagnosis. Besides, a lack of awareness among health care professionals, limited availability of diagnostic tests, and incorrect treatment restrict the",22_12,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"tests, and incorrect treatment restrict the timely and optimal management of HAE [<xref ref-type=""bibr"" rid=""CR80"">80</xref>, <xref ref-type=""bibr"" rid=""CR81"">81</xref>]. As a result, it has been found that 8.6% of patients with HAE have experienced laryngeal edema, which has led to death caused by asphyxiation. These concerning statistics emphasize the critical need for early diagnosis and increased awareness of the disease. The HRQoL is the patients’ perception regarding the multidimensional impact of",22_13,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"regarding the multidimensional impact of the disease [<xref ref-type=""bibr"" rid=""CR82"">82</xref>]. Evidence from this review illustrates the negative impact of HAE on the QoL. Twenty-three studies assessed the burden of HAE on the QoL of patients; however, only 3 reported QoL of children aged 2 to 18 years with HAE highlighting a significant knowledge gap [<xref ref-type=""bibr"" rid=""CR73"">73</xref>–<xref ref-type=""bibr"" rid=""CR75"">75</xref>]. In this study, we observed that most patients were provided with",22_14,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"we observed that most patients were provided with an SF-12/SF-36 survey questionnaire or an HAE-QOL/AE-QOL questionnaire. The majority of the studies showed poorer PCS and MCS in patients with HAE relative to the control. There was a significant association of psychological implications such as anxiety and depression with HAE identified by either high score values on rating scales or during conversations with the participants [<xref ref-type=""bibr"" rid=""CR83"">83</xref>]. HAE had a significant negative",22_15,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"HAE had a significant negative impact on the QoL both during and between attacks that reflected on absenteeism at work or school [<xref ref-type=""bibr"" rid=""CR55"">55</xref>]. The World Allergy Organization guidelines about C1-INH-HAE suggest considering the HRQoL when determining maintenance treatment, and HAE experts advise to assess the HRQoL annually [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR84"">84</xref>]. Data derived from large populations are necessary to accurately",22_16,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"large populations are necessary to accurately measure the HRQoL in patients with C1-INH-HAE, its trigger factors, and the effects of therapeutic interventions. To our knowledge, only 2 studies from the US and France have estimated the economic burden associated with HAE. Although the evidence is sparse, the present review identified hospitalization cost, medication cost, and other procedural costs such as surgery, physician visits, and nursing services ($1000-$3510 among the US patients and €135 among",22_17,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"($1000-$3510 among the US patients and €135 among French patients with HAE) to be the main components of direct costs, whereas outpatient visits and other outpatient services ($189) were the minimal components of economic burden as reported in the included studies [<xref ref-type=""bibr"" rid=""CR59"">59</xref>, <xref ref-type=""bibr"" rid=""CR67"">67</xref>]. Economic assessments of HAE indicated decreased work productivity because of disease burden added to the indirect costs. The loss of income because of",22_18,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"the indirect costs. The loss of income because of reduced productivity was $5750 per patient per year as reported by Wilson et al. and lost wages for missed work because of a single attack was estimated to be ~ $525; conversely, the lost wages per annum would be ~ $3402; and the reduction in income because of absenteeism was ~ $6512 [<xref ref-type=""bibr"" rid=""CR67"">67</xref>]. These estimates indicate a considerable economic burden associated with HAE ascertaining the need to prevent functional limitation",22_19,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"the need to prevent functional limitation and improving the QoL for patients is vital in reducing absenteeism. Meanwhile, there was a huge variation in the reported data pertaining to the cost; few studies provided a detailed breakdown of direct and indirect costs, whereas other studies described only major cost categories, which limited the comparisons between studies. Finally, variability in outcome measures was observed across studies. The study heterogeneity in terms of patient characteristics and",22_20,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"in terms of patient characteristics and study setting (eg, recruitment at secondary or tertiary clinics and claims databases) across the included articles may have contributed to the wide ranges of the observed data in the results. Future studies using standardized approaches to conduct and report the burden of illness would reduce this data heterogeneity and enable better burden comparisons between studies. With the approval of new drugs for HAE globally, there is an urgent need to determine the direct",22_21,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"there is an urgent need to determine the direct medical costs incurred by patients using these drugs. The lack of comprehensive epidemiologic data on the incidence of HAE creates a knowledge gap regarding the true overall burden of HAE on society. However, there is considerable evidence indicating that delayed diagnosis of HAE is associated with decreased physical function, increased risk of mortality, negative psychological impact, and higher direct and indirect costs. This review compiles evidence",22_22,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
"and indirect costs. This review compiles evidence highlighting the need for early diagnosis, improved disease management, and increased awareness among health care professionals to mitigate the excessive burden on patients.",22_23,"Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review",8 7 2024,,Hereditary_Angioedema
Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study Full text not available in PMC,23_0,Physician- and patient-reported outcomes by hereditary angioedema type: Data from a real-world study,7 2024,,Hereditary_Angioedema
"Navigating the swells: A case report of hereditary angioedema Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of localized edema caused by a deficiency or dysfunction of C1 inhibitor (C1-INH). This case report presents the clinical features, diagnostic evaluation, and management of a 23-year-old man with HAE. We discuss the challenges of diagnosing and treating this condition, emphasizing the importance of early recognition and appropriate therapeutic",24_0,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"of early recognition and appropriate therapeutic interventions. Hereditary angioedema (HAE) is a rare, autosomal dominant genetic disorder characterized by recurrent and unpredictable episodes of localized edema in various body parts.[<xref rid=""R1"" ref-type=""bibr"">1</xref>] It is caused by a deficiency or dysfunction of C1 inhibitor (C1-INH), a regulatory protein involved in controlling the complement and coagulation systems.[<xref rid=""R2"" ref-type=""bibr"">2</xref>] The condition leads to uncontrolled",24_1,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"The condition leads to uncontrolled activation of bradykinin, resulting in increased vascular permeability and angioedema formation.[<xref rid=""R3"" ref-type=""bibr"">3</xref>] HAE affects approximately 1 in 50,000 individuals worldwide[<xref rid=""R4"" ref-type=""bibr"">4</xref>] and can manifest at any age, with onset typically occurring during childhood or adolescence.[<xref rid=""R5"" ref-type=""bibr"">5</xref>] The clinical manifestations of HAE are diverse and often overlap with other conditions, making",24_2,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"and often overlap with other conditions, making diagnosis challenging. Despite significant advancements in the understanding and management of HAE, the condition remains underdiagnosed and undertreated, leading to potential complications and decreased quality of life for affected individuals. Early diagnosis and appropriate management are crucial to mitigate the impact of HAE on patients and prevent life-threatening complications. The patient is 23-year-old man with a medical history significant for",24_3,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"man with a medical history significant for recurrent episodes of angioedema affecting various sites, including the face, hands, and abdomen. The patient reported a positive family history of similar symptoms in his mother. He first experienced episodes of angioedema at the age of 12, which initially presented as swelling of the lips and tongue following a respiratory tract infection. Over the years, the episodes increased in frequency and intensity. The patient also reported that the episodes were usually",24_4,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"also reported that the episodes were usually triggered by minor trauma, emotional stress, or infections. In the current episode, he presented to us with facial swelling predominantly lip swelling [<xref rid=""jfmpc_1254_23-f001"" ref-type=""fig"">Figure 1</xref>]. The episode was associated with nausea and diffused dull aching abdominal pain. There was no history of cough, dyspnoea, or fever. On examination during this episode, the patient displayed facial swelling, which included the lips and mild periorbital",24_5,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"which included the lips and mild periorbital region swelling [<xref rid=""jfmpc_1254_23-f001"" ref-type=""fig"">Figure 1</xref>]. The abdominal examination revealed diffuse tenderness with minimal guarding. There was no evidence of urticarial rash or erythema. Laboratory investigations revealed low levels of C1-INH (quantitative assay by the radial immunodiffusion method), that is, 173 mg/L. The diagnosis was further supported by low C4 complement levels, that is, 0.9 gm/L. Based on the clinical presentation",24_6,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"is, 0.9 gm/L. Based on the clinical presentation and laboratory findings, the patient was diagnosed with HAE type 1. He was advised for intravenous C1-INH concentrate therapy; however, due to financial restrain, the patient could not afford the therapy. So, he underwent administration of fresh frozen plasma (FFP), which contains C1-INH. FFP can be used as an acute treatment option in patients without access to specific C1-INH concentrate. However, FFP administration is associated with a risk of adverse",24_7,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"is associated with a risk of adverse reactions and may not be as effective as C1-INH concentrate. He was also given tranexamic acid, an antifibrinolytic agent, which acts by preventing the breakdown of blood clots and reducing bradykinin release. For symptomatic relief, he had an anti-histaminic, a short course of steroids, anti-emetics, and analgesics. He was counselled to identify and avoid triggers, such as trauma, stress, and infections, which could potentially precipitate angioedema attacks. He was",24_8,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"precipitate angioedema attacks. He was instructed to seek immediate medical attention during the acute attack and asked for regular follow-up appointments. Additionally, the patient’s family members were offered genetic testing and counselling to identify potential carriers of the HAE-causing mutation. HAE is a rare and potentially life-threatening disorder, making its diagnosis and management challenging. HAE can be broadly classified into three types:[<xref rid=""R6"" ref-type=""bibr"">6</xref>]",24_9,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"<list list-type=""order""><list-item><p>Type 1 HAE: Characterized by a quantitative deficiency of C1-INH protein.</p></list-item><list-item><p>Type 2 HAE: Characterized by a dysfunctional C1-INH protein.</p></list-item><list-item><p>Type 3 HAE: A less understood form associated with normal C1-INH levels, but with mutations in the coagulation factor XII gene (FXII-HAE).</p></list-item></list>",24_10,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"Clinical manifestations of HAE include recurrent episodes of angioedema affecting various sites, such as the skin, gastrointestinal tract, and upper airways.[<xref rid=""R7"" ref-type=""bibr"">7</xref>] Skin-related angioedema commonly involves the face, lips, tongue, and extremities, while gastrointestinal symptoms can lead to severe abdominal pain, nausea, and vomiting. Laryngeal edema is a potentially life-threatening complication that may lead to airway obstruction.[<xref rid=""R7""",24_11,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"may lead to airway obstruction.[<xref rid=""R7"" ref-type=""bibr"">7</xref>] HAE is a rare genetic disorder characterized by recurrent episodes of localized edema. Timely diagnosis, differentiation from other forms of angioedema, and appropriate management are essential to minimize the burden of the disease. Clinicians should be familiar with the diagnosis, available laboratory tests, and treatment options to provide optimal care for patients with HAE.",24_12,Navigating the swells: A case report of hereditary angioedema,7 2024,,Hereditary_Angioedema
"Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy Hereditary angioedema (HAE) is a rare autosomal-dominant disease that is caused by a deficiency (type I) or dysfunction (type II) of the C1 inhibitor (C1-INH) due to a mutation in the <italic toggle=""yes"">SERPING1</italic> gene, which codes for C1-INH. HAE with quantitatively and qualitatively normal C1-INH (type III) is often caused by a mutation in the <italic toggle=""yes"">F12</italic> gene and no mutations in the",25_0,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"gene and no mutations in the <italic toggle=""yes"">SERPING1</italic> gene and is a group of very rare diseases. The C1 esterase inhibitor (C1-INH) is a major regulator of critical enzymes that are implicated in the cascades of bradykinin generation, which increases vascular permeability and allows the flow of fluids into the extracellular space, resulting in angioedema. HAE clinically manifests with intermittent attacks of swelling of the subcutaneous tissue or submucosal layers of the respiratory and",25_1,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"or submucosal layers of the respiratory and gastrointestinal tract. Young children are typically asymptomatic, and those affected by HAE usually present with symptoms in their early 20s. This article describes the case of very early onset of hereditary angioedema caused by C1-INH deficiency in a 2-year-old boy who experienced recurrent episodes of hand and abdominal angioedema not associated with urticaria or pruritus. His father suffered from severe HAE due to a <italic toggle=""yes"">de novo</italic>",25_2,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"due to a <italic toggle=""yes"">de novo</italic> mutation of the <italic toggle=""yes"">SERPING1</italic> gene. The same mutation of the <italic toggle=""yes"">SERPING1</italic> gene was detected in his son at the age of 9-months prior to the occurrence of angioedema symptoms, during genetic family counseling. This paper advances the understanding of HAE and highlights the importance of genetic counseling of families with HAE to avoid late or inaccurate diagnosis and to initiate treatment on time. Hereditary",25_3,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"and to initiate treatment on time. Hereditary angioedema (HAE) is a rare autosomal-dominant disease that is caused by a deficiency or dysfunction of the C1 inhibitor (C1-INH) and affects 1/50,000 people worldwide (<xref rid=""B1"" ref-type=""bibr"">1</xref>–<xref rid=""B3"" ref-type=""bibr"">3</xref>). Three main types of HAE exist. Type I of HAE is characterized by a low level of C1-INH and type II (dysfunction of C1-INH) is caused by a mutation in the <italic toggle=""yes"">SERPING1</italic> gene that codes for",25_4,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"gene that codes for the C1 inhibitor protein. Type III (quantitatively and qualitatively normal C1-INH) is often caused by a mutation in the <italic toggle=""yes"">F12</italic> gene and no mutations in the <italic toggle=""yes"">SERPING1</italic> gene. In this rare type of HAE, clinical manifestations are similar to those of C1-INH deficiency HAE, except that there is a higher female predominance due to aggravation during pregnancy and estrogen dependency (<xref rid=""B1"" ref-type=""bibr"">1</xref>–<xref rid=""B8""",25_5,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"rid=""B1"" ref-type=""bibr"">1</xref>–<xref rid=""B8"" ref-type=""bibr"">8</xref>). Currently, more than 700 different <italic toggle=""yes"">SERPING1</italic> variants are known to be linked to HAE type I and II (<xref rid=""B9"" ref-type=""bibr"">9</xref>). The pathophysiology of HAE is described as bradykinin-mediated. The C1 esterase inhibitor (C1-INH) is a regulator of the complement and contact systems and a major regulator of critical enzymes that are implicated in the cascades of bradykinin generation; such",25_6,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"in the cascades of bradykinin generation; such regulation increases vascular permeability and allows the flow of fluids into the extracellular space, resulting in angioedema. HAE clinically manifests with intermittent attacks of swelling of the subcutaneous tissue or submucosal layers of the respiratory or gastrointestinal tract (<xref rid=""B10"" ref-type=""bibr"">10</xref>). Attacks of swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway are triggered by precipitating factors such",25_7,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"are triggered by precipitating factors such as emotional stress, trauma, hormonal influences, infections, and surgical or dental procedures (<xref rid=""B1"" ref-type=""bibr"">1</xref>–<xref rid=""B3"" ref-type=""bibr"">3</xref>). The severity and course of HAE may vary greatly even among family members harboring the same mutation (<xref rid=""B7"" ref-type=""bibr"">7</xref>, <xref rid=""B8"" ref-type=""bibr"">8</xref>). The gene defect is already present at birth, but symptoms are uncommon in neonates and infants.",25_8,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"symptoms are uncommon in neonates and infants. Angioedema attacks can first occur at any age, but usually young children are asymptomatic, and those affected by HAE usually present with symptoms in their early 20s (<xref rid=""B3"" ref-type=""bibr"">3</xref>). In this study, we present the case of very early onset of hereditary angioedema caused by C1-INH deficiency in a 2-year-old boy who experienced recurrent episodes of angioedema of the extremities and face without urticaria and pruritus and an abdominal",25_9,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"without urticaria and pruritus and an abdominal angioedema attack and also had a family history of HAE. A 2-year-old boy started experiencing attacks of painful swelling in his face and upper extremities, which were triggered by a minor trauma and not associated with urticaria or pruritus. He was born normally from the first pregnancy and weighed 3,405 g at birth. The first episode of bilateral hand angioedema after the boy started playing with toys occurred at the age of 23 months and lasted 4 days (<xref",25_10,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"at the age of 23 months and lasted 4 days (<xref rid=""F1"" ref-type=""fig"">Figures 1</xref>, <xref rid=""F2"" ref-type=""fig"">2</xref>). The boy was immediately consulted by an allergologist-clinical immunologist and the serum complement component C4 and C1 inhibitor were evaluated, which revealed reduced levels of the following: C4 was 0.07 g/L (normal: 0.16–0.38), the C1 inhibitor was 0.05 g/L (normal: 0.15–0.35), and C3 in serum was 0.78 g/L (normal: 0.79–1.52) (<xref rid=""T1""",25_11,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"was 0.78 g/L (normal: 0.79–1.52) (<xref rid=""T1"" ref-type=""table"">Table 1</xref>). As the patient's father was suffering from HAE type I due to C1-INH deficiency and the same mutation of the <italic toggle=""yes"">SERPING1</italic> gene was detected in his son at the age of 9 months during genetic family counseling 1 year ago, the diagnosis of HAE type 1 due to C1-INH deficiency was established for this 2-year-old boy. HAE type I was diagnosed for the patient's father at the age of 23 years following",25_12,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"patient's father at the age of 23 years following recurrent peripheral and abdominal angioedema attacks with reduced C4 and C1-INH in serum. This diagnosis was made when he was consulted by an allergologist-clinical immunologist at the tertiary university hospital, and replacement therapy with C1-INH was initiated. For the father, it took 8 years from the onset of angioedema to confirm the diagnosis of HAE, before he was misdiagnosed as having systemic lupus, Crohn's disease, and appendicitis. Six years",25_13,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"Crohn's disease, and appendicitis. Six years later when genetic testing was established in Lithuania, <italic toggle=""yes"">de novo SERPING1</italic> gene mutation was detected, and all of the boy’s family members, except his father who died at the age of 63 years from heart attack, were tested. The boy’s mother and sister had no mutations, but the same <italic toggle=""yes"">SERPING1</italic> gene heterozygous mutation (c.[473C>G]; [473=], p. [(Ser158Ter)]; [(Ser158=]) was detected in the boy, who was a",25_14,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"[(Ser158=]) was detected in the boy, who was a 9-month-old asymptomatic child. At the time, this child was healthy with only a slightly reduced C1-INH level in serum (0.12 g/L, normal: 0.15–0.35 g/L). At the age of 2 years, the boy started experiencing angioedema attacks and treatment with plasma-derived C1 esterase inhibitor concentrate 500 IU (30 IU/kg) was initiated. At the follow-up of 2 years, it was found that the patient had experienced peripheral angioedema attacks only two times, but he had a",25_15,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"angioedema attacks only two times, but he had a history of one abdominal pain attack with vomiting that started 2 weeks after a common cold episode. In the emergency room, the abdominal ultrasound revealed terminal ileum wall thickness and a small amount of fluid in the pelvis and around the terminal ileum. Plasma-derived C1 esterase inhibitor concentrate 500 IU (30 IU/kg) was given intravenously for the angioedema attacks, following which symptoms resolved within 30 min. The patient was asked to continue",25_16,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"within 30 min. The patient was asked to continue the C1 inhibitor on-demand treatment. We present the case of very early onset of hereditary angioedema caused by C1-INH deficiency in a 2-year-old boy who experienced recurrent episodes of angioedema of the extremities and face without urticaria and pruritus and later an abdominal angioedema attack and also had a family history of HAE I. Our case is similar to the ones described in the literature, which shows that most attacks, and most first attacks, in",25_17,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"that most attacks, and most first attacks, in children manifest with angioedema of the skin, and the earlier the onset of symptoms, the more severe the subsequent course of HAE I/II (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B2"" ref-type=""bibr"">2</xref>). For C1-INH-HAE, the autosomal-dominant mode of inheritance has been described as that which occurs when one of the two alleles of the C1-INH gene (<italic toggle=""yes"">SERPING1</italic>) that encodes C1-INH is mutated. Mutations in <italic",25_18,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"encodes C1-INH is mutated. Mutations in <italic toggle=""yes"">SERPING1</italic> are responsible for the majority of cases of hereditary angioedema type I and II (<xref rid=""B6"" ref-type=""bibr"">6</xref>–<xref rid=""B9"" ref-type=""bibr"">9</xref>). The genotyping of subjects suffering from HAE has become diagnostically indispensable in clinical practice (<xref rid=""B11"" ref-type=""bibr"">11</xref>). In our presented case, the same <italic toggle=""yes"">SERPING1</italic> gene heterozygous mutation of one amino acid",25_19,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"gene heterozygous mutation of one amino acid was confirmed for both the patient and his father, who had <italic toggle=""yes"">de novo SERPING1</italic> gene mutation. In the literature, it has been shown that only patients carrying missense mutations leading to a change in a single amino acid exhibited a less severe clinical phenotype; however, in our study, the boy started experiencing HAE symptoms at a relatively early age of 2 years when compared with his father, who had these symptoms when he was 15",25_20,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"his father, who had these symptoms when he was 15 years old. It is probable that there is no correlation between the same type of mutations and clinical phenotype. The involvement of epigenetic changes and environmental factors (i.e., temperature, pH, and oxidative stress) in the pathogenesis of HAE can also be postulated (<xref rid=""B6"" ref-type=""bibr"">6</xref>–<xref rid=""B8"" ref-type=""bibr"">8</xref>). The detection of <italic toggle=""yes"">SERPING1</italic> mutation in a 9-month-old asymptomatic boy makes",25_21,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"mutation in a 9-month-old asymptomatic boy makes a strong argument for an early and timely diagnosis of HAE before peripheral angioedema attacks start at the age of 23 months, excluding other diseases and allergic angioedema. Apart from delayed diagnosis, misdiagnosis leads to inappropriate treatment, and by the time patients realize that they are misdiagnosed and want to make amends, it becomes too late, resulting in the denial of timely, , effective, and lifesaving treatment for them. However, in the",25_22,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"lifesaving treatment for them. However, in the presented case, early detection of <italic toggle=""yes"">SERPING1</italic> gene mutation and a family history of HAE prevented misdiagnosis and shortened the time to HAE diagnosis. From a large database of patients, HAE patients with family members diagnosed as having C1-INH-HAE were significantly less likely to be misdiagnosed than patients without a family history. Approximately 50% of patients with C1-INH-HAE type I or II have previously had their conditions",25_23,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"type I or II have previously had their conditions misdiagnosed, most commonly as allergic angioedema or appendicitis (as was the case of our patient's father, when the HAE diagnosis was delayed for 8 years) (<xref rid=""B12"" ref-type=""bibr"">12</xref>–<xref rid=""B14"" ref-type=""bibr"">14</xref>). Therefore, we highly recommend that genetic family counseling be made standard care for patients affected by HAE. Early diagnosis and appropriate treatment are essential for improving the lives of patients with this",25_24,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"for improving the lives of patients with this life-threatening disorder and disabling disease. HAE attacks of the upper airways can result in asphyxiation, abdominal attacks are painful and debilitating, and peripheral attacks of the hand and feet result in impaired function (<xref rid=""B1"" ref-type=""bibr"">1</xref>). The ultimate goals of treatment in HAE are to achieve total control of the occurrence of symptoms, which will reduce the frequency and severity of attacks, and to normalize patient lives",25_25,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"of attacks, and to normalize patient lives (<xref rid=""B12"" ref-type=""bibr"">12</xref>). During the course of the Icatibant Outcome Survey (international, prospective, and observational registry collecting demographics and clinical outcomes in patients with HAE type I/II angioedema), triggers were identified in 56.0% of angioedema attacks, with the most common triggers being emotional distress, physical trauma, and infection (<xref rid=""B13"" ref-type=""bibr"">13</xref>). In the presented case, the 2-year-old",25_26,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"In the presented case, the 2-year-old boy experienced HAE attacks and these were associated with minor hand trauma while playing with toys and infection in case of abdominal attacks. During the course of the above-mentioned survey, the most commonly reported prodromal symptoms associated with attacks were erythema marginatum (13.2%), nausea (9.3%), irritability (7.3%), and change in estrogen levels in women (7.1%) (<xref rid=""B12"" ref-type=""bibr"">12</xref>). Probably because of the boy’s young age,",25_27,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"Probably because of the boy’s young age, prodromal symptoms were not observed in him. Disease management for patients with HAE is currently achieved through the use of on-demand medications and short- and long-term prophylaxis. HAE attacks should be treated as early as possible and prophylaxis should be considered before known triggering events to reduce morbidity and mortality (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B2"" ref-type=""bibr"">2</xref>). Acute treatment options include C1-INH",25_28,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"Acute treatment options include C1-INH replacement therapy [plasma-derived or recombinant human C1-INH (rhC1-INH) via intravenous administration], the kallikrein inhibitor ecallantide (subcutaneous administration, not approved for use in the EU including Lithuania, but approved in the United States), and the bradykinin B2 receptor antagonist icatibant (subcutaneous administration, not available in Lithuania). Short-term prophylaxis may be indicated before known triggers of swelling such as surgical or",25_29,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"known triggers of swelling such as surgical or dental procedures. The available options include intravenous plasma-derived C1-INH (pdC1-INH), fresh frozen plasma, and attenuated androgens (e.g., danazol, oxandrolone). For long-term prophylaxis, there are options to include C1-INH (via intravenous or subcutaneous administration); subcutaneous lanadelumab, the fully human monoclonal antibody (mAb) against plasma kallikrein; attenuated androgens; and antifibrinolytics (tranexamic acid) (<xref rid=""B1""",25_30,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"(tranexamic acid) (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B2"" ref-type=""bibr"">2</xref>, <xref rid=""B5"" ref-type=""bibr"">5</xref>, <xref rid=""B14"" ref-type=""bibr"">14</xref>, <xref rid=""B15"" ref-type=""bibr"">15</xref>). For children under the age of 12 years, the updated Lithuanian and international guidelines, including the World Allergy Organization (WAO)/European Academy of Allergy and Clinical Immunology (EAACI), recommend intravenous plasma-derived C1-INH and icatibant. Both are effective,",25_31,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"C1-INH and icatibant. Both are effective, well tolerated, and show a good safety profile (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B16"" ref-type=""bibr"">16</xref>). The intravenous plasma-derived C1-INH concentrate given for the child in our study when he suffered acute angioedema attacks was the treatment of choice according to the guidelines, availability, and the fact of it being the only reimbursement option in Lithuania (<xref rid=""B16"" ref-type=""bibr"">16</xref>). For abdominal attacks,",25_32,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"For abdominal attacks, parenteral fluid replacement may be required as children are more susceptible to hypovolemia and dehydration, and extravasation into the peritoneal cavity and intestinal lumen can be substantial (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B14"" ref-type=""bibr"">14</xref>, <xref rid=""B15"" ref-type=""bibr"">15</xref>). Our presented case is an original case report and strongly suggests that hereditary angioedema caused by C1-INH deficiency can occur very early in life. Early",25_33,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"deficiency can occur very early in life. Early diagnosis and appropriate treatment are essential to improve the lives of patients with this disabling disease. As this disease is inherited in an autosomal-dominant way, the importance of genetic counseling of families with HAE is highly recommended to avoid late or inaccurate diagnosis of HAE and to initiate timely treatment to the affected members.",25_34,Case Report: Early presentation of hereditary angioedema symptoms in a 2-year-old boy,24 6 2024,,Hereditary_Angioedema
"An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema Hereditary angioedema (HAE) is a rare, debilitating, and potentially life-threatening autosomal dominant disease [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. The majority of patients with HAE have either a deficiency in C1-esterase inhibitor (type I) or dysfunctional C1-esterase inhibitor (type II), resulting in",26_0,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"C1-esterase inhibitor (type II), resulting in dysregulation of the kallikrein–kinin pathway and overproduction of bradykinin, which leads to unpredictable episodes of increased vascular permeability, extravasation, and subsequent angioedema attacks [<xref ref-type=""bibr"" rid=""CR2"">2</xref>–<xref ref-type=""bibr"" rid=""CR4"">4</xref>]. These intermittent attacks involve cutaneous and mucosal swellings that may affect the extremities, face, larynx, gastrointestinal tract, or genitourinary area [<xref",26_1,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"tract, or genitourinary area [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. Abdominal symptoms including pain, nausea, diarrhea, and vomiting occur frequently [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Laryngeal swelling occurs infrequently but makes asphyxiation an omnipresent risk for patients with HAE [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>]. The disease burden extends beyond the frequency and severity of attacks, as a result of interference with activities of",26_2,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"as a result of interference with activities of daily living, emotional disturbance, and the need for lifestyle modification. Physical functioning may be limited during attacks, restricting participation in work and social activities [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Anxiety and depression are common between attacks, due to fear of the next attack and uncertainty regarding the severity of future attacks [<xref ref-type=""bibr"" rid=""CR8"">8</xref>]. Thus, HAE interferes with health-related quality of",26_3,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"HAE interferes with health-related quality of life (HRQoL) both during and between attacks [<xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Several recent publications have noted the overall disease burden and adverse effects on quality of life associated with HAE and the unmet need for more effective treatment [<xref ref-type=""bibr"" rid=""CR9"">9</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>]. According to international (World Allergy Organization/European Academy of Allergy and Clinical Immunology)",26_4,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"Academy of Allergy and Clinical Immunology) guidelines, the goals of treatment of HAE include achieving complete control of the disease, which for patients means absence of all attacks and normalization of quality of life; the guidelines stipulate that this can only be realized with long-term prophylaxis (LTP) [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Hence, LTP is a critical part of pharmacological care for patients with HAE [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr""",26_5,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Treatment guidelines from the US Hereditary Angioedema Association (HAEA) advisory board also recognize that further advancements with novel long-term prophylactic treatment options for HAE (namely C1-esterase inhibitor SC [human], lanadelumab, and berotralstat) have led to a shift in the paradigm of care, with the ability to achieve the realistic treatment targets of reducing the frequency and severity of attacks [<xref ref-type=""bibr""",26_6,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"and severity of attacks [<xref ref-type=""bibr"" rid=""CR2"">2</xref>]. C1-esterase inhibitor SC (human), a plasma-derived concentrate of C1-esterase inhibitor (human) for subcutaneous administration twice weekly [<xref ref-type=""bibr"" rid=""CR12"">12</xref>]; lanadelumab, a human monoclonal antibody inhibitor of plasma kallikrein administered subcutaneously once every 2 or 4 weeks [<xref ref-type=""bibr"" rid=""CR13"">13</xref>]; and berotralstat, an oral plasma kallikrein inhibitor administered once daily [<xref",26_7,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"inhibitor administered once daily [<xref ref-type=""bibr"" rid=""CR14"">14</xref>], are currently recommended as first-line LTP in the international guidelines [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. All three agents provide protection from HAE attacks versus placebo in randomized controlled trials, with sustained long-term prophylactic effects [<xref ref-type=""bibr"" rid=""CR13"">13</xref>, <xref ref-type=""bibr"" rid=""CR15"">15</xref>–<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. By comparison, LTP available",26_8,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"By comparison, LTP available prior to the introduction of these agents mainly consisted of attenuated androgens and intravenous C1 inhibitor concentrate administered twice weekly. Although androgens do prevent HAE attacks, they are commonly associated with side effects including virilization, menstrual disorders, and amenorrhea in women, as well as weight gain, headaches, myalgia, depression, and drug interactions [<xref ref-type=""bibr"" rid=""CR11"">11</xref>, <xref ref-type=""bibr"" rid=""CR18"">18</xref>].",26_9,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. Treatment with intravenous C1 inhibitor concentrate was burdensome and often led to vein fatigue [<xref ref-type=""bibr"" rid=""CR19"">19</xref>]. Patients with HAE not taking LTP have typically relied on on-demand therapy when an HAE attack occurs [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. In Phase 3 clinical studies of these novel agents, the reported reduction in HAE attacks and the proportion of HAE patients who were",26_10,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"and the proportion of HAE patients who were attack free were different for different agents, which might be due to differences in study designs, patient populations, and durations of follow-up. There was a 95.1% median reduction in HAE attacks compared with placebo over 16 weeks in the Phase 3 study for C1-esterase inhibitor SC (human) based on the recommended dose of 60 IU, with 40% attack free during this time [<xref ref-type=""bibr"" rid=""CR16"">16</xref>]. In the 26-week pivotal Phase 3 lanadelumab study,",26_11,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"In the 26-week pivotal Phase 3 lanadelumab study, the mean reductions in HAE attacks were 87% or 73% compared with placebo for the recommended 300 mg dose given every 2 or 4 weeks, respectively. Approximately 44% or 31% of patients on the 300 mg dose given every 2 or 4 weeks, respectively, were attack free during the 26-week treatment period, compared with 2.4% of placebo-treated patients [<xref ref-type=""bibr"" rid=""CR20"">20</xref>]. For berotralstat, in the pivotal Phase 3 study at the recommended dose of",26_12,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"pivotal Phase 3 study at the recommended dose of 150 mg daily, the mean reduction in HAE attacks compared with placebo was 44.2% over 24 weeks [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. The proportions of patients attack free over the 24-week treatment period were no different in the berotralstat- and placebo-treated groups [<xref ref-type=""bibr"" rid=""CR17"">17</xref>]. A recent real-world study found that use of novel LTP was associated with a 77% reduction in the number of attacks each year compared",26_13,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"in the number of attacks each year compared with those who used only on-demand treatment [<xref ref-type=""bibr"" rid=""CR1"">1</xref>]. Older agents such as attenuated androgens and antifibrinolytic agents are recommended as second-line LTP, for use only when first-line medications are not available. With the availability of novel LTP with greater efficacy and fewer adverse effects compared with androgen therapy, guidelines are focused on reducing the burden of illness due to HAE, which can be achieved by",26_14,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"of illness due to HAE, which can be achieved by further reducing the frequency of HAE attacks and enabling patients with HAE to experience the same HRQoL as people without this condition [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. Several disease-specific and generic patient-reported outcome tools are available to evaluate HRQoL for HAE. The Angioedema Quality of Life Questionnaire (AE-QoL) [<xref ref-type=""bibr"" rid=""CR21"">21</xref>, <xref ref-type=""bibr""",26_15,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"rid=""CR21"">21</xref>, <xref ref-type=""bibr"" rid=""CR22"">22</xref>] was the disease-specific patient-reported outcome measure included in the development programs for all three novel LTP therapies [<xref ref-type=""bibr"" rid=""CR8"">8</xref>, <xref ref-type=""bibr"" rid=""CR23"">23</xref>–<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. Although not specific for HAE, it has been validated as a reliable instrument for measuring HRQoL in adult patients with HAE [<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. Reductions in",26_16,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"rid=""CR26"">26</xref>]. Reductions in HAE attacks mean that patients may be attack free for more time, which has the potential to improve their HRQoL. A survey of 737 patients with HAE who were members of the US HAEA, conducted by Castaldo et al. [<xref ref-type=""bibr"" rid=""CR1"">1</xref>], showed that median AE-QoL scores for those who had been attack free for 3 months were better than for those who were attack free for only 1 month before completing the AE-QoL. Those on any LTP experienced better QoL than",26_17,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"Those on any LTP experienced better QoL than those using only on-demand treatment. In the clinical development programs for the novel prophylactic agents, the relationship between AE-QoL scores and time attack free was not reported in any of the studies apart for an open-label extension study for lanadelumab [<xref ref-type=""bibr"" rid=""CR20"">20</xref>], which showed that most of the improvements in AE-QoL scores were observed during the early follow-up period (day 0 to day 56) and then reached a plateau;",26_18,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"(day 0 to day 56) and then reached a plateau; the scores were maintained during subsequent visits. Here, we sought to further build on the earlier research of Castaldo et al. [<xref ref-type=""bibr"" rid=""CR1"">1</xref>] and evaluate the real-world benefits of LTP over a longer time period. Jean-Baptiste et al. have recently evaluated the symptom experience of HAE patients and concluded that more research is needed on the effect of longer attack-free durations on HRQoL [<xref ref-type=""bibr""",26_19,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"durations on HRQoL [<xref ref-type=""bibr"" rid=""CR27"">27</xref>]. Using data drawn from a wide-ranging survey of members of the US HAEA and Hereditary Angioedema International (HAEi), we examined the relationship between duration of time attack free, and HRQoL, exploring the possibility that there is an association between observed improvement in HRQoL and attack-free duration.   This study reports the results from an international survey of patients with HAE who are currently on LTP and are members of the",26_20,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"who are currently on LTP and are members of the HAEA or the HAEi, conducted in the US, Australia, Germany, Canada, the UK, and Japan. The survey included the AE-QoL as well as 52 questions related to HAE medical history and the impact of HAE on participants’ HRQoL before and after receiving LTP. The analysis reported here was designed to assess the importance of longer attack-free time at the time of the survey through its relationship to better reported HRQoL. In recent years, several published studies",26_21,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"HRQoL. In recent years, several published studies have shown reductions in HAE attacks with the use of novel prophylactic regimens [<xref ref-type=""bibr"" rid=""CR16"">16</xref>, <xref ref-type=""bibr"" rid=""CR17"">17</xref>, <xref ref-type=""bibr"" rid=""CR20"">20</xref>, <xref ref-type=""bibr"" rid=""CR29"">29</xref>], allowing patients with HAE to be attack free longer. Despite this, only one study has examined the relationship between attack-free time and HRQoL. Castaldo et al. [<xref ref-type=""bibr""",26_22,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"and HRQoL. Castaldo et al. [<xref ref-type=""bibr"" rid=""CR1"">1</xref>] reported that, for those receiving any LTP, the median AE-QoL total score was 25.7 for those who had been attack free for 1 month before completing the AE-QoL compared with 20.6 for those attack free for 3 months. The results reported here extend that research by including patients who reported being attack free for longer periods of time and examining the association of attack-free duration with AE-QoL scores and several HAE status",26_23,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"with AE-QoL scores and several HAE status factors (including attack frequency and severity, psychological status, and everyday activities). The association between being attack free and the number of doses of rescue medication used is also reported. The benefits of a longer attack-free duration include less anxiety/fear of having an attack, fewer psychological problems, fewer days missed from school or work, and fewer limitations on social and/or physical activity. The mean AE-QoL scores improved from 51.8",26_24,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"The mean AE-QoL scores improved from 51.8 in those attack free for < 1 month to 19.9 in those attack-free for ≥ 6 months. These benefits of LTP for HRQoL are consistent with the goals of therapy reported by the survey participants, which include lower attack frequency and severity, fewer of the most troublesome attack symptoms, and fewer psychological problems associated with HAE. These findings are consistent with a recent real-world study showing that LTP with a novel agent contributes to the goal of",26_25,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"LTP with a novel agent contributes to the goal of normalizing patients’ lives by reducing the frequency and severity of attacks and improving quality of life [<xref ref-type=""bibr"" rid=""CR30"">30</xref>]. Both US and international guidelines emphasize that the introduction of novel LTP has resulted in a paradigm shift, due to their greater efficacy in reducing HAE attacks, better tolerability, and beneficial effect on quality of life compared with earlier therapies [<xref ref-type=""bibr"" rid=""CR2"">2</xref>,",26_26,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"[<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR11"">11</xref>]. The ANCOVA models showed a correlation between the use of novel LTP and better AE-QoL score but the strength of association was reduced after controlling for attack-free duration, indicating that the longer attack-free time associated with the use of novel LTP had an influential role for the better AE-QoL total scores. Increasing the attack-free period is an important goal of therapy and can be achieved with currently",26_27,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"of therapy and can be achieved with currently available first-line LTP with novel agents. However, findings from this survey highlight that opportunities still exist to improve the treatment impact on attack free duration and HRQoL if new therapies are approved that allow more people to be attack free for longer time periods. Recent publications also emphasize the enduring disease burden and adverse impact of HAE on quality of life despite the availability of novel LTP [<xref ref-type=""bibr""",26_28,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"availability of novel LTP [<xref ref-type=""bibr"" rid=""CR31"">31</xref>, <xref ref-type=""bibr"" rid=""CR32"">32</xref>]. Less use of rescue medication was also associated with longer attack-free durations: all those attack free for ≥ 6 months reported using no more than one dose per month, compared with only 48% of those attack free for < 1 month; conversely, 12% of those attack free for < 1 month used more than five doses/month. Several additional aspects of the survey results deserve further discussion,",26_29,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"of the survey results deserve further discussion, including some apparent inconsistencies. It should be acknowledged that the responses reflect patients’ experience and perception. Prior to starting LTP, 65% reported that their HAE was not at all controlled, while 74% indicated that their attacks were mostly severe, and 84% were always or often anxious about the next attack. These potential contradictions might be attributable to the way the survey questions were phrased and the respondents’ understanding",26_30,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"were phrased and the respondents’ understanding of control. Other possible response options to the question “How well controlled would you say your HAE was prior to taking any LTP” were “a little,” “somewhat,” “well,” and “very well,” so the remaining 35% believed their HAE was at least partially controlled. Only 69% of patients reported using rescue medication prior to starting LTP, which may have had an adverse effect on their quality of life. Somewhat surprisingly, only 41% of all respondents stated",26_31,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"surprisingly, only 41% of all respondents stated that they experienced fewer psychological problems after starting LTP, although this was higher at 56% in those who had been attack free for ≥ 6 months. Nevertheless, the proportion feeling less anxious was higher and is likely to continue to be better with longer treatment, as indicated by 84% reporting that they would have less anxiety about having an attack the longer they remained attack free. It may also reflect the impact of adverse effects in those on",26_32,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"reflect the impact of adverse effects in those on older, non-novel LTP. Interestingly, only 54% of respondents reported less hospitalization due to HAE attacks since starting LTP (49% in those attack free for ≥ 6 months), even though 85% reported lower attack frequency. This may seem lower than expected but given that a significant proportion of patients may not have had any hospitalization prior to starting LTP, these patients would not have been able to report a reduction in it. Similarly, despite",26_33,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"to report a reduction in it. Similarly, despite reporting lower attack frequency and severity, only 43% indicated that they used less rescue medication (62% in those attack free for ≥ 6 months). It should be noted that guidelines state that it is essential that patients have on-demand (rescue) medication available to treat all attacks as early as possible [<xref ref-type=""bibr"" rid=""CR11"">11</xref>]. This study has certain weaknesses and limitations. The diagnosis of HAE was self-reported and was not",26_34,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"diagnosis of HAE was self-reported and was not verified. Respondents were asked about their use of medication, but it is possible that not all drugs potentially used for LTP were available in every country at the time of the survey. There is the potential for recall bias when asking survey participants about the impact of HAE many years ago, before starting prophylactic therapy, which may limit our ability to accurately interpret the experiences of the survey participants before and after starting LTP. As",26_35,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"participants before and after starting LTP. As this is an observational study in a real-world setting, the analyses may not have accounted for all the differences between groups. This could have introduced bias, especially if other factors without control in the model were associated with such differences. Despite these limitations, the study adds important new information on the broader role of LTP beyond the physical effect of reducing attack frequency and severity. It describes the benefit of being",26_36,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"and severity. It describes the benefit of being attack free for specific time periods with respect to the amount of rescue medication used. Longer reported attack-free time at the time of the survey is associated with better AE-QoL total scores and other quality of life benefits, as well as fewer doses of rescue medication used. Most importantly, this study shows that the association of LTP with better HRQoL is substantially influenced by longer attack-free time, thereby supporting the importance of having",26_37,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"time, thereby supporting the importance of having treatments available that may enable patients to have an extended time free of attacks.",26_38,An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema,22 6 2024,,Hereditary_Angioedema
"Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia Hereditary angioedema due to deficiency (type 1) or defective function (type 2) of C1 inhibitor protein is caused by loss of function mutations in the SERPING1 gene which may be autosomal dominantly inherited or occur through de-novo gene mutation.<xref rid=""bib1"" ref-type=""bibr""><sup>1</sup></xref> Although the precise mechanism is unknown, haploinsufficiency of SERPING1 results in C1 inhibitor functional deficiency, with",27_0,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"in C1 inhibitor functional deficiency, with resultant dysregulated activation of factor XII and prekallikrein leading to excessive generation of bradykinin, which mediates vasodilatation and vasopermeability. Clinically HAE manifests as recurrent episodes of localised angioedema of cutaneous and mucosal regions, resulting in swelling episodes (“attacks”) which may be debilitating, painful and life-threatening if involving the airway. HAE prevalence has been investigated in several studies with population",27_1,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"investigated in several studies with population frequency reported between 1 in 30,000 to 1 in 92,000,<xref rid=""bib2"" ref-type=""bibr"">2</xref>, <xref rid=""bib3"" ref-type=""bibr"">3</xref>, <xref rid=""bib4"" ref-type=""bibr"">4</xref>, <xref rid=""bib5"" ref-type=""bibr"">5</xref> varying by region and by study methodology. Estimates for de-novo mutational rate of 1 in 72,000,<xref rid=""bib2"" ref-type=""bibr""><sup>2</sup></xref> suggest that this may be a lower limit of disease prevalence. However, in Australia",27_2,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"of disease prevalence. However, in Australia there have been no systematic studies assessing local prevalence of the condition. Furthermore, patient disease burden vs. disease control in the context of recent newly available therapeutic options has not been reported. In this study we aimed to ascertain the prevalence of HAE in South Australia, a state with a population of 1.8 million, and undertake a survey of genealogy, HAE disease activity, quality of life, therapeutic experiences, and unmet needs in the",27_3,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"therapeutic experiences, and unmet needs in the cohort. This study was approved by the Central Adelaide Local Health Network Human Research and Ethics committee (Ref. 14221). The study was designed in 2 phases. Firstly, a multipronged ascertainment of all children and adults with HAE in South Australia, with recording of basic demographic parameters and current prophylactic therapy where possible from hospital and pharmacy records. Secondly, administration of a comprehensive multi-dimensional questionnaire",27_4,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"a comprehensive multi-dimensional questionnaire to all consenting adults with review of clinical records for further information.  In this paper we report the first study of HAE prevalence in Australia. We attempted to identify all individuals with HAE through a variety of ascertainment methods and whilst there may be other cases missed, our figure represents a minimum and probably close to accurate prevalence figure, and is in line with international reports. In our cohort 4 individuals identified",27_5,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"reports. In our cohort 4 individuals identified as aboriginal or Torrens strait islander (ATSI), providing a population prevalence which is three times higher than in the non-indigenous. This represents the first report of HAE prevalence in ATSI peoples, where founder effects<xref rid=""bib12"" ref-type=""bibr""><sup>12</sup></xref> and poor access to genetic services<xref rid=""bib13"" ref-type=""bibr""><sup>13</sup></xref> may result in higher incidence and diagnostic delay. Therefore, in patients of indigenous",27_6,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"delay. Therefore, in patients of indigenous heritage presenting with angioedema, HAE should be considered. Historically, HAE sufferers incurred a high burden of disease, with high levels of depression, anxiety and absenteeism.<xref rid=""bib14"" ref-type=""bibr"">14</xref>, <xref rid=""bib15"" ref-type=""bibr"">15</xref>, <xref rid=""bib16"" ref-type=""bibr"">16</xref>, <xref rid=""bib17"" ref-type=""bibr"">17</xref> The unpredictable nature of attack occurrence as well as frequency and severity of attacks have been",27_7,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"as frequency and severity of attacks have been identified as a key factors causing impaired quality of life.<xref rid=""bib18"" ref-type=""bibr""><sup>18</sup></xref> Past therapies for HAE included the androgen danazol, the plasminogen antagonist tranexamic acid (TXA), and fresh frozen plasma (FFP). Danazol can be highly efficacious for some patients but may not be tolerated due to side effects and carries long-term risks;<xref rid=""bib19"" ref-type=""bibr""><sup>19</sup></xref> hence, it has fallen out of",27_8,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"hence, it has fallen out of favour and is not used at all in many countries. In our cohort, low-dose danazol was associated with high participant satisfaction in some males and post-menopausal females, with limited perceived androgenic adverse effects, and as an oral route medicine, is consistent with known therapeutic preferences in HAE patients.<xref rid=""bib20"" ref-type=""bibr""><sup>20</sup></xref> This is, of course, a result of selection since those who required a higher dose to achieve control, or who",27_9,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"required a higher dose to achieve control, or who did not tolerate the drug, would have been transferred to a different therapy. Thus, our study reiterates that danazol may be an option in certain patients, and that there remains a need for simple, accessible, oral prophylaxis options, with good risk profiles. Over the past 2 decades numerous effective and targeted therapies for HAE have emerged including regular prophylactic intravenous or subcutaneous donor derived or recombinant C1 INH, inhibitors of",27_10,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"derived or recombinant C1 INH, inhibitors of kallikrein (berotralstat, lanadelumab, and ecallantide) and the bradykinin receptor antagonist icatibant. Appropriate usage of highly effective therapies, where available, may now facilitate near normal quality of life with potential for prevention of most or all attacks and access to effective acute therapies in case of breakthrough. In Australia, access to government-funded expensive prophylactic agents such as C1 INH and lanadelumab has been restricted to",27_11,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"as C1 INH and lanadelumab has been restricted to patients meeting threshold attack frequency criteria. Despite availability of newer therapies, danazol remained the most frequently prescribed HAE prophylaxis in our cohort, with recipients having high therapeutic satisfaction and low disease activity. Notably, however, danazol access in Australia was restricted by discontinuation of supply immediately prior to commencement of this study,<xref rid=""bib21"" ref-type=""bibr""><sup>21</sup></xref> which likely",27_12,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"ref-type=""bibr""><sup>21</sup></xref> which likely contributed to the relatively disproportionate increase in treatment difficulties as judged by the HAE-QOL domain (<xref rid=""fig3"" ref-type=""fig"">Fig. 3</xref>E), although availability was re-established by special access programs. Australian guidelines mandate regular monitoring of patients on danazol for adverse effects.<xref rid=""bib22"" ref-type=""bibr""><sup>22</sup></xref> On the contrary, other oral therapies like tranexamic acid and berotralstat",27_13,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"therapies like tranexamic acid and berotralstat (available through a clinical trial with open label extension) in our cohort were generally considered ineffective and unsatisfactory, in patients with high disease activity (as required for involvement in the trial). Lanadelumab, which became available for poorly controlled HAE in Australia immediately prior to the study period (December 2021), showed a rapid adoption, largely in subjects on C1 Inhibitor concentrates (C1-INH) or with poor disease control,",27_14,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"(C1-INH) or with poor disease control, aligning with expectations. For women, danazol's frequent virilising effects compound on other adverse effects such as hepatic adenomas, rarely carcinomas and liver function abnormalities, headaches and psychological disturbances.<xref rid=""bib19"" ref-type=""bibr""><sup>19</sup></xref> Additionally, estrogens are known to contribute to disease activity by increasing activity of bradykinin and fibrinolytic pathways,<xref rid=""bib23"" ref-type=""bibr""><sup>23</sup></xref>",27_15,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"rid=""bib23"" ref-type=""bibr""><sup>23</sup></xref> summating to danazol being less well tolerated and less effective especially at low dose. Consequently, a majority of lanadelumab users in our study (6 of 10) were premenopausal females. Quality of life measures across our cohort are comparable with initial validation and subsequent studies in HAE. Overall median scores for WPAI were on par with end of study measures in the COMPACT extension study (WPAI total impairment, 14% (SD 25%) in this study (<xref",27_16,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"impairment, 14% (SD 25%) in this study (<xref rid=""tbl2"" ref-type=""table"">Table 2</xref>) vs 9.45%, SD 21%).<xref rid=""bib24"" ref-type=""bibr""><sup>24</sup></xref> Similarly, HAE-QOL is on par with the end of treatment Self-Administered C1-INH SC In Hereditary Angioedema (SABHA) study,<xref rid=""bib25"" ref-type=""bibr""><sup>25</sup></xref> though in this study the HAE-QOL did not differ significantly before and after treatment. Critical analysis of the study design and the questionnaires applied identified",27_17,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"design and the questionnaires applied identified very clear and close inter-questionnaire correlation between all administered disease activity, productivity and QOL scores (<xref rid=""appsec1"" ref-type=""sec"">Supplemental Fig. 1</xref>). This suggests that future studies may consider a single, comprehensive questionnaire to assess disease activity in one snapshot, though acknowledging that QOL impairment does not necessarily correlate with disease control scores as highlighted by Bork et al.<xref",27_18,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"control scores as highlighted by Bork et al.<xref rid=""bib26"" ref-type=""bibr""><sup>26</sup></xref> However, a limitation of our study is the (fortunate) under-representation of patients with poor disease control, which clearly skews our measures, though reflects the realisation of effective therapies now available for HAE in Australia. Overall, we conclude that disease activity in our HAE cohort is low, on par with international interventional studies, and minimally impacts productivity.<table-wrap",27_19,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"and minimally impacts productivity.<table-wrap position=""float"" id=""tbl2""><label>Table 2</label><caption><p>Quality of life and disease activity questionnaire results by prophylaxis.</p></caption><alt-text id=""alttext0045"">Table 2</alt-text><table frame=""hsides"" rules=""groups""><thead><tr><th>Characteristic</th><th>Overall, N = 17<xref rid=""tbl2fna"" ref-type=""table-fn"">a</xref></th><th>Berinert SC, N = 2<xref rid=""tbl2fna"" ref-type=""table-fn"">a</xref></th><th>Danazol, N = 9<xref rid=""tbl2fna""",27_20,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"N = 9<xref rid=""tbl2fna"" ref-type=""table-fn"">a</xref></th><th>Lanadelumab, N = 6<xref rid=""tbl2fna"" ref-type=""table-fn"">a</xref></th></tr></thead><tbody><tr><td>HAE QOL Total</td><td>106 (65, 134)</td><td>88 (72, 104)</td><td>114 (75, 134)</td><td>100 (65, 133)</td></tr><tr><td>HAE AS</td><td>6.3 (1.0, 19.0)</td><td>9.5 (3.0, 16.0)</td><td>3.0 (1.0, 9.0)</td><td>10.2 (2.0, 19.0)</td></tr><tr><td>AECT</td><td>12.6 (3.0, 16.0)</td><td>10.0 (4.0, 16.0)</td><td>14.6 (10.0, 16.0)</td><td>10.7 (3.0,",27_21,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"(10.0, 16.0)</td><td>10.7 (3.0, 16.0)</td></tr><tr><td>WPAI, Total Impairment</td><td>0.14 (0.00, 0.76)</td><td>0.38 (0.00, 0.76)</td><td>0.03 (0.00, 0.12)</td><td>0.22 (0.00, 0.65)</td></tr></tbody></table><table-wrap-foot><fn id=""tbl2fna""><label>a</label><p id=""ntpara0015"">Mean (Range)</p></fn></table-wrap-foot></table-wrap> Nonetheless, subjects with HAE desire further improvements in therapies, as highlighted by the concern and feelings of regret participants reported in passing on the disease to",27_22,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"reported in passing on the disease to future generations. Thus, future therapies including ultra-long acting RNA-based inhibitors of prekallikrein<xref rid=""bib27"" ref-type=""bibr""><sup>27</sup></xref> and C1INH gene therapy<xref rid=""bib28"" ref-type=""bibr""><sup>28</sup></xref> may further improve the quality of life of patients with HAE. Our study has several strengths-firstly comprehensive case ascertainment likely identified most if not all HAE cases in our population. Secondly, through comprehensive",27_23,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"our population. Secondly, through comprehensive interviews of a high proportion of adults, we could obtain a very clear snapshot of the current impact of HAE and its management on our population. Limitations of this study include incomplete recruitment of subjects to the questionnaire potentially biasing the data to subjects more willing to provide feedback. Secondly, it should be noted our cohort is from a resource-rich setting with specific therapeutic availabilities and histories. In conclusion, the",27_24,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"availabilities and histories. In conclusion, the prevalence of HAE in South Australia is similar to international quoted figures, with a notable occurrence in Indigenous Australians. HAE patients have a range of therapeutic options in Australia and patients with frequent and severe attacks can access recent effective prophylactic agents, while danazol remains an effective and popular orally-administered therapy for those with milder disease who require only low dose, with good tolerance, for disease",27_25,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"only low dose, with good tolerance, for disease control. Future therapies should prioritize continued reduction in the burden of treatment and further normalise quality of life in this population. ATSI, Aboriginal and Torrens Strait islander; C1 INH, C1 Inhibitor concentrate; HAE, Hereditary Angioedema; QOL, Quality of Life; SC, Subcutaneous Authors wish to thank patients and their family members. This study was funded by Allergy and Immunololgy Foundation of Australasia (<funding-source",27_26,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"Foundation of Australasia (<funding-source id=""gs3""><institution-wrap><institution-id institution-id-type=""doi"">10.13039/501100003197</institution-id><institution>AIFA</institution></institution-wrap></funding-source>) Primary Immunodeficiency Grant. De-identified, original data is available on request to corresponding author. AT, KM, PH. AL and WS contributed to study design and production of the manuscript. AT and KM and AL performed data collection. AT performed Data analysis and generated figures and",27_27,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"performed Data analysis and generated figures and graphs. This study was approved by the Central Adelaide Local Health Network Human Research and Ethics committee (Ref. 14221). All authors consent to this publication. WS has received consulting fees from <funding-source id=""gs4""><institution-wrap><institution-id institution-id-type=""doi"">10.13039/100008322</institution-id><institution>CSL Behring</institution></institution-wrap></funding-source> and non-financial support from Takeda. All other authors",27_28,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
support from Takeda. All other authors declare no relevant conflicts of interest.,27_29,Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia,18 6 2024,,Hereditary_Angioedema
"Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema Hereditary angioedema (HAE) is a rare genetic condition characterized by unpredictable episodes of subcutaneous or submucosal swelling attacks due to increased vascular permeability, secondary to the release of bradykinin (<xref rid=""B1"" ref-type=""bibr"">1</xref>–<xref rid=""B4"" ref-type=""bibr"">4</xref>). HAE can manifest with angioedema (AE) attacks in different locations, including the extremities, genitals, face, and",28_0,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"including the extremities, genitals, face, and gastrointestinal tract, as well as the upper airway, where they can be potentially life-threatening (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B2"" ref-type=""bibr"">2</xref>, <xref rid=""B4"" ref-type=""bibr"">4</xref>, <xref rid=""B5"" ref-type=""bibr"">5</xref>). HAE is divided into two types, HAE with C1 esterase inhibitor deficiency (C1INH) named HAE-C1INH, caused by mutations in the <italic toggle=""yes"">SERPING1</italic> gene, coding for C1INH and HAE",28_1,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"gene, coding for C1INH and HAE without C1INH deficiency, known as HAE with normal C1INH (HAE-nC1INH) (<xref rid=""B1"" ref-type=""bibr"">1</xref>). HAE-C1INH is categorized into two subtypes: type 1, characterized by a quantitative deficiency of C1INH, and type 2, marked by a qualitative deficiency of C1INH. In HAE-nC1INH, several mutations have been described in genes coding proteins targeting the kallikrein-kinin system, such as factor XII (<xref rid=""B6"" ref-type=""bibr"">6</xref>, <xref rid=""B7""",28_2,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"rid=""B6"" ref-type=""bibr"">6</xref>, <xref rid=""B7"" ref-type=""bibr"">7</xref>), plasminogen (<xref rid=""B8"" ref-type=""bibr"">8</xref>) or kininogen (<xref rid=""B9"" ref-type=""bibr"">9</xref>) and the vascular endothelium, such as angiopoietin (<xref rid=""B10"" ref-type=""bibr"">10</xref>), myoferlin (<xref rid=""B11"" ref-type=""bibr"">11</xref>) and heparan sulfate-glucosamine 3-O-sulfotransferase 6 (<xref rid=""B12"" ref-type=""bibr"">12</xref>). HAE-nC1INH due to mutations in the <italic toggle=""yes"">F12</italic> gene",28_3,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"in the <italic toggle=""yes"">F12</italic> gene coding coagulation factor XII, is known as HAE-FXII and is the most frequent cause of HAE-nC1INH. Furthermore, in some patients no mutation has been described and are considered as HAE of unknown mechanism (HAE-UNK) (<xref rid=""B1"" ref-type=""bibr"">1</xref>). HAE attacks initiate upon local activation of the contact system (CS) involving the interaction of the kallikrein kinin system (KKS), the fibrinolytic system and the coagulation system. FXII is activated",28_4,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"and the coagulation system. FXII is activated (FXIIa) when it contacts with a negatively charged surface or macromolecules (<xref rid=""B1"" ref-type=""bibr"">1</xref>–<xref rid=""B5"" ref-type=""bibr"">5</xref>, <xref rid=""B13"" ref-type=""bibr"">13</xref>). FXIIa cleaves the prekallikrein (PK) and the high molecular weight kininogen (HMWK) complex, which subsequently turns into plasma kallikrein (pK), and bradykinin (BK) is released (<xref rid=""B1"" ref-type=""bibr"">1</xref>–<xref rid=""B5"" ref-type=""bibr"">5</xref>).",28_5,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"rid=""B5"" ref-type=""bibr"">5</xref>). FXIIa and pK can additionally activate FXII in a positive feedback-loop, leading to an amplified response (<xref rid=""B2"" ref-type=""bibr"">2</xref>, <xref rid=""B4"" ref-type=""bibr"">4</xref>, <xref rid=""B5"" ref-type=""bibr"">5</xref>, <xref rid=""B9"" ref-type=""bibr"">9</xref>, <xref rid=""B13"" ref-type=""bibr"">13</xref>, <xref rid=""B14"" ref-type=""bibr"">14</xref>). BK is a vasoactive nonapeptide that acts on the surface of endothelial cells by binding to its B2 (mainly) and B1",28_6,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"cells by binding to its B2 (mainly) and B1 receptors increasing vascular permeability, and subsequently resulting in AE attacks (<xref rid=""B2"" ref-type=""bibr"">2</xref>–<xref rid=""B5"" ref-type=""bibr"">5</xref>, <xref rid=""B13"" ref-type=""bibr"">13</xref>, <xref rid=""B14"" ref-type=""bibr"">14</xref>). BK is rapidly metabolized by several enzymes, such as angiotensin-converting enzyme (kininase II, ACE), carboxypeptidase N (kininase I), aminopeptidase P (APP), neutral endopeptidase (NEP), and dipeptidyl peptidase",28_7,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"endopeptidase (NEP), and dipeptidyl peptidase IV (DPPIV) (<xref rid=""B13"" ref-type=""bibr"">13</xref>–<xref rid=""B15"" ref-type=""bibr"">15</xref>). Acute phase reactants (APR) are serum proteins that exhibit significant increases in various inflammatory conditions, whether acute or chronic (<xref rid=""B16"" ref-type=""bibr"">16</xref>–<xref rid=""B18"" ref-type=""bibr"">18</xref>). Commonly utilized APR include erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and serum amyloid A (SAA), which play",28_8,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"(CRP), and serum amyloid A (SAA), which play crucial roles in the diagnosis and monitoring of numerous diseases such as severe bacterial or viral infections, as well as chronic inflammatory disorders like Crohn’s disease and rheumatoid arthritis (<xref rid=""B16"" ref-type=""bibr"">16</xref>–<xref rid=""B20"" ref-type=""bibr"">20</xref>). Additionally, in certain conditions, elevated levels of other APR such as haptoglobin, alpha-1-antitrypsin, C3, C4, hepcidin, or fibrinogen may also be observed (<xref rid=""B16""",28_9,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"fibrinogen may also be observed (<xref rid=""B16"" ref-type=""bibr"">16</xref>–<xref rid=""B18"" ref-type=""bibr"">18</xref>). D-dimer is generated through the breakdown of the fibrin mesh by plasmin, an enzyme responsible for fibrinolysis. Additionally, D-dimer acts as an APR, triggering elevated levels of cytokines such as IL-6. Consequently, this reciprocal interaction suggests that D-dimer and other fibrin degradation products might impact inflammatory and acute-phase responses by fostering neutrophil and",28_10,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"acute-phase responses by fostering neutrophil and monocyte activation, thus stimulating the release of IL-6 (<xref rid=""B21"" ref-type=""bibr"">21</xref>–<xref rid=""B23"" ref-type=""bibr"">23</xref>). When an HAE attack occurs, a local increase of BK has been described (<xref rid=""B13"" ref-type=""bibr"">13</xref>), however the role of inflammation in HAE was been poorly explored. Therefore, the aim of this study was to investigate the involvement of inflammatory mediators in patients with HAE during the acute",28_11,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"mediators in patients with HAE during the acute attacks.   This study shows, that conventional inflammatory pathways may be involved in the pathophysiology of acute AE attacks in HAE. Despite the limited acute sample size, we have demonstrated a substantial increase of some APRs such as SAA, ESR and D-dimer during AE attacks, both in HAE-C1INH and in HAE-FXII patients. Coagulation parameters and markers of activation of the fibrinolytic pathway, such as D-dimer and the contact system had been previously",28_12,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"and the contact system had been previously explored in HAE-C1INH (<xref rid=""B21"" ref-type=""bibr"">21</xref>, <xref rid=""B24"" ref-type=""bibr"">24</xref>, <xref rid=""B25"" ref-type=""bibr"">25</xref>). In agreement with findings from previous studies (<xref rid=""B21"" ref-type=""bibr"">21</xref>, <xref rid=""B24"" ref-type=""bibr"">24</xref>, <xref rid=""B25"" ref-type=""bibr"">25</xref>), we have observed an increase of D-dimer during attacks in HAE-C1INH patients. Noteworthy, this study shows for the first time that AE",28_13,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"this study shows for the first time that AE attacks can also increase D-dimer in HAE-FXII. D-dimer is produced during the breakdown of the fibrin mesh by plasmin. Elevation of D-dimer in HAE-C1INH attacks may mean secondary hyperfibrinolysis, rather than hypercoagulation, because plasminogen levels during baseline periods did not differ from those recorded during AE attacks and are similar to the healthy control levels (<xref rid=""B24"" ref-type=""bibr"">24</xref>). In a study of 79 patients with HAE-C1INH,",28_14,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"In a study of 79 patients with HAE-C1INH, 80% of them presented an increase in D-dimer during AE attacks, that was higher in patients with angioedema affecting the submucosa (abdominal and oropharyngeal-laryngeal) compared to subcutaneous (peripheral and facial) (<xref rid=""B25"" ref-type=""bibr"">25</xref>). Nevertheless, severity and activity of HAE-C1INH was not considered. In our study, apart from abdominal attacks, we have also observed an increase of D-dimer during facial and peripheral attacks.",28_15,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"of D-dimer during facial and peripheral attacks. However, these differences should be evaluated cautiously and could be related to the small sample size. In our study, D-dimer was elevated in symptom-free periods only in 14.5% of patients. One study showed a significant elevation of D-dimer at baseline compared with controls (<xref rid=""B24"" ref-type=""bibr"">24</xref>). This discrepancy can be due to the different study design, since we have considered an elevation of D-dimer when values were over the",28_16,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"an elevation of D-dimer when values were over the normal threshold, but we have not compared patients with controls. In addition to fibrinolysis contributing to the generation of D-dimer in HAE patients via contact system activation, it is crucial to underscore that inflammatory states trigger the production of fibrinogen in response to interleukin-6 (IL-6), interleukin-1 (IL-1), and tumor necrosis factor (TNF) (<xref rid=""B18"" ref-type=""bibr"">18</xref>). This reciprocal interaction suggests that D-dimer",28_17,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"This reciprocal interaction suggests that D-dimer and other fibrin degradation products might impact inflammatory and acute-phase responses by promoting neutrophil and monocyte activation, thus facilitating the release of IL-6 (<xref rid=""B22"" ref-type=""bibr"">22</xref>, <xref rid=""B23"" ref-type=""bibr"">23</xref>). In HAE attacks, an elevation of IL-6 has been demonstrated (<xref rid=""B26"" ref-type=""bibr"">26</xref>), so it is plausible to hypothesize that the activation of the inflammatory cascade and the",28_18,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"activation of the inflammatory cascade and the production of fibrinogen by endothelial and inflammatory cells in HAE patients can contribute to the production of D-dimer (<xref rid=""B18"" ref-type=""bibr"">18</xref>). Nevertheless, additional research is required to validate this hypothesis. APRs are known to respond to pro-inflammatory cytokines, such as IL-1, IL-6 or tumor necrosis factor-alpha (TNF-α), and to the local production of endothelial nitric oxide (NO), prostaglandins, and endothelial adhesion",28_19,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"(NO), prostaglandins, and endothelial adhesion molecules (<xref rid=""B16"" ref-type=""bibr"">16</xref>–<xref rid=""B18"" ref-type=""bibr"">18</xref>). Although the liver is the main producer of APR, other non-hepatic sources such as endothelial cells and macrophages have been identified (<xref rid=""B18"" ref-type=""bibr"">18</xref>–<xref rid=""B20"" ref-type=""bibr"">20</xref>). SAA, which belongs to the apolipoprotein family, is produced mainly in the liver and its secretion reasonably increases during inflammatory",28_20,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"reasonably increases during inflammatory states. <italic toggle=""yes"">In vitro</italic> IL-6 has a synergism in the production of SAA either in combination with IL-1β or with TNF-z (<xref rid=""B27"" ref-type=""bibr"">27</xref>). SAA is present constitutively in plasma, and the increase in SAA levels observed in our patients during AE attacks could be in response to the local production of proinflammatory cytokines (IL-6, IL1-β and TNF-z) independently of the hepatic production, as proposed in <xref rid=""f2""",28_21,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"hepatic production, as proposed in <xref rid=""f2"" ref-type=""fig"">",28_22,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
<bold>Figure 2</bold>,28_23,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"</xref>. ESR, is an indirect measure of the amount of fibrinogen produced during inflammatory states, such as infections, in malignancy or other immune diseases (<xref rid=""B16"" ref-type=""bibr"">16</xref>–<xref rid=""B18"" ref-type=""bibr"">18</xref>). We have noted a rise in ESR among a subset of our patients during symptom-free intervals. Notably, during acute attacks, a substantial proportion of our patients experienced a significant increase in ESR, indicating the occurrence of systemic inflammation. Until",28_24,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"the occurrence of systemic inflammation. Until now, no prior study had investigated the role of ESR during HAE acute episodes. While we did not measure fibrinogen levels, a plausible explanation for our observations could be that, following the activation of the contact system and fibrinolysis, there is a localized production of fibrinogen during attacks. In angioedema due to ACE inhibitors (ACEi-AE), a type of AE that, like HAE-C1INH and HAE-FXII, is mediated by BK, a 1.5-fold increase in fibrinogen has",28_25,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"by BK, a 1.5-fold increase in fibrinogen has been observed during attacks (<xref rid=""B28"" ref-type=""bibr"">28</xref>). Moreover, fibrinogen is able to increase the vasodilator potency of BK by 10-fold and to increase bradykinin-induced vasodilator-stimulated phosphoprotein phosphorylation (<xref rid=""B28"" ref-type=""bibr"">28</xref>). This potentiation of bradykinin-induced vasodilation suggest that fibrinogen might contribute to the pathophysiology of ACEi-AE. An elevation of CRP has also been described in",28_26,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"An elevation of CRP has also been described in ACEi-AE (<xref rid=""B29"" ref-type=""bibr"">29</xref>–<xref rid=""B31"" ref-type=""bibr"">31</xref>). CRP, is another APR, mainly produced in the liver, widely used as a biomarker in inflammatory diseases, that increases mostly in response to microbial components during infections and in autoimmune diseases (<xref rid=""B18"" ref-type=""bibr"">18</xref>, <xref rid=""B32"" ref-type=""bibr"">32</xref>–<xref rid=""B34"" ref-type=""bibr"">34</xref>). CRP primarily responds to IL-6",28_27,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"CRP primarily responds to IL-6 and, to a lesser extent, to IL-1β and TNF-α (<xref rid=""B18"" ref-type=""bibr"">18</xref>, <xref rid=""B33"" ref-type=""bibr"">33</xref>). In accordance with a previous study in 25 HAE-C1INH patients (<xref rid=""B35"" ref-type=""bibr"">35</xref>), we found that CRP levels were within normal range during baseline and remained unaltered during HAE attacks. On the other hand, during HAE attacks, levels of IL-1, IL-6 and TGF-b have been found to be significantly higher compared to",28_28,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"been found to be significantly higher compared to remission and those from healthy controls, whereas no activation of liver CPR production has been observed (<xref rid=""B26"" ref-type=""bibr"">26</xref>). Furthermore, it has been established that CRP may be produced extrahepatically by various tissues, including neurons, adipose tissue, lungs, kidneys, and intestines (<xref rid=""B33"" ref-type=""bibr"">33</xref>, <xref rid=""B34"" ref-type=""bibr"">34</xref>). In fact, in our study, CPR remained unaltered even in",28_29,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"in our study, CPR remained unaltered even in abdominal attacks, so further studies are needed to elucidate the reason for the lack of CRP production during AE attacks in HAE patients compared to ACEi-AE (<xref rid=""B29"" ref-type=""bibr"">29</xref>). We postulate that in individuals with HAE, the heightened levels of SAA, ESR and D-dimer during acute attacks could be a result of the localized production of proinflammatory cytokines. Specifically, SAA and ESR may be increasing locally in response to the",28_30,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"ESR may be increasing locally in response to the release of IL-6, IL-1β, and TNF-α, rather than systemic proinflammatory cytokines, suggesting a limited hepatic APR production. This discrepancy might explain the absence of CRP, which is primarily produced in the liver. Moreover, various immune cells, including eosinophils, basophils, neutrophils, mast cells, and lymphocytes, express BK1 and BK2 receptors on their surfaces (<xref rid=""B36"" ref-type=""bibr"">36</xref>). This cellular composition suggests a",28_31,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"This cellular composition suggests a possible pivotal role in the inflammatory process during HAE attacks, as these cells could be activated through BK (<xref rid=""B5"" ref-type=""bibr"">5</xref>). Consequently, in patients with HAE, bradykinin may be implicated in the local production of APR. <xref rid=""f2"" ref-type=""fig"">",28_32,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
<bold>Figure 2</bold>,28_33,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"</xref> illustrates how the release of bradykinin during HAE attacks may contribute to acute phase reactant production through immune cell activation and subsequent cytokine release, highlighting the complex interplay between inflammation and the contact system in HAE pathophysiology. Reliable biomarkers for distinguishing between various types of HAE are currently scarce, with genetic studies being a primary means of differentiation. Assessment of C4 levels and C1INH activity and function remains crucial",28_34,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"and C1INH activity and function remains crucial in delineating HAE types (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B2"" ref-type=""bibr"">2</xref>). Furthermore, there is a notable gap in potential biomarkers for discerning between different types of angioedema (e.g., mast cell-mediated or bradykinin-induced) (<xref rid=""B1"" ref-type=""bibr"">1</xref>, <xref rid=""B2"" ref-type=""bibr"">2</xref>). Bradykinin has been proposed as a potential biomarker, but its rapid metabolism and the technical challenges",28_35,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"its rapid metabolism and the technical challenges associated with its measurement make it impractical for routine use (<xref rid=""B37"" ref-type=""bibr"">37</xref>–<xref rid=""B39"" ref-type=""bibr"">39</xref>). Other groups have put forth alternative candidates. The potential use of HMWK and the plasma PK-HK complex has been explored (<xref rid=""B37"" ref-type=""bibr"">37</xref>), although standardization of techniques for their quantitation remains a hurdle, and they have not yet been incorporated into routine",28_36,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"they have not yet been incorporated into routine clinical practice. Elevated levels of adrenomedullin and urokinase plasminogen activator (uPAR) during acute attacks, measured using transcriptomics, have also been suggested as potential biomarkers, although these techniques require further standardization before widespread use (<xref rid=""B40"" ref-type=""bibr"">40</xref>). Finally, Tie-2 (Angiopoietin-1 receptor), fibroblast activation protein-alpha (FAP-α), and tissue plasminogen activator (tPA) have also",28_37,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"and tissue plasminogen activator (tPA) have also been postulated as biomarkers to distinguish between different types of AE (<xref rid=""B41"" ref-type=""bibr"">41</xref>). However, it is crucial to acknowledge that none of these biomarkers have yet been incorporated into routine clinical practice, and their measurement requires complex techniques. SAA, ESR, and D-dimer, being easily measurable, could be regarded as for AE biomarkers. Nevertheless, a comprehensive analysis is required to understand the role of",28_38,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"analysis is required to understand the role of APR in other types of angioedema. High SAA levels were found in 67 patients with chronic spontaneous urticaria (CSU), with a particularly significant elevation in those with both CSU and AE (<xref rid=""B42"" ref-type=""bibr"">42</xref>). Furthermore, in anaphylaxis, mast cell activation has been linked to contact system activation (<xref rid=""B43"" ref-type=""bibr"">43</xref>, <xref rid=""B44"" ref-type=""bibr"">44</xref>), and in CSU, an increase in plasma D-dimer has",28_39,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"and in CSU, an increase in plasma D-dimer has been reported, correlating with disease activity (<xref rid=""B45"" ref-type=""bibr"">45</xref>–<xref rid=""B47"" ref-type=""bibr"">47</xref>). Although still an unexplored area, it is conceivable that in mast cell-mediated angioedema, APR could also see an increase during acute episodes. To our knowledge, this study shows for the first time that SAA and ESR are elevated in HAE-C1INH and in HAE-FXII attacks and D-dimer is elevated also in HAE-FXII attacks, since the",28_40,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"is elevated also in HAE-FXII attacks, since the elevation in AE attacks in patients with C1INH deficiency has been previously described. Clearly, large scale follow-up studies are needed to elucidate the behavior and clinical usefulness of SAA and ESR in different HAE types. In conclusion, our study provides valuable insights into the inflammatory mechanisms involved during AE attacks in HAE patients. While these attacks are localized, the significant elevation of APRs suggests a broader inflammatory",28_41,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
elevation of APRs suggests a broader inflammatory response. The causal relationship between increased APR levels and HAE attacks warrants further investigation. The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author. The studies involving humans were approved by Comité d’Ètica. Hospital Universitari Vall d’Hebron. The studies were conducted in accordance with the local legislation and institutional,28_42,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin. JG-S: Writing – review & editing, Writing – original draft, Visualization, Software, Project administration, Methodology, Investigation, Formal analysis, Data curation. ML-H: Writing – review & editing, Writing – original draft, Validation, Supervision, Methodology, Investigation, Conceptualization. PG-B: Writing – original draft,",28_43,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"PG-B: Writing – original draft, Writing – review & editing, Methodology, Investigation, Formal analysis. AS-C: Writing – original draft, Writing – review & editing, Project administration, Methodology. PB: Writing – original draft, Writing – review & editing, Methodology, Investigation, Formal analysis. JP-G: Writing – original draft, Writing – review & editing, Project administration, Investigation, Formal analysis. OL: Writing – original draft, Writing – review & editing, Validation, Supervision,",28_44,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"– review & editing, Validation, Supervision, Methodology. VC: Writing – original draft, Writing – review & editing, Visualization, Validation, Supervision, Methodology. MG: Data curation, Writing – review & editing, Writing – original draft, Validation, Supervision, Resources, Methodology, Investigation, Funding acquisition, Formal analysis, Conceptualization.",28_45,Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema,17 6 2024,,Hereditary_Angioedema
"Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration Human plasma kallikrein (PKa) is a member of the serine protease family and serves as a key mediator of the kallikrein-kinin system (KKS), which is known for its regulatory roles in inflammation, vasodilation, blood pressure, and coagulation. Genetic dysregulation of KKS leads to Hereditary Angioedema (HAE), which",29_0,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"KKS leads to Hereditary Angioedema (HAE), which is characterized by spontaneous, painful swelling in various body regions. Importantly, HAE frequently coexists with various cancers. Despite substantial efforts towards the development of PKa inhibitors for HAE, there remains a need for bifunctional agents addressing both anti-cancer and anti-HAE aspects, especially against carcinoma-associated comorbid HAE conditions. Consequently, we investigated the therapeutic potential of the anti-glutamine prodrug,",29_1,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"potential of the anti-glutamine prodrug, isopropyl(S)-2-((S)-2-acetamido-3-(1H-indol-3-yl)-propanamido)-6-diazo-5-oxo-hexanoate (DRP-104), and its active form, 6-Diazo-5-oxo-l-norleucine (DON), recognized for their anti-cancer properties, as novel PKa inhibitors. Utilizing structure-based in silico methods, we conducted a comparative analysis with berotralstat, a clinically approved HAE prophylactic, and sebetralstat, an investigational HAE therapeutic agent, in Phase 3 clinical trials. Inhibiting PKa with",29_2,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"in Phase 3 clinical trials. Inhibiting PKa with DON resulted in relatively heightened structural stability, rigidity, restricted protein folding, and solvent-accessible loop exposure, contributing to increased intra-atomic hydrogen bond formation. Conversely, PKa inhibition with DRP-104 induced restricted residue flexibility and significantly disrupted the critical SER195-HIS57 arrangement in the catalytic triad. Both DON and DRP-104, along with the reference drugs, induced strong cooperative intra-residue",29_3,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"drugs, induced strong cooperative intra-residue motion and bidirectional displacement in the PKa architecture. The results revealed favorable binding kinetics of DON/DRP-104, showing thermodynamic profiles that were either superior or comparable to those of the reference drugs. These findings support their consideration for clinical investigations into the management of carcinoma-associated HAE. Plasma kallikreins (PKa), encoded by KLKB1 on human chromosome 4q35 and synthesized in the liver, belong to the",29_4,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"4q35 and synthesized in the liver, belong to the trypsin-like serine protease sub-family with a pivotal role in blood homeostasis, contributing to both proinflammatory and prothrombotic processes [<xref ref-type=""bibr"" rid=""CR1"">1</xref>, <xref ref-type=""bibr"" rid=""CR2"">2</xref>]. The full-length PKa (619 aa residues) comprises a C-terminal serine protease (SP) domain (ILE391-ALA638) and an N-terminal arrangement of four disc-shaped apple domains, A1 (GLY20-ALA110), A2 (CYS111-GLY200), A3 (CYS201-PRO291),",29_5,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"A2 (CYS111-GLY200), A3 (CYS201-PRO291), and A4 (CYS292-ARG390), interconnected by disulfide bonds (Fig. <xref rid=""Fig1"" ref-type=""fig"">1</xref>). The SP domain hosts the catalytic triad (HIS57, ASP102, and SER195) within the active site, governing PKa proteolytic activity. The SP domain comprises two six-stranded β-barrels, creating a distinctive structural motif. The apple domains collectively contribute to substrate recognition, facilitating the recruitment of molecules like high-molecular-weight",29_6,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"of molecules like high-molecular-weight kininogens (HKs) and factor XII (FXII), as well as substrate-receptor binding. These functions collaboratively modulate the proteolytic activity of PKa [<xref ref-type=""bibr"" rid=""CR3"">3</xref>, <xref ref-type=""bibr"" rid=""CR4"">4</xref>]. The key function of PKa lies in releasing kinins, specifically bradykinin (Bk) and Lys-bradykinin (Lys-Bk), from high-molecular-weight kininogens (HKs) and low-molecular-weight kininogens (LKs), respectively [<xref ref-type=""bibr""",29_7,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"(LKs), respectively [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR6"">6</xref>]. The C1 inhibitor (C1-INH) is a crucial regulator in controlling the physiological activity of plasma kallikrein. It rapidly inactivates PKa, preventing the excessive production of bradykinin. This process is essential for maintaining the balance of the kallikrein-kinin system (KKS) and preventing unwanted inflammation or other physiological effects associated with elevated bradykinin levels.",29_8,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"associated with elevated bradykinin levels. Additionally, other circulating inhibitors like α2-macroglobulin and antithrombin III also contribute to the regulation of PKa activity [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>]. Upon bradykinin release, the activation of bradykinin receptors (B1R and B2R) initiates intracellular signaling cascades, resulting in increased calcium levels, the release of various mediators, and physiological responses, including",29_9,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"mediators, and physiological responses, including inflammation, vasodilation, and pain. In the KKS, PKa is activated from its zymogen, prekallikrein, by factor XIIa (FXIIa). PKa, in turn, contributes to a feedback loop by converting factor XII (FXII) to its active form, FXIIa, further amplifying the activation of the KKS. Beyond its primary role in kinin release, PKa has been reported to mediate other physiological activities such as platelet aggregation, fibrinolysis, complement, pathway and the",29_10,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"fibrinolysis, complement, pathway and the renin-angiotensin system (RAS) [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR7"">7</xref>].<fig id=""Fig1""><label>Fig. 1</label><caption><p>Schematic diagram of (<bold>A</bold>) residue sequence and domain architecture of the four apple domains, A1 (blue), A2 (purple), A3 (pink), and A4 (magenta), and their interconnecting sequence loops (orange) attached to the serine protease domain (sandy brown), and (<bold>B</bold>) 3D crystallized",29_11,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"brown), and (<bold>B</bold>) 3D crystallized structure of full-length human plasma kallikrein (PDB: 6O1G) obtained by refining missing loops using Modeller program. The PKa activation loop is shown as a pre-sequence (green). Also, the relative positions of the S1 and S4 grooves are shown</p></caption><graphic http://www.w3.org/1999/xlink href=""12013_2024_1266_Fig1_HTML"" id=""d33e196""></graphic></fig> In addition to antagonizing PKa, C1-INH also antagonizes FXIIa, and an important regulator of the KKS.",29_12,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"FXIIa, and an important regulator of the KKS. Hence, diminished levels or abnormal variants of C1-INH due to SERPING1 genetic mutations lead to a pathological state marked by the upregulation of PKa and subsequent elevated bradykinin levels. This condition is identified as Hereditary Angioedema (HAE), a rare autosomal dominant genetic disorder marked by recurring painful swelling in multiple body regions, including the face, extremities, abdomen, genitals, and upper respiratory tract. Alongside Type I and",29_13,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"and upper respiratory tract. Alongside Type I and Type II HAE, there is Type III, where individuals exhibit normal C1-INH levels. Management of HAE involves targeting PKa effects, with PKa inhibitors serving as the primary on-demand first-line drug agents [<xref ref-type=""bibr"" rid=""CR2"">2</xref>, <xref ref-type=""bibr"" rid=""CR8"">8</xref>, <xref ref-type=""bibr"" rid=""CR9"">9</xref>]. Besides targeting HAE, PKa inhibitors are under development for the treatment of uncontrolled PKa-related conditions, such as",29_14,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"of uncontrolled PKa-related conditions, such as diabetic retinopathy, macular edema, and sepsis [<xref ref-type=""bibr"" rid=""CR5"">5</xref>, <xref ref-type=""bibr"" rid=""CR10"">10</xref>]. Presently, ecallantide [<xref ref-type=""bibr"" rid=""CR11"">11</xref>], lanadelumab [<xref ref-type=""bibr"" rid=""CR12"">12</xref>], and berotralstat [<xref ref-type=""bibr"" rid=""CR13"">13</xref>] are the Food and Drug Administration (FDA)-approved PKa inhibitor drugs for managing Hereditary Angioedema (HAE). Ongoing investigations",29_15,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"Angioedema (HAE). Ongoing investigations involve several inhibitors, including ATN-249 (phase I) [<xref ref-type=""bibr"" rid=""CR14"">14</xref>], STAR-0215 (phase 1) [<xref ref-type=""bibr"" rid=""CR15"">15</xref>], KVD824 (phase 2) [<xref ref-type=""bibr"" rid=""CR9"">9</xref>], and KVD900 (phase 3) [<xref ref-type=""bibr"" rid=""CR7"">7</xref>], reflecting a commendable effort to develop newer, safer, and administration-friendly PKa inhibitors. However, with a growing number of reported HAE-associated cancer cases, the",29_16,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"of reported HAE-associated cancer cases, the quest for PKa inhibitors exhibiting dual functionality—both anti-carcinogenic and anti-angioedema—has become imperative [<xref ref-type=""bibr"" rid=""CR16"">16</xref>–<xref ref-type=""bibr"" rid=""CR18"">18</xref>]. Particularly crucial is the incorporation of prodrug or advanced drug-delivery systems to bolster efficacy while minimizing off-target tissue toxicities. Although the association between Hereditary Angioedema (HAE) and malignancy is not well-defined,",29_17,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"(HAE) and malignancy is not well-defined, certain cancers have been linked to acquired angioedema (AAE), and comorbidity between HAE and cancer has been observed [<xref ref-type=""bibr"" rid=""CR19"">19</xref>, <xref ref-type=""bibr"" rid=""CR20"">20</xref>]. It is noteworthy that accumulating research suggests a link between the dysregulation of plasma kallikrein (PKa) and the progression of various carcinomas, including lung [<xref ref-type=""bibr"" rid=""CR21"">21</xref>], pancreatic [<xref ref-type=""bibr""",29_18,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"pancreatic [<xref ref-type=""bibr"" rid=""CR22"">22</xref>], colorectal [<xref ref-type=""bibr"" rid=""CR23"">23</xref>], and breast [<xref ref-type=""bibr"" rid=""CR24"">24</xref>] cancers. In this context, we propose a novel anti-glutamine prodrug, isopropyl(S)-2-((S)-2-acetamido-3-(1H-indol-3-yl)-propanamido)-6-diazo-5-oxo-hexanoate] (DRP-104), as a promising PKa inhibitor. Efficacy studies of DRP-104 against murine lymphoblastic lymphoma (EL4), breast cancer (E0771), colon cancer (MC380), and lung cancer (3LL)",29_19,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"colon cancer (MC380), and lung cancer (3LL) cell lines demonstrated clinically accepted tumor regression capabilities, preferential tumor delivery potential, reduced off-target toxicity, and enhanced synergy with anti-PD-1 therapy, accompanied by notable immunologic memory [<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. Our earlier study identified DRP-104 as a potent serine protease inhibitor targeting human TMPRSS2 in the treatment of SARS-CoV-2, warranting further in vitro validation [<xref",29_20,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"warranting further in vitro validation [<xref ref-type=""bibr"" rid=""CR26"">26</xref>]. Our present study utilized in silico methods to explore the structural determinants and dynamic features that govern the inhibitory effects of DRP-104 and its active form, 6-Diazo-5-oxo-l-norleucine (DON), against human plasma kallikrein (PKa). These findings were compared with berotralstat, a clinically prescribed oral prophylactic, and sebetralstat, a Phase 3 oral therapeutic for hereditary angioedema (HAE). Although",29_21,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"for hereditary angioedema (HAE). Although there are no current clinical reports detailing the half-life or longevity profile of DRP-104 in vivo, pharmacokinetic analyses conducted by Rais et al. [<xref ref-type=""bibr"" rid=""CR25"">25</xref>] demonstrated its remarkable stability in human plasma [<xref ref-type=""bibr"" rid=""CR25"">25</xref>]. These studies revealed that over 90% of DRP-104 remained intact even after 60 min in circulation. These findings were corroborated by Yokoyama et al. [<xref",29_22,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"were corroborated by Yokoyama et al. [<xref ref-type=""bibr"" rid=""CR27"">27</xref>], who similarly observed the high stability and integrity of DRP-104 in human plasma, alongside its sustained activity [<xref ref-type=""bibr"" rid=""CR27"">27</xref>]. Based on these observations, we hypothesized that DRP-104 possesses the potential to effectively reach plasma kallikrein (PKa) and modulate its functions, thus justifying its selection as an investigational inhibitor. Our findings highlight the anti-PKa potential",29_23,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"Our findings highlight the anti-PKa potential of both DON and DRP-104 as alternative treatment options for HAE, necessitating further in vitro validation. In view of this, there is a call for drug-design studies focusing on multifunctional prodrug serine protease inhibitors.   Our current study aimed to explore the anti-proteasomal therapeutic functions of DON and DRP-104 beyond the scope of chemotherapy and, in this case, as potential novel chemotherapeutic agents against hereditary angioedema (HAE). In",29_24,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"agents against hereditary angioedema (HAE). In addition, while collating in-depth thermodynamic patterns involved in the inhibition of human plasma kallikrein (PKa), this study also probed the inhibitory advantage of Phase 3 S1/S4 sebetralstat over the clinically approved S4 berotralstat. However, berotralstat induced favorable conformational stability with reduced structural flexibility compared with sebetralstat. Comparatively, DON induced favorable structural stability and rigidity, whereas DRP-104",29_25,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"stability and rigidity, whereas DRP-104 induced restricted residue flexibility in PKa inhibition. Generally, DON induced restricted protein unfolding potential in PKa through increased expulsion of surface loops away from the enclosing solvent and increased formation of intra-atomic hydrogen bonds, compared to DRP-104 and the reference drugs. Furthermore, the residues were more displaced in the PKa complex with DON than in DRP-104, sebetralstat, and berotralstat. Residue displacements were found to be",29_26,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"Residue displacements were found to be bidirectional along both principal components. In addition, all regions in PKa underwent strong synchronized residue motion for all inhibitor complexes. DRP-104 and sebetralstat were found to significantly disrupt the SER195-HIS57 and HIS57-ASP102 arrangements, respectively. Finally, PKa formed stable complexes with all inhibitors with favorable free binding energetics. Our study suggests that DON and DRP-104 are potent and novel drug candidates for the treatment of",29_27,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
"and novel drug candidates for the treatment of HAE and its associated carcinomas. However, clinical investigations of these candidate drugs remain limited, and should be pursued further using in vitro techniques.",29_28,Unveiling therapeutic frontiers: DON/DRP-104 as innovative Plasma kallikrein inhibitors against carcinoma-associated hereditary angioedema shocks - a comprehensive molecular dynamics exploration,13 6 2024,,Hereditary_Angioedema
